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Abstract
Acute myeloid leukemia is a type of blood cancer characterized by an excessive build-up of
immature blood cells in the bone marrow and blood streams. As a result, healthy stem cells
become space- and resource-limited, and do not produce enough functional cells for the body
to operate normally. Treatment is required immediately, consisting of intensive chemotherapy.
Chemotherapy dosage and schedule are derived from established protocols which do not ac-
count for patient-specific and disease-specific heterogeneity. Over- or under- dosage are thus
common; a more rational and personalized approach to chemotherapy treatments is required.
Specifically, incorporating the effect of chemotherapy in a cell cycle phase-specific manner
would be highly beneficial.
In this work, we developed a population balance model (PBM) of the cell cycle based on
the underlying biology that captures the progress of cells within and between phases. It was
validated with three leukemia cell lines separately for the duration of one cell cycle, and in
variable mixtures where forward and backward kinetics as well as clonal identification were
successfully performed.
The model was compared against two other cell cycle models: an existing ODE model and
a newly developed DDE model featuring phase durations as delays. The PBM outperformed
the other two in recapitulating biological features, and displayed a higher sensitivity to treat-
ment when coupled to an existing pharmacokinetic/pharmacodynamic model of chemotherapy
treatment.
The PBM was further used in the prediction of clonal evolution during chemotherapy, high-
lighting the important heterogeneity in treatment response between clones but also the compet-
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itive features among them that could be critical in the success of the treatment.
Finally, the first steps towards implementing this technology at clinical level were taken by
defining converted, measurable data sets. A prototype application, “ChemoApp”, was devel-
oped at the user interface level for the introduction of this research into clinical practice.
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Chapter 1
Introduction
Acute Myeloid Leukemia (AML) is a cancer of the blood characterized by an overproduction
of immature, non-functional myeloid cells. AML is the second most common type of leukemia
(34% of all leukemias, 2011, Cancer Research UK).
The most frequent treatment for AML is chemotherapy which aims at eliminating the can-
cerous bone marrow (BM) population by attacking highly proliferative cells (immature blasts).
Chemotherapy represents a reactive approach to the disease initiating after the disease symp-
toms appear, and involves the infusion into the blood of drugs that are toxic to rapidly prolif-
erating cells. Survival relies not only on the eradication of the malignant cells but also on the
maintenance of a minimum level of healthy cells.
Current chemotherapy treatment protocols are designed based on: (i) pre-clinical animal
experiments, (ii) empirical clinical trials, and (iii) the acquired experience of subspecialist
physicians. Clinically, drug dosage is currently being calculated with the patient’s weight and
height (BSA body surface area) which correlates with blood/bone marrow volume before the
start of the treatment. The treatment is delivered in one or more cycles, depending on the
efficiency of previous cycles and on the overall health of the patient. The duration and the
resumption timing of the cycles are only limited by the patient’s health condition (if he/she still
has not reached remission). Hence, the current treatment protocols (both in dose, timing and
duration) rely basically on the theoretical maximum tolerance level of the patient.
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It is well known that the mechanism of chemotherapeutic agents is cell cycle phase-specific,
i.e. they block cell growth at only one of the phases of the cell duplication process. Cell cycle
equilibrium is lost and cells accumulate in the phases which are the least affected, leaving a
very small population susceptible to drug action. It is therefore crucial to assess the number of
proliferating cancer and healthy cells (and their cell cycle distribution) over time to maximize
the efficiency of the treatment (targeting the times when cells re-enter the susceptible phase),
which is not currently performed clinically. Because of its dynamic nature and complexity, it
is impossible to predict the cell cycle distribution without quantifying the cellular exchanges
taking place through suitable mathematical models. Additionally, modeling the way drugs
enter the body, are transported and react with their target cells is required to link cell kill to cell
proliferation.
One of the most prominent features of modeling biomedical systems is the existence of
phenomena occurring at multiple scales. Between molecular, cellular, patient and population
scales, appropriate translations are necessary for evaluating the effects small-scale processes
have at large scale and vice-versa [46]. Deriving patient data directly is not always possible,
thus making ex vivo observations and studies imperative. For the latter to be accomplished it
is essential to develop appropriate experimental setups that reproduce in vitro the biological
characteristics and behavior of the in vivo system. In silico techniques may bridge the gap
between the in vitro and in vivo scales, through simulating the patient response [3, 14, 47, 50].
Ultimately, clinical trials are required at the very final stage to elucidate the in vivo validity of
research findings.
Personalized healthcare is expected to deliver a step change in quality and value of care,
through more precise and personalized diagnostics as well as cost-effective and targeted ther-
apies. Some of the challenges in the delivery of personalized medicine lie in (a) In vitro: the
fidelity and validity of current experimental systems used to investigate human diseases; (b) In
silico: the integration of patient-specific and disease-specific datasets and the development of
validated predictive adaptive models; and (c) In vivo: the application of these models to iden-
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tify simple targets and more efficient, yet less toxic therapies and drugs for a specific condition.
The study of leukemia faces these challenges and many others related to the complexity of the
underlying biological system and the heterogeneity observed in hematological malignancies.
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Chapter 2
Literature review
2.1 Acute Myeloid Leukemia (AML)
2.1.1 Normal hematopoiesis
Hematopoiesis is a process that starts at the early stages of development of the fetus. Stem cells
are primarily created in the yolk sac, subsequently in the liver and spleen and finally in the bone
marrow [94]. They are the source of all the blood cell descendants, as they have the ability to
proliferate into more stem cells and to differentiate into the different blood cell lineages. When
born, the majority of stem cells are found in the bone marrow (initially tibia and femur, later
pelvis, cranium and spine), where they remain for life. However, hematopoietic stem cells
(HSCs) can still be found in the cord blood of newborns.
Differentiation in hematopoietic stem cells occurs through two different paths: myeloid
and lymphoid [69]. The myeloid progeny is formed by erythrocytes, monocytes, neutrophils,
eosinophils, basophils and platelets (from megakaryocytes). The lymphoid lineage results in
B- and T- lymphocytes and natural killer cells (Figure 2.1).
Erythrocytes are those cells in charge of transporting oxygen in blood. They are the most
common type of blood cell. Monocytes, neutrophils, eosinophils and basophils belong to the
immune system, and are also released in the blood when produced, although some of them
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Figure 2.1: Differentiation pathways of hematopoietic stem cells. [107]
are stored in other organs such as the spleen. They have several specific roles, ranging from
attacking the extraneous organisms to inflammatory response in allergies. Platelets, which are
generated as fragments from megakaryocytes, release growth factors that help regenerate the
tissue in wounds.
Lymphoid cells mature in the thymus, and are then secreted into the blood when needed. B-
cells are in charge of producing specific antibodies for antigens and T-cells carry out different
tasks in the immune system depending on their subtype. Helper T-cells assist in the activation
of the immune response. Cytotoxic T-cells react against dysfunctional or infected cells. Mem-
ory T-cells provide a faster immune response by reacting against the antigens from previous
immune reactions. Regulatory T-cells are in charge of deactivating the immune resources once
the immune reaction has been effective. Natural killer T-cells balance the responses of the
adaptive and innate immune systems. Natural killer cells have a yet unknown function in the
immune system.
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Proliferation of stem cells occurs in the bone marrow cavity [97]. This is a highly porous
and vascularised environment; blood irrigation brings in the required amounts of nutrients
and oxygen, removes metabolites and incorporates mature cells that are ready to circulate in
the body. There are two types of cells in the bone marrow: hematopoietic and stromal cells.
Hematopoietic cells duplicate and divide; they are the ones responsible for the production of
blood and more hematopoietic stem cells. Stroma cells, for their part, release colony stimulat-
ing factors and provide a connective tissue structure.
2.1.2 Development of the disease
BM failure is characterized by the inability of HSCs to produce healthy blood cells at an ac-
ceptable rate and quality, leading to a variety of health issues and diseases, including leukemia.
Leukemia is a cancer of the hematopoietic system characterized by the incapability of blood
progenitors (HSCs) to mature normally; this induces immature white blood cells accumulation
in the bone marrow [69], reducing the possibility of healthy cells to proliferate, differentiate
and travel through the blood. Leukemia can be classified into chronic or acute, depending on
the suddenness of the disease, and into myeloid or lymphoid, depending on the blood cell lin-
eage affected. Acute Myeloid Leukemia (AML) is the second most common type of leukemia
(34% of all leukemias, 2011, Cancer Research UK); it affects only cells from the myeloid
blood lineage. According to Cancer Research UK, approximately 3.4 new cases of AML occur
annually per 100,000 people in the UK alone (2011)[128].
Acute myeloid leukemia (AML) is characterized by the sudden growth of an abnormally
high amount of myeloid cells, which are in a premature stage of development. This interferes
with the normal hematopoiesis, by taking the nutrients and the space the healthy cells need to
grow. The first symptoms are a drop in blood cell count; scarcity of white blood cells results
in propensity to infections and low red cell count leads to anemia [6]. Unfortunately, those are
very generic symptoms that do not reveal the disease by themselves. The most common way
of primarily identifying leukemia is by carrying out a blood test; confirmation of this result is
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made by a bone marrow aspiration and biopsy.
As many other cancers, AML originates by successive genetic mutations caused by expo-
sure to carcinogenic events (such as certain chemicals, radiation or exposure to chemother-
apy; usually inducing a loss or gain of chromosomes) or by previous blood disorders, such
as myelodysplasia. Long-term exposure to these events leads to survival and proliferation of
cells with genetic abnormalities, that acquire reproductive autonomy. In particular, the genetic
alterations found in AML are lack of differentiation, enhanced proliferation and inhibition of
apoptosis.
2.1.3 Current treatments and pharmacology
Patients suffering from leukemia are currently being treated with chemotherapy in two phases.
The first one is the induction, where the aim is to suppress as many malignant cells as possible,
given that the patient is usually at an early stage of the disease and has substantial amounts of
healthy cells to live on. A resting period allows the patient to recover from the first dose, and
then the consolidation phase commences. In this second phase, the objective is to eliminate
the cells that may have proliferated after the first chemotherapy phase, or any cells not targeted
then. A bone marrow transplantation can be considered at this point or between the two phases,
depending on the overall health of the patient. Apart from the obvious effect of replenishment
of the healthy hematopoietic stem cells, the BM graft seems to have a positive influence on
the eradication of the cancer. One of the hypotheses is that allogeneic tissues may develop an
immune reaction against leukemic cells only [52].
Standard treatment for AML is chemotherapy, with normally two different drugs: cytara-
bine (Ara-C) and daunorubicin (DNR), given intravenously through a Hickman line. Under
a high dose treatment (DA), Ara-C is given intravenously twice a day for 10 days in a row
(100 mg/m2), while DNR is given as an intravenous pulse (50 mg/m2 for over 60s, 60 mg/m2
for under 60s) on days 1, 3 and 5. Under a low dose treatment (LDAC), Ara-C is given at a
smaller dose (20 mg) twice a day for 10 days. These chemotherapeutic drugs act at a particular
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point of cell duplication. Clinical dosage (per body-surface area, BSA) and infusion route de-
pend on overall patient fitness and age. Dosage is calculated according to the patient’s weight
and height measurements (BSA). However, leukemia exhibits a very high heterogeneity both
between patients and also within a specific patient [105]; this heterogeneity leads to unpre-
dictable treatment outcomes. Clinical treatment protocols for AML could, therefore, benefit
from a more rational and personalized treatment scheduling strategy.
In vivo specifications include all the details of the treatment (dose, schedule, infusion route
etc...), patient characteristics (age, weight, height) and any tests performed (percentage of AML
cells prior to chemotherapy, any follow-up measurements).
2.1.4 Heterogeneity
Leukemia arises when blood cell progenitors experience an aberrant combination of genetic
alterations [99] [138]; these heterogeneous clonal changes induce reduced cell death[29], in-
creased cell proliferation [56] and blockage of differentiation pathways [133]. Cooperative
effects of several mutations, as well as their order of appearance, might result in different sets
of cellular populations [135] that acquire highly unique behavioral traits [61]. Making mat-
ters worse, minority leukemic populations can become dominant by developing drug-specific
resistance that confers a competitive advantage over other subclones [78]. Ding et al. [27]
tracked the evolution of the karyotypes of cancer found over time in different patients undergo-
ing chemotherapy treatment. Only a small percentage of the clones survive chemotherapy; they
all belong to a relapse enriched karyotype that becomes resistant to the treatment and relapses
into a new, relapse-specific, karyotype. This is one of the explanations for the fact that patients
apparently cured after chemotherapy relapse after a certain period. It is important to highlight
that current tests for the detection of leukemic cells have a detection minimum that might not
be capturing the presence of extremely low amounts of cancerous cells.
The resulting disease heterogeneity is one of the main sources of variation in treatment
response between individual patients.
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2.1.5 Future and personalization
In the particular case of Acute Myeloid Leukemia (AML), most treatments focus on the sim-
pler task of tumor debulking rather than restoring normal cell function. A common type of
chemotherapy treatment for highly proliferative cells relies on cell cycle phase-specific (CCS)
drugs. CCS drugs selectively attack duplicating cells, by interfering with the processes carried
out in only one of the cell cycle phases. Importantly, CCS drugs affect not only malignant
cells but also normal cells in duplication; achieving a trade-off between eradicating the tumor
and maintaining a sufficient number of healthy cells is crucial. However, clinical treatment
protocols do not incorporate this constraint in their calculations from the start of treatment;
instead, only factors that are believed to be related to drug tolerance are taken into account
(patient’s weight, height, other diseases etc.). One of the biggest challenges in this area is that
of delivering truly personalized chemotherapy based on specific proliferative features.
2.2 Leukemia models
2.2.1 In vitro models
New treatment strategies are routinely validated first in vitro before proceeding to be tested in
vivo. However, it is often the case that promising experimental results prove to be ineffective
when applied in clinical trials. Many hypotheses have been formulated as to where the source
of this discrepancy might reside. Patient recruitment surely plays an important role, due to
the inherent heterogeneity of the disease [126]. But there is little focus on bridging the gap
between ex vivo and in vivo cell growth behaviors to extract reliable patient data that is both
relevant for the clinicians and valuable for the development of more accurate models. Cell
proliferation occurs when favorable environmental conditions are met - they are the aftermath
of an appropriate ex vivo culture system.
The activation of the proliferative pathways in vitro will depend on how well the cell culture
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conditions meet the cells’ requirements. In particular, matrix morphology and composition as
well as growth medium characteristics play a key role in biological signaling pathways [7].
2.2.1.1 2D models
Traditional 2D culture systems constitute high-throughput platforms that are easy to handle
and give reproducible results [125]. However, their lack of three-dimensionality (restricting
the surface and space available for cells to settle, but also forcing them to become flattened)
and the addition of exogenous growth factors at non-physiological levels make the relevance
of their output questionable for the translation to in vivo[33]. Accordingly, it is crucial to
reproduce experimentally an environment that mimics the physical and chemical properties of
the extracellular matrix (ECM) if patient-specific AML kinetics are to be derived.
2.2.1.2 3D models
Several 3D systems have been developed that reproduce more explicitly the microenvironment
found in the bone marrow, and comparing their performance against 2D reveals that the “good-
ness of a culture” needs to be redefined [97, 26].
Integrins, which are the cell surface proteins in charge of liaising between the cell and its
environment, are highly sensitive to the mechanical and chemical properties of the ECM. In the
bone marrow, the ECM is organized in niches that present high porosity and interconnectivity,
allowing for cell migration and chemical signals and at the same time providing sufficient space
for cell attachment. The surface of these niches is rich in adhesion proteins (such as laminin,
fibronectin and collagen) that are secreted by the stroma. These proteins selectively serve as
anchors to different types of integrins (α and β ); this suggests that specific environments will
suit cells with a particular set of integrin receptors. Malignant cells have been reported to be
heterogeneously responsive to different ECM characteristics [11], but also responsible for their
modification [59, 85] in a bidirectional manner. In addition, integrins from neighboring cells
can also bind to each other. Once the connection (cell-cell or cell-matrix) has been made, inte-
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grins inform the cell and a set of intracellular signaling pathways is initiated. The downstream
events taking place in the cell are of three types: proliferation, differentiation and apoptosis.
Mediation occurs through the expression of protein kinases, which are known to play an im-
portant role in the regulation of the cell cycle by binding cyclins and favoring entrance and
progression through the cell cycle [116]. Once a cell leaves its non-proliferative state, it enters
the cell cycle, where it stays sensitive to environmental cues (which can lead to exit from it or
even apoptosis if required).
Environmental niches play an important role in drug resistance by protecting the cells from
the cytotoxic substances. Increasingly, efforts in vitro are being directed to reproducing the
BM microenvironment in order to capture the undesirable phenomena observed only in vivo.
As a matter of fact, Garrido et al. [39] tested the effect of chemotherapeutic drugs (cytosine
arabinoside (Ara-C), daunomycin) on AML primary cells, and on the same cells co-cultured
with a BM stroma cell line (the function of stroma cells is to support stem cell growth by
producing growth factors and enhancing cell adhesion). Interestingly, the cells co-cultured
resisted better the chemotherapy than the primary cells alone, in addition to increasing their
proliferative potential and overall survival.
Dainiak et al. [19] followed a different approach, culturing cells of the KG-1 AML cell line
in macroporous hydrogels (modified to present different surface characteristics) and treating
them with Ara-C. After 18h, there was no statistical difference in the cell numbers in compar-
ison to the controls, while the standard 2D cultures showed a decrease in the cell population.
Similar observations regarding 2D systems being more responsive to cytotoxic drugs than their
3D counterparts have been reported for other cancers, in particular endometrial cancer [15],
lung cancer [91] and ovarian cancer[71].
In parallel with the extracellular proliferative events, intracellular response to chemother-
apy needs to be defined. In the case of Ara-C (one of the most commonly used drugs for the
treatment of AML), there are two main important consequences: cytotoxicity on S-phase cells
and cell cycle arrest during treatment, reducing the number of new cells resulting from cycling.
12 Marı´a Fuentes Garı´ Chapter 2
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Radosevic et al. [108] studied the intracellular events taking place during treatment with Ara-C
at different experimental levels for 41 fresh patient samples. G1-specific cell cycle proteins
(pRb (at higher levels only), cyclin E and cdk2) were overexpressed, indicating a correlation
between cytotoxicity response and cdk2 levels in particular. Increasing doses of cytosine arabi-
noside progressively enhanced the expression of other proteins (p21). In addition, they report
a relationship between the scheduling of treatment and the cell cycle regulatory mechanisms.
The right combination of time and dose seems to lead to optimized chemotherapy treatments
with higher apoptosis rates (not always with the highest dose of Ara-C). Cyclin D2 in conjunc-
tion with pRb seems to be responsible for the lineage affected: higher levels (cycD2+/pRb+)
potentially indicate myeloblastic lineages will be produced while lower levels (cycD2-/pRb-)
mainly result in monocytic descendants. In contrast, cyclin E seems to be responsible for the
proliferation status, as would be expected in normal systems. When stimulated with growth
factors, cells are recruited into the cell cycle and exhibit cyclin E production.
In this sense, in vitro 3D systems provide more realistic observations than their 2D coun-
terparts.
2.2.2 In vivo models
Animal models have been used extensively in the study of drug delivery and absorption, as
well as in understanding origin and evolution of the disease. Some examples are the discovery
of the important role of stroma in chemotherapy response [90], the possibility of activating
healthy cells of the immune system against AML cells [54, 73], or the finding that leukemic
stem cells only represent a very small fraction of all leukemia cells in a patient [65]. Drugs
such as cytarabine have emerged thanks to research carried out using animal models [123].
Xenografts, involving the addition of primary patient samples into animals, have been suc-
cessfully presented where a more representative human cell behavior inside the body can be
obtained (stroma interactions, response to specific drugs) [65, 141]. In all previously cited ex-
amples, murine models have been used for AML research; rat [100] and fruit fly models [95]
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have been used to a lesser extent.
One of the major drawbacks of animal models is the fact that the animal developed leukemias
are not relevant to human leukemogenesis, since they are induced (human leukemias seldom
originate chemically) and the genetic origins cannot be tracked back. Additionally, many dif-
ferent approaches (xenograft, genetically engineered models) are required in order to assess
different aspects of disease progression, since each approach provides only partial information.
For example, xenografts on immunodeficient mice can provide useful information on leukemia
development but no results on the interaction between leukemic cells and the immune system.
For dosing purposes, appropriate translations between animal model tolerance and human
tolerance are required, which need additional resources to be formulated (mathematical mod-
eling is an example).
2.2.3 Limitations of lab-adapted cell lines
Cancer cell lines are cells originated in real patients that have been adapted to grow in suspen-
sion cultures in vitro. The existence of cell lines was justified by the need to have a consistent
cancer model to validate results across different experiments and different research groups, but
also as a convenient way to test new chemotherapeutic drugs in a more systematic fashion.
A first issue with established cell lines is the reproducibility/robustness in genetic material.
It is often the case that cell lines that initially had a particular gene acquire mutations that result
in genetically different cells. This invalidates the comparison between results of different ex-
periments, and is in fact a major concern in experimental publications with cell lines (requiring
passages - feeding cycles of 2/3 days - lower than 20 due to environmental cues enhancing
changes in genetic material after prolonged culture time).
A second and major issue in the application to clinical results is the fidelity of the cells to
the original tumor in vivo. A study of cell lines originated by 6 cancer types showed that they
resembled more to each other than to the original, primary cells from which the cell line was
established [41]. Cell lines are often fast growing, with doubling times ranging 15-70h and
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very small fractions of the total cells remaining in a resting state, as opposed to their primary
cell counterparts, which generally consist of a large fraction of quiescent cells and a smaller
fraction of cells proliferating with heterogeneous kinetics. Culture factors also contributing to
their enhanced proliferation include abnormally high amounts of glucose, oxygen and growth
factors [42]. Finally, the heterogeneity of the disease itself, within and between patients, limits
the relevance of the results obtained to individuals possessing the leukemic clones remaining
in the established cell line.
A final consideration, which has been discussed in the previous section, is the culture en-
vironment and the way it influences the growth of leukemic cell lines as compared to primary
cells cultured under the same conditions. Drug sensitivity is an especially significant domain
since primary cells are more often quiescent and therefore more resistant, while cell lines pro-
liferate more often and faster, becoming more susceptible. Increasingly, cell lines are being
used for specific aspects of research only, but alternative experimental models (such as animal
models or primary cells in appropriate culture systems) are required for translation into human
relevant findings (for example whenever the interaction with other organs or rates of absorption
are required).
2.3 Leukemia in silico
2.3.1 Pharmacokinetics
Pharmacokinetics (PK) models the absorption, distribution, metabolism and excretion (ADME)
of drugs or other compounds administered to react with one of the body compartments [111,
25]. They typically represent the organs involved in any of the ADME processes as compart-
ments i (i ∈ B: brain, H: heart & lungs, G: gut, L: liver, PN: pancreas, K: kidney, P: muscles
and skin), resulting in a PK multi-compartment mathematical model, and blood flow or other
transport processes as exchange connections (QXi ). A very simple (for a chemical engineer)
set of compartments exchanging the compound administered through mass balances is created
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(Figure 2.2). In the case of chemotherapy, the drug is delivered subcutaneously (skin patch)
or intravenously (hickman line). Subcutaneous delivery is modelled with a delay due to a pro-
longed absorption rate through the skin into the blood, but also limits the final concentration in
the blood according to the bioavailability of the drug (part of it is lost during diffusion). It is
then transported through the body following the mass balances in each organ:
dXi
dt
= Qi ·
(
Cin− XiPi ·Vi
)
(2.1)
where Xi is the concentration of the drug in organ i, Qi is the blood flow into the organ, Cin
is the concentration of the drug in the arteries, Pi is the tissue over blood partition coefficient
(adimensional, grams of tissue over grams of blood) and Vi is the volume over compartment i.
The drug is finally excreted (via urine in this case), which is accounted for with an additional
negative term.
Models accounting for all body organs interacting with the drug (one per compartment) are
known as physiological models while those that group organs into compartments in any way
are denominated compartmental models.
PK modeling is central in the in vitro to in silico translations since drug transport and
metabolism can only be studied in animals which do not have the same ADME rates as humans.
2.3.2 Pharmacodynamics
Pharmacodynamics (PD) models the effect of the compound at the target point of action. Typi-
cally, pharmacodynamics are based on in vitro studies (on primary cells or animal models) that
correlate drug dose/concentration reaching the target cells to actual effect. For chemotherapy,
dose vs cell kill % curves are used to select appropriate dosing (Figure 2.3). EC50 represents
the dose producing 50% of the maximal effect, Emax, which results in 50% cells killed in the
case of chemotherapy. Dose-response models are widely used in PD models such as linear,
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Figure 2.2: Representation of a hypothetical PK model with organs as compartments and blood flow as
exchange route
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Figure 2.3: Sample dose-response curves for two agents: a strong (effective) agent in blue and a weak
(ineffective) agent. A low dose of the strong agent affects 50% of the cells, while the same dose of the
weak agent would have no effect.
log-linear and Emax models. Sigmoid Emax models have the following form:
E =
Emax ·Cn
EC50+Cn
(2.2)
where E is the effect seen at drug concentration C, n is the shape factor and Emax is the maximal
response observed.
For an accurate representation of PD, detailed PK models are essential since they provide
the available dose at the target point of action (C). Of note, the actual EC50 found in vitro is
normally used directly in the PD model (without accounting for animal-to-human or ex vivo-
to-in vivo translations).
2.3.3 The Pefani et al. PK/PD model
Increasingly, implementing more advanced pharmacokinetic/pharmacodynamic models be-
comes critical for applying personalized treatment. Additionally, linking a small subset of
measurable variables to unique individual characteristics is necessary[24]. Ultimately, apply-
ing such a tool could inform not only optimal timing and type of personalized treatment for
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Figure 2.4: Schematic of the interactions between PK, PD and cell cycle components of the Pefani et al.
[102] model, together with input of patient data.
improved outcomes, but also provide a platform for pre-clinical assessment of novel targeted
therapies for leukemia and other cancers [48].
Pefani et al. [101, 102] developed a PK/PD model simulating and optimizing chemother-
apy treatment for leukemia, from the time the drug is given to the patient, followed by the
circulation in the body until it reaches its target (the bone marrow where leukemia resides) and
finally the calculation of its effect according to cellular susceptibility (defined by the prolifera-
tive state). Figure 2.4 represents an overview of the simulation / optimization model structure.
For simulation purposes, the particular drug and schedule (chemical stimulation) chosen by the
doctor is used as a known input for the model.
Pharmacokinetics (PK) considers the transport and transformation the drug undergoes once
it reaches the blood stream, and in turn the relevant organs which absorb it at different rates.
Mass balances are performed in each of these organs, giving the drug concentration profiles.
Parameters for this compartment include patient characteristics and treatment schedule, which
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can be derived from clinical data (always reported).
Chemotherapy interacts with cells that are proliferating; more specifically, only cells that
are in one of the cell cycle phases (i.e., duplicating cells) are eliminated. Accordingly, detailed
cell cycle equations, modeling the point of drug action are needed. Drug pharmacodynamics
(PD) can be applied in this way to the susceptible cell cycle compartments of the proliferating
populations. The drug concentration profiles calculated in the PK model are the only input
required for the PD model, in which the drug effect on cell growth is computed according to
cell cycle kinetics of each population. Since healthy cells also proliferate in order to renew the
cellular material, they will equally be affected; it is very important to keep a balance between
the number of cancer cells killed and the loss of healthy cells.
In Pefani et al. [101], cell growth is modeled differently for normal and abnormal cells.
Because most of the cancer cells are proliferating, the cell cycle model in this case incorporates
3 compartments in which the cells are non-resting: G1, where cells grow and stock up on
nutrients; S, where cells duplicate their DNA; and G2/M where cells divide[83]). Each of them
is described by the mass balance between compartments (including cell death by drug action if
applicable). The transition rates are dependent on cell cycle times and natural apoptosis rates
in each of the phases [8]. Cell cycle kinetics are modeled through a set of Ordinary Differential
Equations (ODEs) (one per compartment) [102]. The normal cell population model considers a
proliferative population and a resting population that can move into a proliferative state, which
are modeled as delay differential equations. Duplication times of leukemic cells can be inferred
from the number of cancer cells before and after treatment (if clinically performed). However,
more specific information on the distribution within each phase is unavailable clinically and
has to be determined experimentally (if required).
Cellular metabolism is an important phenomenon in the area of cancer, as it influences
both the tumor growth rate and its susceptibility to drugs. To mathematically model cellular
metabolism, a mechanistic description of those phenomena is essential. Advanced genetic and
metabolic laboratory analysis will enable the accurate correlation of environmental stress with
20 Marı´a Fuentes Garı´ Chapter 2
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
the cell cycle via the detection, selection and quantification of intracellular biomarkers that
have a key role on the cell stress response. Mathematical models linked to cell growth have
been also developed [60] which could be used to further personalize treatment for patients with
hypo- or hyperglycemia, diabetes, etc. No information on cellular metabolism is provided on
clinical reports; any data required for parameter estimation must be obtained from experiments
on the leukemic cells.
2.4 The cell cycle
2.4.1 Biological processes occurring during the cell cycle
Cellular proliferation is the macroscopic result of single cell duplication through a process
known as the cell cycle, which occurs in four phases (G1, S, G2 and M) that are governed
by the periodic expression of cyclins (Figure 2.5) [20]. Cyclins are a set of proteins that bind
to cyclin-dependent kinases (cdks, present in non-limiting concentrations), triggering events
taking the cell to the next phase [103].
Periodically, and given favorable environmental conditions, cells exit their resting state
(quiescence - G0) and enter G1 (gap 1), in reaction to increasing cyclin D expression. During
G1, they stock up on nutrients and grow in size to accommodate the new cellular material that
will be created. In addition, an intracellular regulatory protein is produced (cyclin E) that sums
up the overall progress in completing the G1 tasks - the higher the level of cyclin E, the closer
the cell is to being prepared to move to the next phase. Once the cyclin E expression threshold
is reached, cyclin E binds to its partner cdk (primarily cdk-2) and triggers the phosphorylation
of other proteins that in turn activate the DNA duplication mechanisms in the nucleus. Cells
enter now the DNA synthesis (S) phase. During this phase, cells can be distinguished by their
increasing DNA content and the production of cyclin A. As soon as these cells have finished
the DNA synthesis, they are said to be in G2 (gap 2). In this phase, they check for errors
in the DNA duplication and they prepare for division. Progression in G2 is reflected by an
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Figure 2.5: a. Schematic of the cell cycle; and b. key regulatory proteins involved in transitions from
phase to phase.
increase in cyclin B expression, a protein that, similarly to cyclin E in G1, accumulates as G2
tasks are completed. Once its threshold expression is reached, cyclin B binds to its partner
cdk (cdk-1) and results in the commencement of mitosis (M) [51, 74]. During M phase, each
of the chromosome pairs migrates to one side of the cytoplasm until the membrane physically
divides, giving birth to two new G0 or G1 cells.
2.4.2 Relevance of the cell cycle in leukemia
Cyclin expression and cell cycle phase duration of hematopoietic cells are similar between
healthy individuals; however, patients suffering from leukemia present extremely discrepant
phase durations [105] and characteristic overexpressed/unscheduled cyclin patterns in a patient-
specific manner [43]. Additionally, cyclin E expression can be used as a prognosis marker in
AML [53] and has potential in the development of new therapies [75]. Together, cyclin expres-
sion patterns and cell cycle times can serve as a unique signature to identify patient-specific
disease characteristics in a simplified manner. This is of vital importance for the development
of more accurate cell cycle models that can be incorporated into the design of optimal person-
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alized treatments.
2.4.3 Mathematical models of the cell cycle
There are several ways to describe cell culture growth [121]. Depending on how deep the de-
scription needs to be for the purpose, models consider a segregated or unsegregated culture.
Segregated models take into account the existence of different populations within the same
culture (based on certain properties that are characteristic of each population) while unsegre-
gated models describe the culture as a whole, considering the properties are the same for every
cell (an average of the total). A second criterion divides these models in structured or unstruc-
tured. If there is a need to describe part of the processes that take place inside the cell, then the
model will consider a structured cell (either the organelles where reactions really take place
or compartments that accommodate groups of reactions but that do not need to exist in such
form in a real cell). Otherwise the model will just describe the cell as a block without taking
into account the inner processes, only the exchanges with the medium around it. Typically,
mechanistic models provide a very detailed representation of processes at the single cell level
(unsegregated, structured) while descriptive models give a more macroscopic view at the cell
population level (segregated), either unstructured (all descriptive models) or structured (some
population balance models)[2].
2.4.3.1 Mechanistic models
Mechanistic models typically represent protein networks or other biological signals (“high
amounts of transition protein cyclin E will result in likely transition to S phase”) in an effort
to explain the underlying causes for cell growth[137, 122, 63]. In this approach, the system is
represented from the individual point of view of a single cell where it moves within and be-
tween phases as time goes by (discrete cells, continuous phase progression). Protein levels are
modelled via ODEs, linking activation/deactivation processes to the levels of other regulatory
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Figure 2.6: Hypothetical regulatory network and interactions with protein A
proteins in the form (Figure 2.6):
d[A]
dt
= kB→A · [B]+ kD−E→A · [D] · [E]− kA−F→C · [A] · [F ]− kA→G · [A] (2.3)
Not all terms in the presented equation need to be included. The first term, kB→A · [B],
accounts for protein A production starting from component B, at a rate kB→A, while the final
term kA→G · [A] accounts for the same behaviour for G, starting from A. kD−E→A · [D] · [E]
and kA−F→C · [A] · [F ] respectively represent production of A in the reaction of D and E and
consumption of A reacting with F for the production of C. Other interactions are possible
between components other than A, but they are not taken into account in this example.
However, this is very computationally expensive given the need to model millions of cells
[122], and this in-depth single cell data is not needed and not always experimentally feasible
to gather. A trade-off between accurate intracellular process description and a limited param-
eter number (for experimental reasons) has to be reached. Experimental limitations such as
the difficult (if not impossible in some cases) determination of reaction rates of intracellular
processes are also a drawback to detailed regulatory models.
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2.4.3.2 Descriptive models
Descriptive models represent observable cause-effect phenomena (“one cell gives birth to an-
other cell after 24h”) as an explanation of the overall system behavior [22, 32]. Prior work has
mathematically modeled cell cycle phase compartments using ordinary differential equations;
these models indicate how the total cell number changes in each phase as a function of time. A
very simple 3 compartment model with transition between phases and cell death in each phase
is exemplified in Figure 2.7 and the equations outlined below:
dG1
dt
= 2 · k3 ·G2M− k1 ·G1− kG,d ·G1 (2.4)
dS
dt
= k1 ·G1− k2 ·S− kS,d ·S (2.5)
dG2M
dt
= k2 ·S− k3 ·G2M− kM,d ·G2M (2.6)
Viable = G1+S+G2M (2.7)
dDead
dt
= kG,d ·G1+ kS,d ·S+ kM,d ·G2M (2.8)
Phase compartments can be subdivided into the main cell cycle phases (G1, S, G2 and M)[8],
or aggregated phases (G1, S and G2M) [101], or even into two subgroups of fast and slow pro-
liferating cells, each having three phases (G1, S and G2/M)[23]. More complex representations
include cell cycle phases (G1, S and G2/M) together with a nonviable cell compartment and
an apoptotic compartment [96]. This time-based simplification usefully captures macroscopic
responses of cellular populations, but a more detailed description of the system requires: (i)
defining the position of the cell within the phase and (ii) validating intra-phase kinetics exper-
imentally.
A more efficient and tractable approach is to observe the circulation of cells in time at a
specific point within the phase through a population function (continuous cells, continuous
phase progression) [121]. This results in a model that is dependent on time but also on a state
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Figure 2.7: Hypothetical descriptive compartmental model of the cell cycle with 3 phases and cell
death
variable that distributes each phase considered into a continuum of populations, known as a
population balance model (PBM) [119, 38].
2.4.3.2.1 Population Balance Models (PBM) and relevance to the cell cycle
Hybrid mechanistic/descriptive approaches have arisen, benefiting from the advantages of both
(the in-depth insights in mechanistic models, and the fast computation of key variables in
descriptive models), of which PBMs are a clear example.
PBMs are descriptive mathematical models that classify single entities according to a state
variable (property), which represents a form of progress within the system. Single entities
with the same properties are grouped into a population; different populations exchange single
entities (vary in number) with time and in accordance with the rate of increase of state variable.
The resulting equations are therefore dependent on time and a second variable (sometimes even
a third); hence, for the analysis of changes in the system both need to be considered. The
standard equation for a population balance is the following[104]:
26 Marı´a Fuentes Garı´ Chapter 2
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
∂F(x, t)
∂ t
+
∂
∂ t
[
F(x, t) · dx
dt
]
= Entrance(x, t)−Exit(x, t) (2.9)
where:
• F(x, t) is the population distribution function
• x is the vector of state variables
• ∂∂ t
[
F(x, t) · dxdt
]
is the growth, or evolution of a particle with property x
• Entrance(x, t) represents the particles that enter the population
• Exit(x, t) represents the particles that exit the population
Inevitably, the mass balance in this type of system comprises partial differential terms to in-
dicate progress of the populations with time and with the state variable, and integral terms to
account for the summation of entity populations stemming from different state variable levels,
that have reached a transition state [109]. This type of model is relevant to the cell cycle in
that it allows tracking the movement of cells inside each phase through the increase in the state
variable, and interprets the transition between phases as the summation of exiting populations
from different parts of the phase.
Solving PBMs explicitly is practically impossible in most cases; the complex task of state
variable space discretization is often required. PBMs are relevant to the cell cycle in that they
enable tracking of the movement of cells inside each phase through the increase in the state
variable and interpret the transition between phases as the summation of exiting populations
from different parts of the phase. Typically, PBMs of the cell cycle consist of three stages,
namely an aggregated G0/G1 phase, S phase and an aggregated G2/M phase [120]. Tradition-
ally, properties such as cell age, size or volume have been used as state variables. Age-based
PBMs cannot be directly validated as age is not a biological property; it can be used as a mathe-
matical artifact theoretically correlating phase coordinate to phase time; however, perturbations
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in the transition state cannot be explained by time alone [119]. Size- and volume- based PBMs
have perhaps more relevant qualitative biologically-meaningful state variables; high variabil-
ity in the experimental data renders validation of these models extremely difficult requiring
the estimation of the necessary parameters [70]. Some approaches to model proliferative and
quiescent compartments (with unrealistic constant transition rate from proliferative to quies-
cent compartment) according to cyclin D vs age have been proposed at the mathematical level,
without any experimental validation [10]. Finally, whereas DNA content is a very good state
variable choice for S phase, where it is synthesized and can be measured, it bears no relevance
to the progress of cells in other phases. Consequently, traditional PBM models cannot inform
experiments with regards to the expected state variable level (since it is either a “virtual” state
variable or very difficult to measure); only models that specifically predict cellular properties
(for a single cell) explicitly quantify these levels, but at the expense of macroscopic growth
[127, 136]. Hence, there is a need for cell cycle PBMs that can be seamlessly validated ex-
perimentally and for explicit models of cell cycle checkpoints which can incorporate growth
kinetic behavior.
Pefani et al. [102] previously showed that assessment of proliferation kinetics and cell cycle
times in AML may provide optimized chemotherapy protocols in order to improve tumor cell
kill yet minimize toxicity for the patient. Defining the changes that occur in the cell cycle
is central to these optimized treatment protocols since many chemotherapeutic drugs are cell
cycle phase-specific and heterogeneity of patient responses may be broadly defined in terms of
cell cycle phase distributions and timings [105].
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2.5 A platform for the delivery of personalized chemother-
apy: application of the design framework to the treat-
ment of leukemia
The design framework developed at the Centre for Process Systems Engineering [129, 36] es-
tablished the interactions between the in vitro, in silico and in vivo environments in biomedical
systems, and for each of them, the specific scales at which processes that are of interest occur.
From the environment point of view (represented as columns on Figure 2.8), biomedical
systems’ processes are captured in vivo, in vitro and in silico. Clinical chemotherapy treat-
ment is composed of an in vivo component, corresponding to a particular patient undergoing
medical treatment. Patient characteristics (in vivo specifications) and details of the treatment
clinically administered are used to derive patient-specific parameters. Body processes affecting
or affected by the medical treatment in vivo are rendered in silico through appropriate math-
ematical equations that simulate patient response. Sensitivity analysis on the model points
out which model parameters are most significant. If those parameters are not available from
in vivo measurements, experiments have to be designed in order to specifically obtain the re-
quired parameters in vitro. Finally, in silico optimization calculates the optimal scenario on a
case-by-case basis, by delivering values of the operating variables for maximizing treatment
efficiency / minimizing side-effects / minimizing treatment cost, in accordance with medical
constraints.
From the scale point of view (represented as rows on Figure 2.8), biomedical systems’ cir-
cuitry can be defined as the abstract representation of physiological processes into a network of
compartments where exchange and/or reaction can take place at different levels. These physio-
logical processes are subject to external cues that are tunable depending on medical/biological
needs. Thus, the backbone of the design framework is composed of the following elements, un-
der all three environments (in vitro, in vivo, in silico): (i) chemical stimulation: administering
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molecules capable of interacting with cellular material for inducing the desired transformation;
(ii) molecular transport, either with biological modification (activation, degradation, elimina-
tion) or unmodified, to the target point of action; (iii) effect: molecular interaction with the
target cells to transform their characteristics towards the desirable outcome; (iv) cell growth:
stem cell proliferation, defining overall cell number which could then become susceptible to
transformation; and (v) cell metabolism: cellular interaction with its environment to exchange
the resources needed to sustain cell growth. Note that not all systems need accurate represen-
tations at all scales.
30 Marı´a Fuentes Garı´ Chapter 2
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Figure 2.8: A framework for the design and optimization of biomedical systems (highlighted in
orange with black arrows) and its application to personalized leukemia treatments (in blue). Scales are
shown as rows, environments are shown as columns. The areas covered in this thesis are highlighted in
red.
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Chapter 3
Aims & Objectives
The development of a more rational approach to leukemia chemotherapy dosing and schedul-
ing is required. The cell cycle is at the center of leukemia heterogeneity, therefore a detailed
mathematical model capturing patien and clone heterogeneity is needed. Population balance
models (PBMs) are particularly suitable as they account for phase-specific property changes of
single cells to describe the evolution of the whole population. Previously developed cell cycle
PBMs were structured in mass/size [58] or age [119] (or a combination of both). Experimental
determination of these properties for a single cell is not trivial; in the particular case of age,
indirect measurements involving labeling of a subpopulation over time need to be performed.
These limitations, together with data vs. model fitting differences, highlight the need for a
PBM structured on measurable properties that naturally contribute to cell growth.
The objective of this thesis is to develop a detailed PBM of the leukemia cell cycle in silico,
capturing patient-specific and disease-specific features, which can be seamlessly validated in
vitro, and provide a first approximation to the way this could be applied in vivo.
The cell cycle is inherently regulated by the scheduled expression of cyclins, which activate
their partner cyclin-dependent kinases (cdks) in a phase-specific manner leading to progression-
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related events. The experimental detection of these regulatory proteins in parallel with DNA
content is now possible [92]. In this work, we develop the experimental methods to track cell
population over one cell cycle and record cell cycle characteristics (cyclin expression, phase
fractions) unique to the particular cell line (Sections 4.1- 4.2) and we assess the impact of
culturing cells in suspension culture (2D) instead of more native environments (3D scaffolds).
Moving towards primary cells, we apply some of the methods developed in 2D to the 3D cul-
ture of patient samples with promising results (Section 4.3).
The population balance model is validated against experimental cell cycle data of four dif-
ferent leukemia cell lines and used to predict backward and forward co-culture evolution, as
well as to identify clones based on their cell cycle kinetics (Section 5.1). It is then compared
against two other types of differential models (ODE and DDE) in their ability to fit experi-
mental data, satisfy short-term and long-term kinetics and capture the oscillatory properties
inherent of the cell cycle (Section 5.2). The models are then coupled to a PK/PD model and
their sensitivity to chemotherapy treatment is compared (Section 5.3). Finally, the coupled
population balance - PK/PD model is used to demonstrate that clonal heterogeneity in cell
cycle kinetics plays a key role in chemotherapy outcomes (Section 5.4).
Further, this research highlights the importance of accurately representing biological events
and paves the way in bringing PK/PD methods into the clinic. Additionally, the use of this
platform could be considered to test treatment outcomes ex vivo and for the development of
new drugs, as well as for off-line personal healthcare assessment.
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Chapter 4
In vitro platform
An appropriate in vitro platform is required to faithfully capture leukemia dynamics ex vivo. As
part of the framework, the in vitro environment aims at carrying out the experiments defined in
silico, providing sufficient data to extract the required model parameters and serve as a suitable
platform to execute ex vivo tests in parallel with the patient treatment.
In this chapter, the existing in vitro 3D bone marrow mimicry for the culture of leukemic
samples will be assessed and compared against traditional 2D culture systems. The viability of
culturing patient cells in the 3D system and gathering valuable patient-specific measurements
will be evaluated. The experimental methods required to obtain the necessary static and dy-
namic parameters for the models will be developed in 2D as proof-of-concept. Preliminary
results with primary cells will be presented, certifying in vivo applicability upon collection
(static data). Finally, the methods required to grow several leukemia cell lines in co-culture as
a representation of clonal heterogeneity will be reviewed, as well as the procedures to identify
and quantify each of them through flow cytometry measurements.
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4.1 Comparison of suspension and three-dimensional culture
conditions
4.1.1 Introduction
The hematopoietic niche is a highly porous and well vascularized medium, where stem cells
are able to interact with the environment and proliferate naturally. Therefore, the experimental
platform where these cells are expanded also needs to be porous, allow the flow of nutrients
and the contact of the cells to the walls and other cells. Cell-cell and cell-matrix contact
enhances the release of signals that in turn promote the proliferation and differentiation of
cells. Hematopoietic cells are naturally anchorage-independent (i.e. they do not attach to
surfaces to grow). However, their growth is supported by the interaction with stromal cells
that establish adhesion protein matrices (such as fibronectin or collagen physical signals) and
produce cytokines (growth stimulation compounds - “chemical signals”).
Long-term culture of hematopoietic cells in suspension traditionally required the presence
of cytokines, but their dosage is usually uncontrolled and growth does not occur at the in vivo
rate (and the cellular results in terms of cell heterogeneity/viability are not the same). Mortera-
Blanco et al. [84] hypothesized that the establishment of a microenvironment with similar
characteristics as the BM would enhance the growth of hematopoietic cells without the need of
exogenous cytokines.
The 3D structure of the environment was reproduced experimentally by a scaffold with
thousands of interconnected pores, which is made out of a polymer material that is biocom-
patible (does not modify the cells) and non-biodegradable (the cells do not modify it). They
showed that polyurethane (PU) scaffolds (in comparison to scaffolds made out of other ma-
terials) represent a good biomimetical platform for the expansion of AML cells, thanks to
their adequate properties in terms of porosity (%), pore size and surface area. Three different
AML cell lines (HL-60, K-562 and Kasumi-6) were seeded in polyurethane (PU) and poly (L-
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lactic-co-glycolic acid) (PLGA) scaffolds for 8 weeks [11]. The growth kinetics (MTS assay:
representative of enzymatic activity and correlated to number of viable of cells, although not
quantitative) of the cell lines were different, but the PU platform was suitable for the expansion
of all three, and they were viable after nearly two months of culture. As compared to PLGA,
PU gave better results in terms of cell growth in particular for the peak values of absorbance
and maintenance over time.
In addition, Blanco et al. [11] repeated the experiment adding a protein coating prior to
seeding, to emulate the extra cellular matrix present in the bone marrow, which is usually made
out of collagen, elastin, fibronectin, laminin and others. They observed that when coated with
collagen and/or fibronectin and compared to a control uncoated scaffold, the growth kinetics
(MTS assay) were better than without coating, and in some cell lines (Kasumi-6 particularly)
remarkably better, especially at 4 weeks’ time or more. The seeding efficiency was approxi-
mately the same in all cell lines, with or without coating. The one that gave positive results for
all of them (although not best in all the cases) was the collagen coating of 62.5µg/mL.
The next step in the BM biomimicry was the incorporation of fluid and gas circulation. A
pipe bioreactor consisting of a long, cylindrical-shaped scaffold with an inlet and an outlet was
designed by Wu et al. [140] for the support of leukemic cell growth. Macedo [72] upgraded the
existing bioreactor for the production of red blood cells. Simultaneous feed of nutrients and
oxygen and removal of metabolites and CO2 was achieved by the incorporation of selectively
permeable membranes. The hollow-fiber bioreactor (HFBR) consists of a hollow fiber, through
which nutrients are supplied and metabolites are removed, and a scaffold where the cells are
seeded. The hollow fiber walls are permeable to those smaller molecules but not to the cells.
By continuously supplying new medium and removing the old one, the conditions are kept
even closer to the optimal ones in the human body. Robust superstructure optimization of the
bioreactor was later on carried out defining the reactor design and operating conditions for a
more cost-effective operation [79, 80].
These results were obtained in cytokine-free conditions; cord blood stem cells are usually
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not viable after one week culture in suspension conditions without those growth factors. This
highlights the potential of the HFBR to mimic, without interfering, the growth of different
types of blood cells for the study of hematopoietic processes.
4.1.2 Aims & methodology
The objective of this 2D vs 3D comparison is to assess the experimental inaccuracy of per-
forming experiments in standard 2D conditions. Additionally, it will provide an starting point
for future experiments, in which adequately mimicking the human BM is required to support
the growth of patient samples, providing the mathematical platform with patient-specific cell
cycle data that will govern the PBM.
4.1.2.1 Production of 3D polyurethane scaffolds
An artificial 3D microenvironment that mimics the one found in the BM, wherein hematopoi-
etic stem cells reside, was previously developed in our research group. It successfully sup-
ported long term culture of AML cell lines [11] and cord blood cells [84] without the addition
of exogenous cytokines, which can modify the natural kinetics of cell growth. 2D versus 3D
experiments are performed to demonstrate the heterogeneous response of AML cell lines to the
two different environments.
4.1.2.1.1 Scaffold fabrication
First, the PU solution is prepared by dissolving 3g of PU pellets in 60mL of 1,4-dioxane at
80°C overnight, which is then left to cool down at room temperature. Next, the liquid solution
is poured into a 10cm wide Petri dish, which is introduced in a lyophilization flask and sealed.
The whole is then placed at -86°C in the freezer for 2h to solidify. The solvent is then extracted
under vacuum at -15°C and collected by sublimation with liquid nitrogen in a Dewar. When
60mL of liquid solvent have been collected, the foam is ready to be used.
For cell culture, the PU disc is cut down into 5x5x5mm cubes. Because of the softness of
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the material, the PU disc has to be immersed in liquid nitrogen, then taken out and immediately
cut using standard shaving blades. The circular edges are discarded. Generally, one PU disc
prepared in this way can be cut into at least 100 5x5x5mm scaffolds. The measured average
PU scaffold density at this point was 0.9560 g/cm3 (as compared to 1.2 g/cm3 [11]).
4.1.2.1.2 Scaffold coating
Scaffolds are coated with collagen protein for enhanced adhesion. For this, a collagen solution
is prepared by dissolving collagen in phosphate buffered saline (PBS) to a concentration of
62.5µg/mL. The pH of the solution is measured and adjusted to pH=7 adding a 1M sodium
hydroxide solution (drop by drop).
The scaffolds are first dipped in 70% ethanol (50 scaffolds in 30mL, in a 45mL centrifuge
tube) for 1min, and then transferred to another centrifuge tube containing 30mL PBS for 10min.
They are transferred to fresh 30mL PBS and spinned for 10min at 2500rpm. The scaffolds can
then be transferred into a new centrifuge tube with 30mL of the collagen solution and spinned
for 20min at 2000rpm. They’re next placed into a new centrifuge tube with 30mL PBS and
centrifuged for 10min at 1500rpm. At this point they can be stored in the fridge in a newly
prepared 30mL PBS centrifuge tube for 1-2 weeks.
4.1.2.1.3 Scaffold sterilization
Sterilization is performed in two steps: first the scaffolds are dipped in 70% ethanol and then
they are exposed to UV light.
For the ethanol sterilization, the scaffolds are transferred under the laminar flow hood (ster-
ile environment) into 2mL ethanol which have previously been added to each of the wells of a
24 well plate. After 2h, the ethanol is removed and two rounds of 2mL of sterile PBS washes
are carried out, 15min each.
For the UV sterilisation, the PBS is removed and the scaffolds are exposed to UV light
directly (approximately at 15min distance from the light) for 8min. 2mL of culture medium
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are added to each well and left in the incubator at 37°C and 5% oxygen for at least two days to
check for contamination.
4.1.2.1.4 Scaffold seeding
Culture medium and sterile scaffolds are prepared and checked for contamination prior to the
start of the experiment. A 2D culture running in parallel (or primary samples) is required in
order to seed 0.5 million cells per scaffold.
To start, the old medium is removed from the scaffolds and they are replaced in the incu-
bator for temperature homogeneity, as well as the culture medium to be used. The cells to be
used are centrifuged at 750rpm for 6min, the supernatant is removed and the cells are resus-
pended to a concentration of 5M cell/mL with fresh medium. 100µL of this solution is pipetted
and introduced in each empty scaffold by carefully distributing the liquid in the largest pores
visible.The scaffolds are then left in the incubator without culture medium for 15min, to let
the cells settle. 1.5mL of culture medium at 37°C are added into each well. Every 2-3 days
(depending on the cell line), the old medium is removed and 1.5mL of fresh culture medium
is added. For cell collection (FC, viability, cell numbers), the old medium is removed by as-
piration and all the sides of the scaffold are carefully aspirated with a pipette, collecting the
cells in labeled centrifuge tubes for analysis. The extraction process possibly selects part of the
cellular population, reducing its number but also its diversity.
4.1.2.2 Cell lines
Two cell lines are used in this occasion: K-562, which are cells derived from a CML patient in
blast crisis, and MEC-1 which come from a patient with B cell leukemia. Both are available
commercially (K-562: from ATCC, cat. n. CCL-243 and from DSMZ, cat. n. ACC 497).
K-562 and MEC-1 cells were cultured first under 2D conditions and seeded into 3D scaffolds
(see protocol in Blanco et al. [11]) or maintained in suspension (2D).
40 Marı´a Fuentes Garı´ Chapter 4
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
4.1.2.3 Measurement of cellular growth
Growth kinetics cannot be evaluated through direct methods in the scaffolds (i.e. cell count),
due to the inherent cell attachment and difficulty in the extraction. For this reason, indirect
methods such as the MTS assay have to be used.
The MTS assay relies on the reducing capability of cell enzymes which is an indirect way
of measuring the number of live cells by their relative activity. MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) is added in a known pro-
portion to the cell medium and the whole is incubated at the standard conditions (37C, 5%
CO2) for 3-4hrs. The dehydrogenase enzymes reduce MTS into formazan which is a colored
substance that can be excited at 492nm. The amount of formazan produced, and therefore the
intensity of the light detected in the analysis, is proportional to the number of viable cells in
the sample.
The MTS reactant is added to the scaffolds together with fresh medium and is left protected
from light in the incubator for 3 hours. The same procedure is followed with the cells in 2D,
except that they need to be centrifuged to remove the old medium and to be placed in new
plates. Specifically:
• Cell samples are collected (seeded polyurethane scaffolds (without media) or cell sus-
pensions) and placed in wells of a 24 well plate.
• 200µL of MTS are added to each well containing a sample (and to a control without
cells), in addition to 1mL of growth medium.
• The plate is kept under sterile conditions in an incubator at 37°C and 5% O2 for 3 hours.
• 100µL of each well are placed in 10 different wells of a 96 well plate (making up to a
total of 1mL).
• The absorbance is then recorded at 490nm, and the base absorbance from the controls is
subtracted to the samples for calculation.
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4.1.2.4 Flow-cytometry analysis of cyclins and DNA content
Flow-cytometry analysis was performed weekly on the cells after centrifugation (2D) or after
manual extraction with a syringe (3D). Labeling of cells expressing cyclin E was achieved with
cyclin E antibody unconjugated (Abcam ab3927) and a conjugation step to IgG FITC antibody
(Abcam ab96879). For cyclin B, a one-step staining with a FITC conjugated antibody (BD
bioscience 554198) was performed. The final step was the addition of propidium iodide, which
binds stoechiometrically to DNA.
4.1.3 Results & discussion
4.1.3.1 2D vs 3D growth kinetics
The MTS data over the three weeks is presented in Fig. 4.1. A similar proliferation pattern was
observed for both cell lines in the 3D scaffolds: an initial phase of 9 days when the cells were
growing consistently, and later a stabilization with a few fluctuations over time. 2D growth
kinetics appear faster and do not seem to stagnate like the 3D kinetics. In order to have more
insight on the real cause for this (i.e. lack of nutrients, deficient access to oxygen etc.), analysis
of the metabolic data obtained with a bioprofiler is insightful. Scanning Electron Microscopy
images (SEM) were also obtained to confirm the presence of cells after 21 days in 3D cultures
(Figure 4.2). Observe the formation of cell aggregates in the regions where a higher surface
area is available.
4.1.3.2 2D vs 3D metabolism
Metabolites are analyzed by using a bioprofiler on the supernatants collected from the cultures
(days 11 through 28 as earlier data was lost). Glucose and lactate are tracked at every feeding
for each cell line under 2D and 3D conditions (Figure 4.3).
For K-562 in 3D, glucose fluctuates heavily, with minima at days 11 and 19, which correlate
to an increase in lactic acid production. MTS results showed 3D growth peaks on days 9 and 16,
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Figure 4.1: MTS results for K-562 (top) and MEC-1 (bottom) cells, 2D (blue) and 3D (red) growth
conditions. Three replicates were used for each data point.
Chapter 4 Marı´a Fuentes Garı´ 43
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Figure 4.2: SEM of K-562 cells (left) and MEC-1 cells (right) cultured in the scaffold after 21 days.
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Figure 4.3: Bioprofiler results for K-562 (right) and MEC-1 (left) cells, 2D (blue) and 3D (red)
growth conditions. Three replicates were used for each data point. The x-axis represents time in days
since the start of cultures.
occurring slightly before the aforementioned glucose minima. Cellular metabolism, especially
in cancer, is prone to glucose consumption, so this observation validates the hypothesis that
K-562 cells were growing on those days. For K-562 in 2D, glucose consumption stagnated
on days 16-18 and increased towards the end of culture (day 23) indicating an increase in cell
number. The stagnation was also observed in the MTS results, where days 16 and 20 had
similar absorbance values.
For MEC-1 in 3D, a very constant trend in glucose consumption/lactate production is ob-
served during days 15-24, which is overtaken by an important increase in glucose / decrease in
lactate on days 27 and 28. MTS results overlap with bioprofiler results only between days 15
and 20, where the stable growth trends are confirmed. However, the bioprofiler results suggest
there was a drastic decrease in cell number between days 24 and 27. For MEC-1 in 2D, an
initially decreasing glucose trend together with an initially increasing lactate are followed by
a constant trend in both, coinciding in value with the MEC-1 3D results. The slight decrease
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Figure 4.4: Flow cytometry data obtained for K-562 cell line Cyclin B versus DNA content. Top
panels represent day 7 (left) and day 21 (right) for 3D cells and bottom panels represent day 7 (left) and
day 21 (right) for 2D cells.
in glucose on days 14-15 corresponds to the clear increase in cell number observed in MTS
between days 14 and 16.
4.1.3.3 2D vs 3D cyclin expression
Cyclins B and E expressions were recorded against DNA content (propidium iodide staining)
in triplicate for each condition. Figure 4.4 presents the results for cyclin B expression in K-562
cells on day 7 and day 21, both in 2D and 3D conditions:
Qualitatively, cyclin B is less expressed in 3D (59.4% & 54.4% positive) cells than in 2D
(61% & 66% positive) cells. In addition, cyclin B expression on day 21 (54.4% positive)
compared to day 7 (59.4%) appears to be less frequent in 3D cells. This suggests that the
growth kinetics might be slowing down (as indeed shown by the MTS data).
4.1.4 Conclusion
From the 2D vs 3D experiment results on 2 leukemia cell lines, it was clear that kinetics were
highly dependent on environmental conditions: culture type, cell-cell contact, access to nu-
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trients are all factors that can affect cellular growth. 3D cultures expose cells to a completely
different set of environmental cues that can affect the cell cycle in yet unknown ways. A higher
proliferation in 2D than 3D was observed in terms of cyclin expression (cyclin B less expressed
in 3D than in 2D), metabolic activity (less glucose consumed and more lactate produced to-
wards the end of culture) and cell number (higher proliferation in 2D than 3D, cells in 3D
stabilize after a certain time, around 2 weeks). Further research in this area is required in the
future to elucidate the cell cycle-environment relationship and to make the transition towards
patient samples.
4.2 Obtaining cell cycle parameters in cell lines
4.2.1 Introduction
Cell lines are amenable to intensive experimentation, producing reproducible and consistent
results. They can be cultured in 2D without the need of supplements or growth factors and they
can be selected to represent specific features of the disease among the wide variety of them
commercially available. Because the first step towards applying the model requires developing
appropriate techniques to obtain the parameters and gather experimental data to validate it, cell
line culture in 2D is useful (although in the future, appropriate translations will be required to
validate these methods for patient samples for clinical relevance).
One of the most complex features of improving leukemia treatments is the heterogeneity
and abundance of clones, within and between patients. A first challenge is identifying the clonal
contents from a primary sample and assessing their prognosis. Several bad prognosis clones
have been identified clinically and are routinely tested for; similarly, some less severe prognosis
clones can be identified and treated with targeted treatments if available. A second and more
difficult challenge is predicting the dynamic evolution of the clonal pool and whether treatment
is going to be beneficial or defining what, when and how to give treatment to maximize the
probabilities of success. To make things easier experimentally, we will artificially combine
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mixtures of three of the cell lines studied in blind combinations to address the challenges of
identifying clones and predicting their dynamic evolution.
4.2.2 Aims & methodology
In this section, we will develop the methods and study the behavior of different leukemia cell
lines relative to cell cycle characteristics: measurement of cell cycle phase durations, obtain-
ing approximately synchronous cell cycle data to follow at least one cell cycle completely,
performing flow cytometry analysis of key cell cycle proteins and normalizing fluorescence
results.
4.2.2.1 Cell cycle chase experiments
The 3D culture system of Section 4.1 provides an ideal laboratory platform to culture hematopoi-
etic cells donated by AML patients, exposing to measurement parameters crucial for cancer
evolution including: cellular growth, cellular metabolism and drug effect. However, proof of
concept studies linking in vitro to in silico are required as a first step to validate the experi-
mental design and possibility to measure the parameters required. These studies are therefore
carried out with leukemic cell lines (easy to handle, lab adapted cells) under 2D conditions.
4.2.2.2 Leukemia cell lines
Four leukemia cell lines were used: K-562 (chronic myeloid leukemia in blast crisis; has un-
scheduled cyclin E production and overexpressed cyclin B [131]); MEC-1 (chronic lymphoid
leukemia, which expresses CD19); HL-60 (promyelocytic leukemia with scheduled cyclin E
expression and uncheduled cyclin B expression in G1 phase[43]) and MOLT-4 (acute lym-
phoid leukemia, has scheduled cyclin E and B [43]). K-562 (ATCC, MD, USA) was cultured
in Isocove Modified Dulbecco’s Medium (IMDM; Invitrogen, CA, USA) with 10% heat inacti-
vated Fetal Bovine Serum (FBS; Invitrogen) and 1% penicillin-streptomycin (P/S; Invitrogen).
MEC-1 (DSMZ, Germany) cells were cultured in IMDM + 20% FBS + 1% P/S for 1 week,
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and in IMDM + 10% FBS + 1% P/S thereafter. HL-60 (ATCC) cells were cultured in IMDM +
20% FBS + 1% P/S. MOLT-4 (ATCC) cells were cultured in RPMI-1640 (Invitrogen) + 10%
FBS + 1% P/S. All cells lines were used at passage numbers (feeding cycles of 2-3 days) lower
than 20.
All four cell lines (K-562, HL-60, MEC-1 and MOLT-4) were processed independently fol-
lowing the same protocol. One day prior to the experiment, the cultured cells were centrifuged
and resuspended in fresh medium in a T-175 flask, so that the cell density when starting the
experiment was 500,000 viable cells/mL. The EdU was added into the culture to a final concen-
tration of 10µM and the whole was left in the incubator for 2h (K-562, HL-60 and MOLT-4) or
1h (MEC-1), according to a preliminary optimization of the protocol for each cell line. Subse-
quently, the cells were twice spinned at 125xg for 6min and washed with warm, sterile PBS to
remove the traces of EdU. They were later resuspended in fresh culture medium at a concentra-
tion of 500,000 cells/mL and placed in 6 well plates, 6mL in each well. The control culture was
processed following the same steps except for the addition of EdU. A cell count was performed
every 6h for each cell line to assess viability and cell number, for 32h. Triplicate samples were
collected for each condition (with or without EdU) every 2h for flow-cytometry analysis, and
processed as follows: the contents of each well plate were centrifuged at 125xg for 6min, re-
suspended in 0.3mL PBS and fixed with 2.7mL ice cold ethanol. The samples were stored at
-20°C at least overnight, and for a maximum of 2 days. The supernatant collected was kept
separately at -20°C for metabolite analysis.
4.2.2.3 Labelling cells with EdU
The AF647 5-ethynyl-2’-deoxyuridine (EdU) kit (Invitrogen) was reconstituted and used ac-
cording to manufacturer’s instructions. Cells were resuspended in fresh medium and pre-
cultured for 12h in T175 flasks (Corning, NY, USA) at 300,000 cells/mL (K-562), 400,000
cells/mL (MEC-1), 250,000 cells/mL (HL-60) or 350,000 cells/mL (MOLT-4). EdU (10µM)
was added (optimal concentration was determined by preliminary experiments in the range of
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Table 4.1: Flow-cytometry groups according to EdU exposure and cocktail addition
EdU cocktail addition No EdU cocktail addition
EdU exposed EE EN
Not EdU exposed NE NN
Table 4.2: Staining steps for each sample type.
EE EN NE NN
EdU cocktail YES (4-7) YES (4-7)
Cyclin B antibody* YES (8-10) every 6h (8-10) every 6h (8-10) YES (8-10)
Cyclin E antibody* YES (8-13) every 6h (8-13) every 6h (8-13) YES (8-13)
Ki-67 antibody* YES (8-10) every 6h (8-10) every 6h (8-10) YES (8-10)
PI YES (14-15) YES (14-15) YES (14-15) YES (14-15)
conditions suggested by the manufacturer, Figure 4.5) and after 1h (MEC-1) or 2h (K-562,
HL-60, MOLT-4), cells were washed twice and resuspended in fresh medium for culture un-
der standard conditions in 6 well-plates (Corning; 4-6mL/well). Two cultures were exposed
with a difference of 11-14 hrs; samples were collected every 2hrs for intervals of up to 14hrs
consecutively and the data was merged (overlap in cell cycle distribution values was confirmed
at matching points). An unexposed culture was used as a control. Samples were analyzed for
cyclins E and B, and Ki67 expression (Tables 4.1 and 4.2).
4.2.2.4 Flow cytometry labelling
The cyclin B IgG1κ antibody kit (clone GNS-1; BD, NJ, USA) was used according to manu-
facturer’s instructions. Anti-human cyclin E antibody (clone HE12), together with the isotype
control IgG1 (clone ICIGG1) and the FITC secondary antibody to IgG were prepared as per
manufacturer’s protocol (all three from Abcam, UK). The V450 Ki-67 IgG1κ (clone B56, BD)
antibody and V450 IgG1κ isotype control (clone MOPC-21, BD) were both diluted 4x. A
propidium iodide (PI; Sigma, MO, USA) solution was prepared by dissolving 10mg/L PI with
100mg/L DNase-free RNase (Sigma) in phosphate buffered saline (PBS; Invitrogen), as pre-
viously described (51). Triplicate samples were collected regularly for each condition (EdU:
every 2h; No EdU: every 6h) and fixed in 70% ethanol at -20°C for a maximum of 2 days prior
to acquisition. Cells were then labelled with antibodies after permeabilisation in the following
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Figure 4.5: EdU calibration tests. K-562 cells were exposed to EdU at different concentrations (10µM
- 20µM) and for different periods of time (30min, 60min or 120min). A control, unstained sample was
used to delimit positive from negative EdU fluorescence (left panel). Plots represent DNA content (x-
axis) versus EdU fluorescence (y-axis). The conditions finally chosen were 120min due to the increased
difference in the EdU fluorescence to the control and 10µM due to the very small difference with a
higher concentration (EdU exposure at higher concentrations can affect cellular growth, so given it did
not provide any advantage, we avoided it).
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Figure 4.6: Flow cytometry staining protocol for EdU, cyclin and DNA.
order: (i) exposure to EdU reagent, (ii) staining with either cyclin B or E antibodies, and (iii)
resuspended in PI (Figure 4.6).
For CD19 labelling in co-culture experiments, labelled or control antibody was added to
each of the three replicate samples and incubated for 30min at 4°C in the dark, fixed in para-
formaldehyde at 4°C, and data was acquired within 2 days with a Guava flow-cytometer (easy-
Cyte 8HT, Millipore, MA, USA); a Fortessa flow-cytometer (LSRFortessa, BD) was used for
all other data acquisition. FACSDiva software was used during acquisition of data on Fortessa,
while easyCyte was used on the Guava; for all samples, 20,000 events were acquired. Data
analysis, gating and geometric mean calculations were performed in FlowJo 8.7 (TreeStar Inc,
OR, USA).
In order to process this data, several steps have to be performed for every sample (Figure
4.7): (i) gating out the debris on the FSC vs SSC (Gate1); (ii) gating out the doublets on the
PI (area) vs PI (width) signal (Gate 2); (iii) gating the EdU positive from the EdU negative
populations (Gate 3b, from control which was unexposed to EdU but exposed to click reac-
tion cocktail, Gate 3a); (iv) deconvoluting the cell cycle distribution (Dean-Jett-Fox method)
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Figure 4.7: Flow cytometry normalization of cyclin expression vs DNA plots. Raw data: FSC (cell
size) vs SSC (cell complexity) segregates the population of cells (Gate 1) from the cell fragments. Gate
1: DNA peak area (signal area below the curve) vs DNA peak width (signal width) eliminates cells
that pass in doublets in front of the laser (those with high DNA peak width) and cell fragments not
removed before (DNA peak area low), resulting in a final population Gate 2. Gate 2: DNA (area) vs
EdU fluorescence is segregated according to EdU content (from control sample NoEdU + cocktail gate
3a) into EdU positive and EdU negative (gate 3b). Gate 3b: DNA vs Cyclin B fluorescence is segregated
according to cyclin B expression (from control isotype sample Isotype B Gate 4a) into cyclin B negative
and cyclin B positive (Gate 4a). Phase G, Phase S and Phase G2 are extracted according to Gate 3b and
DNA distribution gates fron DNA histogram.
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resulting in G0/G1, S (split in 4 equal gates at time 0 only) and G2/M gates (Phase G1, Phase S
and Phase G2 gates); (v) gating the cyclin positive from the cyclin negative populations (Gate
4a; from isotype control exposed to EdU and reaction cocktail, Gate 4a). From this analysis,
4 different populations are identified: EdU+ C+; EdU+ C−; EdU− C+; EdU− C−, in addition
to the ungated total population. For each sample: (i) the geometric mean of the fluorescence in
the C+ population in the phase of interest divided by the geometric mean of the fluorescence in
the total population in the phase where the cyclin expression is minimal gives the normalized
sample expression; (ii) for the isotype samples, the geometric mean of the fluorescence in the
phase of interest divided by the geometric mean of the fluorescence in the total population in
the phase where the cyclin expression is minimal gives the baseline expression of the phase;
(iii) finally, the normalized values obtained in (1) are divided by the baseline values from (2)
giving the normalized cyclin expression of the phase of interest for the sample (Equations 4.1
and 4.2).
CE,norm =
fsample
(
C+E,G1
)
/ fsample
(
CtotE,G2/M
)
fisotype
(
CtotE,G1
)
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4.2.2.5 Co-culture experiments
K-562 and MEC-1 cells were mixed at the appropriate ratios and pre-cultured in IMDM+10%FBS.
After 48h, they were resuspended in fresh medium at a density of 0.5 ·106 cells/mL and culti-
vated in 6-well plates (Corning), 4mL/well. Triplicate samples of 106 cells were taken at 0h, 5h,
10h, 20h, 25h and 30h. For the blinded experiments, operator 1 prepared unknown mixtures of
K-562, MEC-1 and MOLT-4 cell lines (different cell types and ratios), which were pre-cultured
for 48h. Samples were taken every 5-10h for a total of 30h. Triplicate samples were collected
and split into two tests: samples to be stained for CD19 and fixed in para-formaldehyde 4% and
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samples to be fixed in ethanol for later detection of cyclin B concentration. In the segmentation
of co-cultured samples, the percentage of MEC-1 cells were inferred from the population with
CD19 expression, the MOLT-4 content from the population with high cyclin B concentration
(Figure 4.8); K-562 was the % remaining. For samples where only K-562 and MOLT-4 were
present, SSC vs DNA analyses sufficed to gate each cell type. Note that this was impossible
when all three cell lines were together as SSC vs DNA of MEC-1 overlaps with both K-562
and MOLT-4 (only approximate values of percent of each cell line could be deduced).
4.2.3 Results and discussion
4.2.3.1 Viability of cyclin measurements
As an initial validation that cyclin expression could be recorded using flow-cytometry tech-
niques, five leukemia cell lines growing under 2D conditions were tested for expression of
cyclins E and B: HL-60, Kasumi-6, K-562, MEC-1 and MOLT-4. Cyclin B in healthy cells is
produced during S phase and peaks at G2 phase, while cyclin E is produced in G1, peaking at
the end of it and then decreases in S until it is eliminated in G2/M (Figure 4.9, top left panel).
All cell lines expressed both cyclins, albeit with very heterogeneous patterns (Figure 4.9).
HL-60 expresses cyclin B in an unusual pattern, with very weak peaks at the G1 and G2 phases
and lower expression in the S phase; cyclin E in HL-60 is produced throughout the cell cycle,
although part of the cells in G1 do not express it (possibly the ones at the very early stages of
the phase) and production towards G2 and M phases seems lower. These results are confirmed
by findings from the literature [43]. Kasumi-6 expressed cyclin B in a relatively synchronous
fashion, with a very marked peak at the G2 phase and very low levels in S and G1 (despite
a few disperse cells appearing above the baseline). Cyclin E expression was very high but
the decreasing pattern from G1 through S and G2/M was observed (compared to the upward
slope of the baseline). K-562 begins cyclin B production in G1, continuing throughout S
and G2 phases, while cyclin E is expressed throughout the cell cycle, which was also found
elsewhere[131]. MEC-1 cells expressed cyclin B in a scheduled manner, and cyclin E in a
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(a) FITC CD19 vs SSC plot of a K-562,
MEC-1 and MOLT-4 mixture - CD19 positive
population gated based on a separate MEC-1
single culture.
(b) FITC Cyclin B vs DNA plot of a K-562,
MEC-1 and MOLT-4 mixture - MOLT-4 pop-
ulation gated based on a separate Cyclin B vs
DNA plot of MOLT-4 single culture.
(c) DNA vs SSC plot of a K-562 and MOLT-
4 mixture - K-562 and MOLT-4 populations
gated based on single cultures.
Figure 4.8: Flow cytometry plots of co-cultures.
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Figure 4.9: Flow-cytometry plots of cyclins E and B vs DNA content in five leukemia cell lines.
Red regions indicate the actual samples while cyan regions represent the isotype control (baseline ex-
pression). *Healthy cells reproduced from Darzynkiewicz et al. [21].
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seemingly normal pattern in G1 and S, with an increased expression in G2/M. Finally, MOLT-
4 cells had a clearly normal production of cyclin B, and a decreasing cyclin E trend in S through
G2/M (as in normal cells), which was confirmed in [43]. To the best of our knowledge, this
is the first time cyclins E and B expression have been identified for the Kasumi-6 and MEC-1
cell lines.
4.2.3.2 EdU chase results in four leukemia cell lines
When following the cell cycle in leukemia cell lines over time, two main features are observed:
the cell cycle controls (cyclin expression) and the resulting phase fractions from a synchronous
population. Because EdU exposure can slightly affect cell proliferation, the EdU− population
(exposed to EdU but not uptaking it because in either G1, G2 or M phases) is used throughout.
The phase fraction results are shown in Figure 4.10. As a first observation, all cell lines
follow the same pattern in the first few hours: G1 fraction at a maximum and then decreases,
S phase at a minimum and then increases, and G2/M at a maximum and decreases almost
to zero. This is a result of the delay in the replenishment of the final stages of S phase and
subsequently in the delay of cells entering G2 phase. A second observation is related to the
density of cells at any one time in each of the three phases. Because G2/M is generally shorter,
less cells are likely to be found. This is reflected in the symmetry between G1 and S phases
dynamically: one increases when the other decreases and vice-versa. For a detailed description
of the particularities of each cell line, several features have to be observed: the times at which
maxima and minima occur, their values and the apparent steady state value (the average value
at which the population fraction seems to stabilize). For K-562, we observe that the peaks are
very pronounced, reaching values of almost 0% (G2/M) for the minima and maxima of around
80% for the maxima (in S and G1 phases). The steady state values seem to be around 40% for
G1, 45% for S and 15% for G2/M. Peak cyclin expression is expected to occur at 10h for cyclin
E and at 4-8h for cyclin B. For MEC-1, changes seem significantly less abrupt; interestingly,
the phase fraction trend can be followed from S phase into G2/M, with a delay of around 4:
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starting from t=2h in S which corresponds to t=6h in G2/M, all time points shaping the peak
seem to follow the same pattern, although at a smaller scale for G2/M. Peak cyclin expression
is expected to happen at 8-10h for cyclin E and at 4-6h for cyclin B. For MOLT-4, the first
thing to be noticed is that the G2/M fraction is much lower, stabilizing at around 6% with G1
at 40% and S at 54%; it seems MOLT-4 takes longer to complete a cell cycle since only one set
of maximum/minimum can be seen per phase. Cyclin expression is expected to peak at 8-12h
for cyclin E and at 0-4h for cyclin B. Finally, HL-60 is clearly different than all other three cell
lines in that peaks are only pronounced in the first hours, seeming to stabilize later on at 40%
for G1, 50% for S and 10% for G2/M. This results in expected cyclin peaks at 8-10h for cyclin
E and at 4-8h for cyclin B.
The correlation between cyclins and phase expression is verified when exit from a phase
(decreasing trend in the phase fraction) matches the peak of expression in its phase-specific
cyclin (i.e., cyclin E for G1 and cyclin B for G2).
With the cell cycle output analysis, we are now ready to verify our predictions of cell cycle
controls with cyclin expression data (Figure 4.11). For K-562, a peak in cyclin E can be seen at
t=8h and a large peak in cyclin B at t=4h is observed. This is in accordance with the predictions
made from the phase fraction data (10h for cyclin E and 4-8h for cyclin B). For MEC-1, cyclin
E expression peaks at 6h and at 12h, while cyclin B starts at a maximum between 0-2h. When
comparing it with the predictions made earlier (cyclin E at 8-10h and 4-6h for cyclin B), they
reasonably match although cyclin B peak happens earlier than expected. For MOLT-4, there
is a region between 4h and 12h where cyclin E expression is high, while cyclin B is very high
only at t=0h (peaking later for a second cycle at t=14h, which correlates to entrance of cells
in G1 from 12h in Fig 4.10). Comparing this against the values predicted earlier: t=8-12h
for cyclin E and 0-4h for cyclin B, they match very well with the cell cycle control findings.
Finally, HL-60 has what looks like a very regulated cyclin E expression pattern, peaking at 14h
after a constant growth starting at 2h, while cyclin B expression is extremely weak and seems
to peak at 6h and at 18h. The earlier predictions suggested cyclin E peaks at 8-12h and cyclin
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B peaks at 4-8h, which were confirmed with the protein expression data.
4.2.3.3 Dynamic co-culture evolution over time
The dynamic evolution of each cell line in the co-culture blind experiment is shown in Figure
4.12. A first observation is that cell lines seem to remain at the percentage where they started,
varying only slightly (10% maximum). In most cases, K-562 content seems to increase over
time, likely due to the fact that it has a lower doubling time. Similarly, MOLT-4 content seems
to decrease in all mixtures where K-562 is also present, suggesting a depletion related to its
longer cell cycle time (also relative to K-562’s). Finally, MEC-1 is generally quite stable,
decreasing only slightly its content in some mixtures (see T2, T6 and T9).
4.2.4 Conclusions
In order to obtain synchronous cell cycle phase distribution data, it is essential to develop
appropriate techniques that isolate a specific population, allowing the tracking of cells during at
least one cell cycle over all phases. Analyzing cyclin expression in parallel with phase fractions
can help elucidate the mechanisms regulating the cell cycle in vivo. Cell cycle heterogeneity
can be seen at the cause (cyclin expression) and effect (phase percents) levels and is clearly a
marked characteristic of each clone.
Improving the methods for the identification of leukemia clones and the quantification rel-
ative to other clones is critical in assessing clonal dynamics. In this section, we demonstrated
how a simple flow cytometric analysis based on CD19 for MEC-1 identification and the seg-
regation of MOLT-4 and K-562 cells based on the cyclin B vs side scatter (complexity) plot
allows us to directly quantify the contents based on two samples only, without the need for
further genetic analysis. The use of this technique is restricted to known clones expressing
membrane or intracellular proteins that can be fluorescently labeled and that are a unique fea-
ture of that particular clone. In order to link this technique with other cell cycle measurements,
it is of utmost importance to identify clones based on these flow cytometry tests instead of their
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genetic tests counterparts, since measuring cell cycle properties for a particular subpopulation
requires first selecting the information relative to that subpopulation only.
4.3 3D culture of patient samples
4.3.1 Introduction
Culturing patient samples requires a more sophisticated setup since these cells are not adapted
to standard 2D laboratory conditions; they required a three dimensional environment suitable
for enhancing cell-matrix and cell-cell contact in all directions. The 3D scaffold made out of
polyurethane previously presented is a perfect candidate.
4.3.2 Aims & methodology
The use of patient samples allows validating the applicability of our techniques to real life
patients at the time of diagnosis. The first step towards this goal is to identify cyclin expression
and heterogeneity and to establish whether patient cells proliferate and follow the standard cell
cycle patterns within the scaffolds in a measurable way.
For this, two different analyses were carried out: (i) cyclins E and B expression were
recorded for 6 different patient samples upon collection; and (ii) cell from a particular patient
(P33) were cultured in 3D for four weeks and several tests were performed on supernatants and
cells within the scaffolds. For the first analysis, patient samples were processed in Ficoll-Paque
and the monocyte layer was collected for further processing. The standard techniques presented
in the previous section for flow-cytometry analysis of cyclins E and B as well as DNA staining
for phase discrimination were applied to those cells within hours of their collection from the
patient. For the second analysis, 2M cells were seeded per scaffold, 1.5mL of medium (IMDM
with 30% FBS) was exchanged every 2-3 days. Two analyses were carried out in parallel: cells
remaining in the scaffold (analyzed weekly) and cells exiting to the supernatant (analyzed at
every medium exchange). Consistent cell counts were performed on the supernatants collected
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during medium exchange to assess cell exit from the scaffold and overall viability.
4.3.3 Results
A very large number of the cells seeded were found to exit the scaffold on the first days (day
3: average of 1.4M cells per scaffold - 70% of the cells seeded, neglecting cell growth; Figure
4.13). On subsequent medium exchanges, cells found in the supernatants halved at each count,
until day 10 when they seemed to maintain (excluding day 12). This was also observed visually
when examining the scaffolds under the light microscope (Figure 4.14). If summed, the average
total number of cells collected per scaffold is beyond 4M - double the amount originally seeded
in the scaffolds, confirming there was cell growth at some point during culture. Cell viability
in the supernatant stayed above 70% until day 21, when it dropped below 60% for the rest of
the culture. Since viability measurements on cells extracted from the scaffolds are not reliable,
we consider the viability found on cells from the supernatant to be similar to the one of cells
remaining inside. If that is the case, then cells are maintained for three weeks at a good viability
permitting the assays performed.
Cell number in the scaffolds seems to decrease according to both MTS and DNA quantifica-
tion measurements (Figure 4.15 - trends and quantities were consistent in both, see the bottom
panel). This seems to occur between day 3 (first measurement taken) and day 10. However,
we have already seen that many cells were exiting the scaffolds during that time (Figure 4.15,
bottom panel); cell exit rate seems to be decreasing between days 3 to 10 and stagnates at a low
level until day 19, where hardly any cells are found outside the scaffold anymore. DNA quan-
tification fluorescences were converted to cell numbers according to a P33 -specific calibration
curve. Thus, DNA quantification results confirm the presence of over 1M cells in the scaffolds
by the end of culture (composed of cells seeded and cells created as a result of cellular growth).
As an additional confirmation that cells adhered to and grew in the scaffolds, SEM images of
the middle section of scaffolds on day 27 of culture were taken (Figure 4.16). Scaffold walls
were covered with cells in a heterogeneous manner: some areas were fully populated (Figure
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Figure 4.13: Analysis of P33 supernatant cell number (left) and cell viability (right). n=3 except
for d24 and d27.
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Figure 4.14: Microscope images of the surroundings of the scaffolds containing P33 cells. Observe
how a high number of cells are visible in the beginning, while lower amounts are found as days go by
(day 19 - d19).
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Figure 4.15: MTS absorbance (top left) and DNA quantification results (top right) for P33 seeded
3D scaffolds, weekly for 4 weeks. Normalization to day 3 (bottom) shows the decrease is quantita-
tively similar using both techniques, except for day 27. Normalized cell counts of the supernatant are
superposed for comparison purposes
Figure 4.16: SEM image of P33 cells on day 27 of 3D culture.
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4.16, right) while some others were almost empty (Figure 4.16, left).
Additionally, five other patient samples (P24, P25, P28, P33, P34, P35) obtained from
Northwick Park Hospital were used to confirm cyclins are also deregulated in primary cells
(upon collection from the patient - except from P33; Fig 4.17). P24, P25 and P35 were re-
lapsed AML patients; P28 was a secondary AML, from a treatment-related Myelodysplastic
Syndrome (MDS); P33 and P34 were de novo AML. Heterogeneous cyclin expression patterns
were seen in all of them. Cyclin E was correctly expressed at high levels during G1 and de-
creased in S and G2/M (where visible). Cyclin B was barely observable in most cases since the
fraction of cells in the S and G2/M phases was extremely low. The clearest cases are P25 and
P35, where cyclin B seems to be produced in a scheduled manner during S phase and peaks at
G2/M.
An additional phenomenon worth highlighting is the resonant DNA peaks seen for P33
and P34. They are caused by DNA tri/tetraploidy which results from incorrect partitioning of
chromosomes at mitosis. Cells with double genetic material at the start of the cell cycle (G1)
are present and can duplicate, creating new cells with quadruple genetic material etc. This
condition appears to indicate a bad AML prognosis[44] and is rare (1.2% of the cases [57]).
4.3.4 Conclusions
This section demonstrated the possibility to measure cyclin expression in patient samples, al-
though further experimentation is required to improve the processing of cells to recover a larger
portion of the cells originally available. A patient sample was cultured and expanded in the 3D
scaffold, showing the potential as a suitable platform for the study of cell cycle kinetics ex
vivo. A more systematic approach to patient cell culture, where a mass balance between cells
seeded, cumulative number of cells collected from the supernatant and final number of cells
remaining inside the scaffold is required to disentangle primary cells’ growth kinetics.
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Figure 4.17: Flow-cytometry plots of cyclins E and B vs DNA content in six AML patients. Red re-
gions indicate the actual samples while cyan regions represent the isotype control (baseline expression).
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In silico platform
Mathematical modeling is a robust tool which receives a limited number of inputs for the
prediction of a large number of outputs. Importantly, it enables accounting for a large number
of phenomena to a point where human processing capabilities could never reach. However, for
mathematical predictions to be of use, the structure of the model must stem from the underlying
phenomenon so that: (i) the correct behavior is simulated; and (ii) the outputs of the model
can be compared against the experimental measurements head-to-head for validation purposes.
Within the framework, the in silico component is of utmost importance since it indicates which
experiments are to be performed in order to obtain the missing parameter values, which have
to be properly combined with in vivo specifications in a cohesive manner, and finally simulates
and optimizes the treatment in a virtual patient within the PK/PD module. Because of its
interaction with both in vitro and in vivo components, it is highly dependent on the quality
of the data received but also highly decisive in (and responsible for) the in vitro and in vivo
responses. A good quality model built based on measurable parameters proving the answers to
the clinical questions is required.
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5.1 Development of a population balance model (PBM) of
the cell cycle
5.1.1 Introduction
Existing models of the cell cycle capture either the intracellular processes occurring at the
single-cell level, or the macroscopic events taking place at the culture or whole patient level.
Biologically, events happening intracellularly (cyclin production, DNA replication) lead to
cell growth and proliferation observable at the macroscopic level. In the particular case of
chemotherapy, DNA damage and induced apoptosis block the signaling pathways that result
in macroscopic growth. Therefore, building models that are able to translate the small-scale
processes to results occurring at the large-scale level is critically needed.
5.1.2 Aims & methodology
In this section, we develop a population balance model of the cell cycle featuring cyclin ex-
pression (for G1 and G2 phases) and DNA content (for S phase) as state variables, establishing
a clear connection in vitro / in silico.
5.1.2.1 Development of a multi-stage PBM based on cyclin concentration
The model is composed of 3 compartments according to DNA content: G (DNA content of 1),
S (increasing DNA content 1-2) and M (DNA content of 2), similar to other models available
[120, 119]. The novelty resides in the fact that cyclin E and cyclin B are used as state variables
(defined as CE and CB in the model) for G0/G1 and G2/M respectively, as these are the phases
where their concentration actively increases linked to phase progression. DNA content (defined
as DNA in the model) is used as in previous models [70] for the representation of progress in
S phase. Each of the three phases is modeled by a PBM equation (Equations 5.1–5.3; refer to
Table I.3 for variable definitions), and these equations are linked by the transfer of cells from
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phase to phase (Figure 5.1).
∂G(CE , t)
∂ t
+
∂
(
G(CE , t) · dCEdt
)
∂CE
=−rG→S (CE) ·G(CE , t) (5.1)
∂S (DNA, t)
∂ t
+
∂
(
S (DNA, t) · dDNAdt
)
∂DNA
= 0 (5.2)
∂M (CB, t)
∂ t
+
∂
(
M (CB, t) · dCBdt
)
∂CB
=−rM→G (CB) ·M (CB, t) (5.3)
G(CE , t) represents the number of cells in G0/G1 at time t that have a cyclin content CE ;
similarly, S(DNA, t) and M(CB, t) represent the number of cells in S and G2/M that have a
DNA content DNA and a cyclin B content CB respectively at time t. rM→G (CB) and rG→S (CE)
represent the transition rates from G2/M to G0/G1 and from G0/G1 to S respectively (both
dependent on the particular phase state variable). Biologically, growth rates account for the
speed at which the accumulation or production of cyclin/DNA occurs in a cell in the relevant
phases. Mathematically, growth rates represent how quickly cells progress through the phase.
Phase durations (TG, TS and TM) are defined as the average time a cell spends in a phase.
Cyclin minima represent the baseline expression at the start of the phase (CE,min and CB,min
for G0/G1 and G2/M) while cyclin thresholds (CE, thr and CE, thr) account for the average cyclin
level at which cells move to the next phase. A constant cyclin E production rate (rG) is used
for G1 (Eq. 5.4) [92]. DNA production (rS) is approximated as a linear function (Eq. 5.5)
based on normalized results [5]. Constant cyclin B production (rM) occurs during G2 with a
concentration plateau at transition [58]; since transition occurs rapidly, we assume a constant
cyclin B production throughout G2 (Eq. 5.6).
rG =
dCE
dt
=
CE, thr−CE,min
TG
(G0/G1) (5.4)
rS =
dDNA
dt
=
2−1
TS
(S) (5.5)
rM =
dCB
dt
=
CB, thr−CB,min
TM
(G2/M) (5.6)
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Figure 5.1: The cell cycle. Outer circles represent biological events (succession of phases and phase-
specific cell cycle protein expression); inner “pie” circles summarize model simplifications and the
discretization strategy based on state variable level. State variables are chosen according to relevance to
their phase: cyclin E for G0/G1, DNA for S and cyclin B for G2/M. Bins in each phase indicate discrete
state variable levels: CE(e), DNA(d) and CB(b) correspond to the state variable levels of bin number
e, d and b, while cell numbers in each bin are represented by Ge(t), Sd(t) and Mb(t) in G0/G1, S and
G2/M respectively. Transition rates (rG→S,e for G0/G1 and rM→G,b for G2/M) account for the likelihood
of cells moving to the next phase and growth rates (rG, rS and rM) reflect progress within the phase.
74 Marı´a Fuentes Garı´ Chapter 5
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
A cell in G0/G1 or G2/M can either move to the next phase or move to the next cyclin level.
Biologically, the higher the cyclin concentration and the more likely it is for the cell to transi-
tion. Mathematically, the transition probability (Γ(CE) and Γ(CB)) accounts for the likelihood
of a cell at a particular position in the phase moving to the next phase, which is explicitly calcu-
lated as the ratio between transition happening (rG→S or rM→G) and all of transition and growth
happening (rG→S + rG or rM→G + rM). A recent study of different transition rate functions in
cell cycle PBMs has indicated that the particular function used had little impact on the ability
of the model to fit the experimental data [13]. We assumed a normal cumulative distribution
function for the transition probabilities Γ(CE) and Γ(CB).
ΓG (CE) =
1
σE
√
2 pi
∫ CE
CE,min
e−(CE−CE, thr)
2
/(2·σ2E)dCE (5.7)
ΓM (CB) =
1
σB
√
2 pi
∫ CB
CB,min
e−(CB−CB, thr)
2
/(2·σ2B)dCB (5.8)
The transition probability is related to the transition rates as follows:
ΓG(CE) =
rG→S (CE)
rG→S (CE)+ rG
or rG→S (CE) =
rG ·ΓG(CE)
1−ΓG(CE) (5.9)
ΓM(CB) =
rM→G (CB)
rM→G (CB)+ rM
or rM→G (CB) =
rM ·ΓM(CB)
1−ΓM(CB) (5.10)
The variability in the transition probability is related to the cyclin thresholds as:
σE = σE,% ·
(
CE, thr−CE,min
)
(5.11)
σB = σB,% ·
(
CB, thr−CB,min
)
(5.12)
The boundary conditions address the discontinuities between phases, where cells from a
different phase enter a new phase. Since cells transitioning to S or to G0/G1 arrive with dif-
ferent cyclin concentrations from G0/G1 (Eq 5.13) or G2/M (Eq 5.14) respectively, the total
number of cells is calculated by taking the integral of the transition term over all cyclin levels.
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For G0/G1, incoming cells are doubled to account for cell division; for S phase, all the cells
with a doubled DNA content are considered to transition to the start of G2 (Eq 5.15):
rG ·G
(
CE = CE,min, t
)
= 2
∫ CB,max
CB,min
rM→G (CB) ·M (CB, t) dCB (5.13)
rS ·S (DNA = 1, t) =
∫ CE,max
CE,min
rG→S (CE) ·G(CE , t) dCE (5.14)
rM ·M
(
CB = CB,min, t
)
= rS ·S (DNA = 2, t) (5.15)
Two assumptions were made: (i) the G0/G1 phase is aggregated: leukemic cell lines are highly
proliferative and therefore only a small percentage of cells with DNA content 1 will actually
be quiescent (Figure 5.2) and, (ii) the G2/M phase is aggregated: the duration of the M phase
is short enough compared to that of G2, such that it does not affect significantly the overall cell
cycle progress [82]. Patient samples are generally less proliferative than cell lines, in which
case the first assumption might not apply and an alternative model with a G0 compartment, or
considering a very long G1 phase duration might be needed.
Given the complexity of the equations (partial differential and integral terms), discretization
of the state variable space is required. Phase domains start at CE,min (G0/G1), 1 (S) and CB,min
(G2/M), and are truncated at CE,max (G0/G1), 2 (S) and CB,max (G2/M). Compartments are
subdivided into ni bins ∀ i ∈ {E; D; B}; each of the bins representing a range of state variable
levels which correlates to the bin number according to the following equations:
νE = nE/(CE,max−CE,min) (5.16)
νD = nD/(DNAmax−DNAmin) = nD/(2−1) = nD (5.17)
νB = nB/(CB,max−CB,min) (5.18)
Each bin corresponds to state variable levels that span: 1/νE (G0/G1 phase), 1/νD (S phase) ,
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Figure 5.2: Evolution of the %Ki-67 positive cells among G0/G1 cells over time (control cells)
as determined by flow cytometry. Ki-67 is a protein expressed by cells out of quiescence; G0 cells
are thus identified by their lack of Ki-67 expression. In the experiments performed with EdU, control
cultures were monitored for Ki-67 levels to validate the assumption that only a small percentage of the
cells is quiescent at any time. Indeed, Ki-67 was expressed by at least 90% of the cells overall, with
the exception of MEC-1 at time 0h which was found to be 80% (this is believed to be an effect of the
washing steps stress and not an ubiquitous condition).
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and 1/νB (G2/M phase). The state variable levels for each bin become:
CE,e = (e−0.5)/νE +CE,min ∀e ∈ {1, . . . , nE} (5.19)
DNAd = (d−0.5)/νD+1 ∀d ∈ {1, . . . , nD} (5.20)
CB,b = (b−0.5)/νB+CB,min ∀b ∈ {1, . . . , nB} (5.21)
In the discrete form, Equations 5.9 and 5.10 become ΓG,e = ΓG (CE,e) and ΓM,b = ΓM
(
CB,b
)
.
The model now considers ni subpopulations ∀ i ∈ {E; D; B} corresponding to each state vari-
able level in the compartment (Figure 2.5), which are defined as a vector of length ni. Follow-
ing discretisation of cyclins and DNA via a fully stable upwind scheme [62, 66], the model
equations are simplified into ni ODEs per compartment as follows:
dGe
dt
=(Ge−1(t)−Ge(t)) ·νE · rG−Ge(t) ·νE · rG→S,e ∀e ∈ {2, . . . , nE} (5.22)
dSd
dt
=(Sd−1(t)−Sd(t)) ·νD · rS ∀d ∈ {2, . . . , nD} (5.23)
dMb
dt
=(Mb−1(t)−Mb(t)) ·νB · rM−Mb(t) ·νB · rM→G,b ∀b ∈ {2, . . . , nB} (5.24)
The discretised counterpart of ∂
(
G(CE , t) · dCEdt
)
/∂CE (Eq 5.1) is (Ge−1(t)−Ge(t)) · νE · rG
(Eq 5.22); the transition term rG→S (CE) ·G(CE , t) corresponds to:Ge(t) · νE · rG→S,e in the
discretized form; change with time is converted from ∂G(CE , t)/∂ t to dGe/dt. In addition,
the boundary conditions become:
dG1
dt
= 2 ·
nB
∑
b=1
Mb ·νB · rM→G,b−G1(t) ·νE ·
(
rG+ rG→S,1
)
(5.25)
dS1
dt
=
nE
∑
e=1
Ge ·νE · rG→S,e−S1(t) ·νD · rS (5.26)
dM1
dt
= SnD ·νD · rS−M1(t) ·νB ·
(
rM + ·rM→G,1
)
(5.27)
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5.1.2.2 Experimental validation of the PBM
EdU is a thymidine analogue that can be incorporated in the DNA of cells during S phase
[105]. Cells undergoing DNA duplication are effectively labeled but not G0/G1 or G2/M cells,
resulting in two separate populations that can later be tracked by flow-cytometry. This provides
a suitable method to generate cell cycle “movies” from which cell cycle times can be extracted.
EdU exposure does not significantly affect cell proliferation so long as the uptake is short
and in low concentrations [12]. Regardless, only information from the unlabeled population
was utilized. Subsequent phase deconvolution can be performed by DNA staining and the
concentration of cyclins E and B is monitored by simultaneous antibody staining.
The experimental system is composed of thousands of cells, each characterized by a fluo-
rescence intensity per channel. Global phase behavior is obtained by normalizing the geometric
mean fluorescence of individual cells [86]. A similar approach can be used in the case of the
discretized model, except the system is composed of groups of cells with similar characteristics
instead of single cells. The equivalence between the data analysis procedure used to aggregate
flow-cytometric data and the mathematical procedure to combine the simulation data of each
of the bins is as follows:
Geometric meanexp =
(Ncells
∏
i=1
fi
)1/Ncells
(5.28)
Geometric meanPBM =
(Nbins
∏
j=1
C
Ncells, j
j
)1/Ncells, tot
(5.29)
where Ncells, tot =
Nbins
∑
j=1
Ncells, j (5.30)
where i indicates the cell index and j the bin index; fi and f j are the normalized fluorescence of
a cell and of a bin, respectively. When raising the cyclin fluorescence in bin j (C j) to the power
of the number of cells in that bin (Ncells, j), multiplying all the factors obtained for each bin
and raising the whole to the power of the total number of cells (1/∑Nbinsj=1 Ncells, j), the geometric
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Figure 5.3: Comparison of calculation paths for processing flow-cytometry and mathematical data to
obtain the same geometric mean of cyclin parameter (example case for G0/G1 phase and cyclin E).
In flow-cytometry, the individual fluorescences of cells are multiplied and the nth root of the product is
calculated (n being the total number of cells). In the PBM, the cyclin values in each bin (Ce) to the power
of the number of cells in that bin (Ge) are multiplied, and then the nthroot of the whole is calculated (n
being the sum of cells in all bins).
mean of cyclin fluorescence in the model is obtained (Figure 5.3). Similarly, when multiplying
the fluorescence of each single cell in the experimental system and raising the whole to the
power of the total number of cells analyzed (Ncells, the geometric mean of cyclin fluorescence
of the experimental data is obtained. Because Eq 5.28 and 5.29 are adapted formulas for each
of the systems to calculate a common variable, the resulting values are equivalent and thus
comparable.
The transition probability function chosen implies that cells statistically never reach the
maximum cyclin value in the model. It is assumed that a maximum probability of 99.99%
can be achieved. Therefore, the maximum value of cyclin is theoretically obtained as the
cyclin value at which 99.99% of the cells would have transitioned, which is equivalent to
solving ΓG (CE,max) = 0.9999 and ΓM (CB,max) = 0.9999. A conservation analysis (detailed
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Figure 5.4: Analyzing the number of discretization intervals needed by the PBM is useful to define the
most computationally efficient conditions satisfying the required resolution in the variables.(A) Evolu-
tion of cell loss with decreasing number of intervals in each phase (Total %: percentage of total cells
remaining after 1000h, G lost %: percentage of total cells that were lost on the last bin of G0/G1 (cu-
mulative), M lost %: percentage of total cells that were lost on the last bin of G2/M (cumulative)). (B)
Changes in Cyclin B expression patterns with increase in bin numbers (Smoothed: nB=5; Unsmoothed:
nB=60; Undersmoothed: nB=200). Examples for K-562 under even phase distribution conditions
next) confirms this does not result in significant cell loss while providing enough flexibility for
“outlier” cyclin expression events to take place (Figure 5.4). By setting the duplication factor
to one, cell numbers in the model are constant over time; the numerical solutions are tested to
fulfil this property at two different levels: total cell number and final phase bins (GnE (t) and
MnB(t)). For the total cell number, the maximum loss recorded was 1.2·10−5% in G phase and
2·10−6% in M phase (K-562). The gPROMS solver used was DASOLV with ε = 1·10−5; the
cell loss is within the error of the numerical solver. Therefore it can be assumed to be zero.
The test for the final phase bins lead to even smaller cell losses (·10−37%).
The model was additionally tested for cell conservation based on the number of discretiza-
tion intervals allowed. The duplication factor was again set to 1 and the model was run for 5
different scenarios with nE , nDNA and nB set to decreasing numbers, for a total of 1000h. The
results in terms of total cells remaining after 1000h compared to initial cell number (repre-
sented as Total %) and percentage of cells in G0/G1 and G2/M phases exiting at the last bin
are presented in Figure 5.4A. Discretization intervals must be reduced to very few to push the
model into conservation issues. However, since we are relying on bin numbers for averaged
cyclin expression, it is still important to keep a wide distribution for a good resolution in cyclin
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expression (otherwise situations like Figure 5.4B can occur).
Because transitions are modeled according to a normal cumulative distribution, the prob-
ability of transition in the last bins of G and M (GnE and MnB) is very high (we have as-
sumed 99.99%). When converted via Eq 5.9 and 5.10, the resulting transition rates (rG→S,e and
rM→G,b) become very high as compared to the growth rates (rG and rM). Therefore, the cell
number that is lost through the passage to the next (nonexistent) bin through growth processes
is minimal, satisfying the conservation requirements:
lim
nE→∞
−GnE (t) · rG ·νnE = 0 (5.31)
lim
nB→∞
−MnB(t) · rM ·νnB = 0 (5.32)
In order to calculate cyclin thresholds, EdU−C+B at time 0 was considered to contain cells in
late G2/M phase. CB, thr and CE, thr were set to the value at the peak, occuring when G% and
M% are minimum, respectively (therefore the cells remaining are towards the end of the phase
and have a cyclin content closer to the threshold). For G%, it occurs after at least TG− texposure
hours, while for M% it is recorded at the very beginning (after TM− texposure, which is usually
close to zero because TM tends to be in the range of EdU exposure durations). The minimum
cyclin values were set as the minimum values reached in the phase of interest throughout the
experiment.
Regarding the intra-phase model initialization, two situations were encountered: even or
biased cell distribution. Even phase distributions occur when cell populations are continu-
ously coming in from the previous phase and leaving to the next phase. At steady-state, the
percentage of cells (with respect to the total cells in a phase) found in a bin is proportional
to the complementary probability of cells transitioning from the previous bin (given constant
intra-phase growth). A more detailed derivation can be found in Appendix E.
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Ge,T % = Ge−1,T % · rG ·νErG ·νE + rG→S,e ·νE +α ∀e ∈ {2, . . . , nE} (5.33)
Sd,T % = Sd−1,T % · rS ·νDrS ·νD+α ∀d ∈ {2, . . . , nD} (5.34)
Mb,T % = Mb−1,T % · rM ·νBrM ·νB+ rM→G,b ·νB+α ∀b ∈ {2, . . . , nB} (5.35)
For the boundary conditions:
G1,T % =
2 ·α
rG ·νE + rG→S,1 ·νE +α (5.36)
S1,T % =
β
rS ·νD+α (5.37)
M1,T % = SnD,T % ·
rS ·νD
rM ·νB+ rM→G,1 ·νB+α (5.38)
Even phase distributions are used for the initial cell cycle distribution in every phase when
modeling the total population. Biased phase distributions correspond to the situation when no
cells are entering a phase but cells in the phase keep progressing and exiting to the next phase,
accumulating towards the end of the phase (until the phase is depleted completely). As a result
of EdU exposure, the EdU− population consists of G0/G1 and G2/M cells only. The G2/M
cells are completely EdU free, which includes only those cells that were not in S phase at the
start of EdU exposure. This means the EdU− G2/M subpopulation is composed of cells that
have been in the phase at least for the duration of the exposure, and have progressed through the
phase. Therefore, the G2/M phase of the EdU− population at time 0 can be modeled as a biased
phase distribution. To capture this behavior, the model was initialized for the duration of the
EdU exposure and cell entrance to G2/M is blocked, resulting in the new boundary condition:
dM1/dt =−M1(t) · rM ·νB−M1(t) · rM→G,1 ·νB (5.39)
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The resulting G0/G1 and G2/M intra-phase distribution at the end of the simulation of the
exposure is used to initialize the model with the experimental data at time 0.
5.1.3 Results and discussion
5.1.3.1 Model analysis and parameters required
The model at this point included 283 variables and 400 parameters (measured and derived, see
Appendix B). Global sensitivity analysis (GSA) identifies the parameters that have an impact
on model output, by observing the change in the outputs when parameter values are varied
simultaneously using Sobol’s method (Appendix G)[60]. It assesses which experimental values
critically need to be determined with experimental accuracy, and which others can be estimated
or kept at their nominal values for model validity. For K-562, TG is significant in G1 at the time
cells are exiting the phase (5-10h), in S phase at the time they are entering the phase (5-10h),
and in G2/M when cells are entering the phase (15h). Similarly, TS is significant in G1 when
cells are entering the phase again (15-20h), in S when cells are exiting the phase (10-20h) and
in G2/M when cells are entering the phase (5-15h). TM is only significant in G2/M throughout
and in the first 2-3h for G1. For MEC-1, TG is significant in G1 and S (to a lesser extent), TS in
S and G2/M (in G1 only at 10h); TM in G2/M only. For MOLT-4, TG is significant after 10h in
both G1 and S; TS in S (10h and 15), G1 (45h) and G2/M (0-10h); TM in G2/M only from 5h.
For cyclin E, CE, thr is the most significant parameter, followed by CE,min. The same pattern is
seen for cyclin B, with CB, thr and CB,min (to a lesser extent) appearing significant throughout.
Initial conditions (Gini and Sini) only appear significant in the first few hours (0-3h) in K-562
and MEC-1. Overall, three groups of significant parameters were identified (Figure 5.5): (i)
CB,min , CB, thr , CE,min and CE, thr for cyclin E & B concentrations; (ii) TG, TS and TM for
cell cycle phase kinetics; and (iii) Gini, Sini and Mini (the percentage of total cells in G1 , S
and G2/M at time zero) for the cell cycle distribution. (i) and (ii) were important throughout
the culture, although phase times (ii) were more significant in their respective phases when a
majority of cells were exiting that phase, or in their subsequent phases, when a majority of
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cells were entering the phase. However, (iii) was only significant in the first few hours. Only
in one of the cell lines (MEC-1) was phase kinetics affected by cyclin threshold/minimum
values (maximum observed sensitivity index value for CE, thr was 0.35). Conversely, cyclin
concentration was only affected by cell cycle times during the initial hours. Finally, since
σE and σB were not identified as significant parameters, they were both fixed at 20% of the
difference CE, thr−CE,min and CB, thr−CB,min. In summary, an accurate determination of the
cell cycle times (TG, TS and TM) for phase kinetics and cyclin thresholds and minima (CB,min,
CB, thr, CE,min and CE, thr) for cyclin expression is essential to fully characterize the model.
5.1.3.2 Experimental validation with cell cycle chase data of three leukemic cell lines
The cell cycle times (TG, TS and TM) were obtained by following the entrance/exit times of the
EdU− population (± 2h) to and from each phase for the first cycle. The initial EdU− cell cycle
distribution was used to initialize and run the model. The agreement between the model and
the experiments was remarkably good for all three phases in each cell line (Figure 5.5), with
the model prediction falling within the 95% confidence region for most time points. For the
geometric mean of cyclin concentration, the trends and magnitudes were captured; although
the experimental data were inherently noisy (due to the need for normalization steps against
isotypes or other phases, which increased the number of sources for data uncertainty, and the
absence of replicates), a reasonable match was achieved.
Experimentally, the fluorescence of thousands of single cells are recorded using flow-
cytometry. This data has to be gathered in a significant manner by aggregating the fluorescences
of all cells and applying statistical analyses to derive significant information. As a downside,
if an event is very fast in time, it is very unlikely that many cells will be found at that stage,
and as a result, the behavior during that short period of time will be lost in the global behavior
of the rest of the population. Oscillations in cyclin concentration appear when the period of
oscillation (the phase time) is larger than both the sampling frequency and the dispersion in the
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Figure 5.5: Cell cycle phase kinetics Comparison of experimental results (red dots) to model output
(black lines) in cell cycle phase percent (top 3 panels: G0/G1, S, G2/M phases) or normalized cyclin E
& B expression (2 bottom panels) over time. 95% confidence areas are shown according to the standard
deviation of G0/G1, S and G2/M (n=2/3). Sensitivity indexes for the most significant parameters (>0.1)
on each output are shown beneath.
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phase. In the case of cyclin E, since G1 phase represents a substantial portion of the total cell
cycle time, oscillations were more evident. However, due to a generally shorter G2/M phase,
the oscillations for cyclin B can only be seen in the beginning, when the EdU− population was
more narrowly distributed. For instance, a cell line with a faster G2/M phase, such as MOLT-4,
will only reveal the cyclin B peak at the very beginning, while K-562, which has much slower
G2/M kinetics, displays the whole cyclin B trajectory. Cyclin concentration, both in vitro and
in silico, is the result of population-wide averaging (geometric mean). If two different popula-
tions appear in the same phase, an averaged cyclin concentration level is reached, which might
not be representative of any of the two.
Table 5.1: Measured Parameter Values
K-562 MEC-1 MOLT-4
CE,min (%) 10 10 0
CB,min (%) 22 20 60
CE, thr (%) 50 30 80
CB, thr (%) 180 135 125
GEdU−,0 (%) 69 74 66
SEdU−,0 (%) 9 14 31
MEdU−,0 (%) 22 12 3
S0,1 (%) 20 42 67
S0,2 (%) 44 4.8 10
S0,3 (%) 32 4.2 8
S0,4 (%) 4 35.9 14
TG(h) 9 8.5 12
TS(h) 10 7.5 15
TM(h) 5 3 2
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Figure 5.6: Recalculation of cyclin B trajectory when accounting for amended initial cell cycle
distribution (EdU−): (A) Entrance of displaced S phase cells at 2-4h into G2/M phase when a small,
previously present population of G2/M reaches the bin where the threshold cyclin B concentration oc-
curs. Effect due to experimental DNA deconvolution errors. (B) Geometric mean of cyclin B evolution
with corrected initial conditions (no cells in the second half of S phase at time zero). Observe how the
match with the model becomes closer. (C) Residual Sum of Squares (RSS) of the experimental and
computational results of (B) over time. All but one data points fall within the experimental error region
(10%).
This is the case for cyclin B concentration profile in K-562: the DNA deconvolution of
the initial S-phase cell cycle distribution places a fraction of the cells that were in the left-
most section of the second DNA peak at the right-most part of S phase. Indeed, this caused a
fraction of the S-phase population to enter G2/M at 2-4h, completely shadowing the high cyclin
B concentration of the remaining G2/M population at that time (Figure 5.6A). If corrected for
no cells at the end of S phase initially, the model matched the experimental data (Figure 5.6B)
in all but one points as determined by the residual sum of squares (Figure 5.6C). Cell numbers
analyzed in this region are significantly lower since cells keep exiting the phase; experimental
data becomes less robust, explaining the mismatch observed at 6h.
GSA revealed that the most significant parameters for phase kinetics were the cell cycle
times. Furthermore, the analysis showed that initial cell cycle distribution values were not
necessary for longer analyses (over 5h). We hypothesized that co-culture conditions would
have an effect on individual kinetics. A preliminary K-562/MEC-1 co-culture experiment was
carried out at 3 set ratios: 10%, 50% and 90% MEC-1. MEC-1 kinetics was clearly slower, so
its time parameters were readjusted to fit the experimental data in one of the cultures (50%),
and the new model results were validated against the 10% and 90% experiments (Figures 5.7(a)
and S2). Observe how the relative RSS is higher towards the end of the culture (Figures 5.7(a)
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and 5.7(b)), especially in the 90% and 10% MEC-1 co-cultures, and much lower in all other
time points.
The model remains sensitive to the quality of the data collected as observed in Figures 5.6
and 5.7(a). The method presented is applicable but it is recommended to increase the number
of replicates for cyclin sampling, as well as shorten the duration of each experiment (or change
culture medium more often) in order to avoid a different behavior towards the end of culture.
5.1.3.3 Forward and backward heterogeneous cell population dynamics can be pre-
dicted using the PBM
Nine different co-culture mixtures of the cell lines were prepared by operator 1 (Table 5.3).
Operator 2, blinded to the nature of the samples, performed the analysis at time 0 and deter-
mined the initial percent of each cell type in order to run the model. Subsequently, the rest
of the samples were analyzed, after which all the data was gathered and compared to model
simulations. In the last three tests, the model was also evaluated for its backward prediction
capability.
Ternary plots are commonly used for the representation of mixtures containing three el-
ements, whose contents are quantified in the axes on the triangle sides. The evolution of
the mixture as a function of temperature (isotherms), pressure (isobars) or others can be di-
agrammed on the ternary plot, which then informs on the routes that can be followed according
to physical constraints. They are frequently used in separation processes in the chemical and
oil industry, but are also useful here as a single diagram of culture evolution over time. For this
application, we will adapt them to a biological scenario, where no environmental conditions
can be changed, at least in the simplest case where the co-culture is performed under standard
conditions. If, for example, a metabolic model was used and glucose and oxygen conditions
were changed in culture, different routes could be followed according to the nutrient levels.
With unchanged properties throughout the culture, the only variable remaining is time which
can then be represented as curves traversing the triangle, calculated based on the individual cell
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line parameters. In order to plot these curves, it is beneficial to assume a mixture composition
as far as possible from equilibrium (which practically means avoiding mixtures with high con-
tents of the fast growing cell line). Simulations are run based on the existing parameters and
the culture evolution over time is plotted on the triangle for each case (Figure:5.8). This allows
us to identify future and past mixture compositions knowing only the current composition and
the time passed between both time points, which is extremely useful in predicting and studying
leukemia dynamics.
Table 5.2: Co-culture parameter values
Co-culture # K-562 MEC-1 MOLT-4
CE,min (%) 10 10 0
CB,min (%) 22 20 60
CE, thr (%) 50 30 80
CB, thr (%) 180 135 125
TG (h) 9 12.1 12
TS (h) 10 10.7 15
TM (h) 5 4.3 2
T1 18 30 52
T2 10 17 73
T3 40 0 60
T4 0 12 88
Measured cell line % T5 31 69 0
T6 13 17 70
T7 81 6 13
T8 64 36 0
T9 15 38 47
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A pre-run plot of model predictions (see Table 5.2 for details on model parameters used)
was used to estimate the evolution of cell line contents (Figure 5.8A) together with the total
cell number. The experimental trends for the total cell kinetics in the last three tests (T7-T9)
were correctly predicted (Figure 5.8B). Later points were over-estimated; the reason for this
is two-fold: (i) nutrient depletion and metabolite accumulation can have a negative effect on
growth which the model does not currently incorporate; and (ii) MOLT-4 and MEC-1 have
maximum recommended densities of 1.5-2M cells/mL while K-562 cannot grow at such high
cell densities: T9, with a higher content of MEC-1 and MOLT-4, was correctly predicted,
while for T7 and T8 (which have a majority of K-562 cells) the model overestimates the last 2-
3 points where the cell density was over 1-1.2M cells/mL. The model accurately predicted the
evolution of all cell populations for the duration of the second part of the experiment (0-30h,
Figure 5.8C). Additionally, the contents of the original mixture (at -48h) were found correctly
in 2 out of the 3 cases (Figures 5.9A and 5.9D).
5.1.3.4 Unknown heterogeneous leukaemic populations can be deconvoluted using the
PBM platform
A second strategy was implemented where operator 2 pre-ran the model assigning each initial
percent to each of the cell lines (resulting in 6 different possible scenarios per blind experi-
ment, Figure 5.10). The whole experimental panel was then revealed (unassigned to specific
cell lines) and compared to the model output of each scenario in terms of Euclidian distance
in the ternary plot: the lower the distance (relative to the other 5 scenario), the likelier to be
a good match. The advantage of using this method is that a single measurement delivers all
the information required to assess the closeness of a particular solution, in comparison with
three (two considering one is dependent through the percentage equation) cell line percents.
The ranking of the scenarios likeliness given by the model for each mixture is shown in Fig-
ure 5.11. In mixtures T1, T2, T3 and T7, the model’s highest ranking candidate matched the
true experimental content (Table 5.3), while in a further 3 mixtures (T6, T8 and T9) the actual
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Figure 5.8: Ternary plot of cell line content evolution. K-562 being the fastest, any combination results
in a higher % K-562. Horizontal ticks denote 100h culture time.
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Figure 5.9: Forward and backward culture evolution: (A) ternary plot of predicted vs experimental
culture evolution: lines represent model simulation of culture evolution while points denote experimen-
tal values; (B)comparison of experimental total cell counts (red dots) vs model output (dashed lines)
for T7, T8 and T9;(C) comparison of experimental cell line content (%) to model output given only the
initial conditions in 9 different blind tests (T1-T9) over time; (C) backward prediction of population
dynamics in T7, T8 and T9 cultures. E: experimental value; M: model prediction. Envelopes in (B) and
(C) represent 95% confidence areas according to experimental standard deviation, n=3.
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Figure 5.10: Example of a model calculation with 6 different scenarios (co-culture T6)
Chapter 5 Marı´a Fuentes Garı´ 95
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Figure 5.11: Ranking of scenarios likeliness according to Euclidian distance between experimental
data and PBM output: K/M4/M1 is the right answer in all cases, as correctly guessed by the model.
(K: K-562; M4: MOLT-4; M1: MEC-1).
Table 5.3: Real cell line contents of blind tests
K-562 MEC-1 MOLT-4
T1 20% 40% 40%
T2 17% 17% 66%
T3 50% 0% 50%
T4 0% 20% 80%
T5 10% 90% 0%
T6 10% 30% 60%
T7 80% 10% 10%
T8 60% 40% 0%
T9 20% 50% 30%
content was found in one of the top 3 candidates. Overall, the correct solution, as a sum of
the Euclidian distances in all 9 tests, scored lowest. Only in two cases (T4 and T5) did the
model fail to identify the actual mixture as a real candidate, partly because other scenarios had
extremely close values (within the experimental error margins). Of note, cells were co-cultured
in non-standard conditions (cell densities and cell culture media used), challenging the ability
of the PBM to work under uncertain conditions. Finally, the cell cycle times of the three cell
lines used were relatively close; primary leukemic cells may have more disparate populations,
with variation of days [105]. In this case, the differences would be largely sufficient for the
model to identify and quantify heterogeneous cell populations based on cell cycle kinetics.
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5.1.4 Conclusion
A PBM of the cell cycle based on cyclin concentration and DNA content was developed and
utilized to deconvolute leukemia population kinetics. GSA established which model parame-
ters were critically required (and which did not need to be identified) and they were obtained
experimentally for three leukemic cell lines by following a synchronous cell population over
time, after which the model was run and compared against the actual cell cycle distribution and
cyclin concentration. The agreement between the model and the experimental data was excel-
lent, for micro (intracellular growth) as well as macro (population growth) kinetics, with most
predictions falling within the 95% experimental confidence area. The model was successfully
used for two different strategies in the context of co-culture kinetics: (i) the prediction of back-
ward and forward culture evolution given known cell line-specific cell cycle kinetics and initial
conditions and (ii) the identification of cell type and content given an unknown experimental
panel.
Clonal heterogeneity of AML and competitive outgrowth of more “fit” clones in a “Dar-
winian” model renders the successful treatment of this disease particularly challenging [45]. It
is currently unclear which factors within a subclone or in the microenvironment make certain
clones out-compete others and how this dynamic can be altered by chemotherapy schedule
[105, 45, 124]. Recently, it has been proposed that tumor-specific cell-autonomous and non-
cell-autonomous factors (e.g. cytokines) can alter growth kinetics and properties of tumors
and that these qualities may be targeted to manipulate tumor growth [76]. Although there are
many other properties relevant to leukemia and the treatment of leukemia, most if not all of
these factors ultimately affect the cell cycle. Hence, this work describes a model of the cell cy-
cle that can be combined or upgraded to capture additional phenomena such as differentiation
(affecting traditional chemotherapy, but also affected by novel agents targeting specific types
of hematopoietic cells) or environmental cues (metabolism, cytokines, contact inhibition etc).
The key is capturing the most important phenomena at a sufficient level of detail in order to
Chapter 5 Marı´a Fuentes Garı´ 97
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
maintain the fidelity and relevance to the biological system. Defining which are the additional
phenomena that are key in response to chemotherapy is definitely a critical step. Pharmacoki-
netics / pharmacodynamic (PK/PD) models capture body processes that are relevant to the drug
distribution and transport to the bone marrow, as well as its effect, for example. Our model may
be able to capture clonal heterogeneity which, combined with PK/PD, may lead to improved
and more effective therapies.
5.2 Comparison of the PBM to different mathematical mod-
els of the cell cycle
5.2.1 Introduction
Mathematical models representing the cell cycle have been widely developed in the past, start-
ing from Gompertzian models to more complex delay differential equation models of the pro-
liferative and quiescent compartments. The structure of these models and their inherent char-
acteristics play a key role in their applicability to particular problems, such as in the calculation
of the optimal chemotherapy dose. It is of utmost importance to define the complexity required
by the system in order to select appropriate models for the purpose.
This section studies three differential equation models of the leukemia cell cycle: a pop-
ulation balance model (PBM) using intracellular protein expression levels as state variables
representing phase progress; a delay differential equation model (DDE) with temporal phase
durations as delays; and an ordinary differential equation model (ODE) of inter-phase pro-
gression. In each type of model, global sensitivity analysis determines the most significant
parameters while parameter estimation fits experimental data.
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5.2.2 Aims & methodology
We present three cell cycle phase models whose parameters can be measured experimentally.
Two of them have been previously proposed: the cell cycle phase PBM (CCP-PBM) developed
by Fuentes-Garı´ et al. [34] and Munzer et al. [88, 87]; and the Pefani et al. [101] CCP-ODE
model. A new cell cycle phase DDE (CCP-DDE) model featuring phase-specific time delays
is presented here as an example of a DDE model with measurable parameters. DDE cell cycle
models have been widely studied by Colijn and Mackey [17, 18], considering proliferating and
resting cell cycle states, but the parameters required are difficult to obtain experimentally. All
three models (CCP-ODE, CCP-PBM, CCP-DDE) are compared in their ability to: (i) fit exper-
imental data [34]; (ii) satisfy short-term and long-term kinetics; and (iii) capture all oscillatory
features required.
5.2.2.0.1 CCP-ODE
Models are presented with increasing levels of complexity (Figure 5.12, bottom to top). Phase
distributions (percents) are important as they account for oscillatory behavior, in contrast with
phase numbers which increase over time. These distributions can be experimentally measured
by aggregating data from single cell DNA content measurement techniques into averaged pop-
ulation data.
An initial approach is to model cell cycle phases with ODEs, with the parameters needed
being the transition rates and the initial cell populations for each phase. Pefani et al. [101] give
Chapter 5 Marı´a Fuentes Garı´ 99
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Figure 5.12: Model structure in CCP-PBM, CCP-DDE, CCP-ODE with discretization intervals for
CCP-PBM, history vectors and lumped phase compartments for CCP-DDE and lumped phase compart-
ments only for CCP-ODE.
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an example with three compartments (G0/G1, S and G2/M):
dG
dt = 2 ·M/τM−G/τG or
dG%
dt = 2 ·M%/τM−G% ·
(
1/τG+ 1T
dT
dt
)
dS
dt = G/τG−S/τS or
dS%
dt = G%/τG−S% ·
(
1/τS+ 1T
dT
dt
)
dM
dt = S/τS−M/τM or
dM%
dt = S%/τS−M% ·
(
1/τM + 1T
dT
dt
)
T = G+S+M
(CCP-ODE)
where G, S and M are the cell numbers in each of G0/G1, S and G2/M phases (in # cells), T
is the total number of cells (in # cells), G%, S% and M% are the phase fractions of total cells
(in %) and τG, τS and τM are the phase durations (in hours) of the G0/G1, S and G2/M phases
respectively.
5.2.2.1 CCP-DDE
An alternative model accounts for the temporal discrepancy between cells entering and exiting
phases. For this, we developed a new DDE model by introducing a time delay equal to phase
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duration:
dG(t)
dt = 2 ·M(t− τM)/τM−G(t)/τG or
dG%(t)
dt = 2 ·M%(t− τM)/τM−G%(t) ·
(
1/τG+ 1T (t)
dT (t)
dt
)
dS(t)
dt = G(t− τG)/τG−S(t)/τS or
dS%(t)
dt = G%(t− τG)/τG−S%(t) ·
(
1/τS+ 1T (t)
dT (t)
dt
)
dM(t)
dt = S(t− τS)/τS−M(t)/τM or
dM%(t)
dt = S%(t− τS)/τS−M%(t) ·
(
1/τM + 1T (t)
dT (t)
dt
)
T (t) = G(t)+S(t)+M(t)
(CCP-DDE)
where all variables and parameters are defined as in CCP-ODE and G(t − τG), S(t − τS),
M(t − τM) (in # cells) represent the phase cell number at times t − τG, t − τS and t − τM re-
spectively. An important advantage of DDEs is that they add a phase coordinate dimension
to the system (i.e., cell populations are not eligible to exit a phase as soon as they enter),
so any disturbances in time will be well captured. Furthermore, CCP-DDE does not require
any additional parameters and maintains a fast computational execution (see Appendix D for
DDE discretization details and initialization equations). Note that the system is not completely
closed (G(t)/τG cells exiting the G phase versus G(t − τG)/τG cells entering the S phase),
however this results in very small (<3%) variations in total cell number which are transient
(total cell number is conserved at the steady state, see Appendix H).
5.2.2.2 CCP-PBM
Because phase to phase transition in CCP-DDE systems is based on total phase numbers at
earlier times, not intra-phase cell numbers, properties related to phase progression cannot be
deduced. In order to account for properties varying within each phase, distributed systems
such as PBMs must be used. Previously developed PBMs rely on state variables that are not
always measurable and/or do not maintain fidelity to the underlying biology[119]. To make
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this biologically relevant, those properties should be experimentally measurable. In Section
5.1.2.1, we presented a CCP-PBM of the cell cycle with cyclins E and B (CE and CB, proteins
related to phase progression; normalized % expression) as state variables for G0/G1 and G2/M,
where their concentration actively increases throughout the phase, and DNA content (in DNA
units) as state variable for S phase (where DNA replication occurs), Equations 5.1-5.3.
Growth rates (rG = dCE/dt, rS = dDNA/dt and rM = dCB/dt; h−1) correlate phase pro-
gression to its state variable; transition rates (rG→S(CE) and rM→G(CB); h−1) account for the
transition probability according to the state variable level. The model was discretized in cyclin
E (resulting in nE bins with indices e ∈ {1, . . . , nE}), in cyclin B (resulting in nB bins with
indices b ∈ {1, . . . , nB}) and in DNA (resulting in nD bins with indices d ∈ {1, . . . , nD}) and
validated for 3 leukemia cell lines (K-562, MEC-1, MOLT-4) experimentally; the discretized
model and a summary of the transformations required to represent phase fractions (see Ap-
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pendix E for an extended derivation) is given below:
dGe
dt = (1−δ (e−1)) ·Ge−1 · rG ·νE −Ge ·νE ·
(
rG+ rG→S,e
)
+δ (e−1) ·2 ·
nB
∑
b=1
Mb · rM→G,b ·νB
dGe,G%
dt = (1−δ (e−1)) ·Ge−1,G% · rG ·νE −Ge,G% ·
(
rG ·νE + rG→S,e ·νE + dGdt · 1G
)
+δ (e−1) · 2G% ·
nB
∑
b=1
Mb,T % · rM→G,b ·νB ∀e ∈ {1, . . . , nE}
dSd
dt = (1−δ (d−1)) ·Sd−1 · rS ·νD−Sd · rS ·νD+δ (d−1) ·
nE
∑
e=1
Ge · rG→S,e ·νE
dSd,S%
dt = (1−δ (d−1)) ·Sd−1,S% · rS ·νD−Sd,S% ·
(
rS ·νD+ dSdt · 1S
)
+δ (d−1) · 1S% ·
nE
∑
e=1
Ge,T % · rG→S,e ·νE ∀d ∈ {1, . . . , nD}
dMb
dt = (1−δ (b−1)) ·Mb−1 · rM ·νB−Mb ·νB ·
(
rM + rM→G,b
)
+δ (b−1) ·SnD · rS ·νD
dMb,M%
dt = (1−δ (b−1)) ·Mb−1,M% · rM ·νB−Mb,M% ·
(
rM ·νB+ rM→G,b ·νB+ dMdt · 1M
)
+δ (b−1) · 1M% ·SnD,T % · rS ·νD ∀b ∈ {1, . . . , nB}
with: G =
nE
∑
e=1
Ge, S =
nD
∑
d=1
Sd , and M =
nB
∑
b=1
Mb;
and Ge,G% = Ge/G, Sd,S% = Sd/S, and Mb,M% = Mb/M
And the total being:
T (t) =
nE
∑
e=1
Ge+
nD
∑
d=1
Sd +
nB
∑
b=1
Mb
with: Ge,T % = Ge/T , Sd,T % = Sd/T , and Mb,T % = Mb/T
(CCP-PBM)
The parameters νE , νD and νB represent the conversion factor from bins to cyclin expression
and are a result of the discretization method, in G0/G1, S and G2/M phases. The terms rG→S,e
and rM→G,b (h−1) account for the discretized transition rates in each of the G0/G1 (e bins) or
G2/M (b bins) phases. A summary of model parameters and how to obtain them is shown in
Table 5.4.
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Table 5.4: Model parameters and experimental methods needed to obtain them (the model source is
clearly stated, otherwise all models use that specific parameter).
Parameter Lab Lab Data
protocol time processing
Cell cycle chase:
τG, τS, τM In vitro culture (24h+) 40-60h 10-15h
Frequent sampling
GSS,%, SSS,%, MSS,% No culturing needed
G0,%, S0,%, M0,% Initial time point only 2-3h 10min
Fast sample preparation
µ (CCP-ODE) 2 samples needed
γ (CCP-DDE) either in vitro culture 5-10h 10-15min
α(CCP-PBM) or in vivo blood sample
CCP-PBM: σB, σE , 1 sample needed
cycB,min, cycE,min, DNA, cyclin E&B labeling 10-15h 1-2h
cycB, thr, cycE, thr segregate 2 subpopulations
5.2.2.3 Solution of the steady state problem
Cell cycle phases may reach steady state with respect to the percentage of cells in each phase
(G%, S%, M%) but not in the phases themselves (G, S, M) as the absolute count will increase
over time as a result of doubling. Cell cycle models usually oscillate initially when they are
taken out of their equilibrium cell cycle distribution (transient state) and progressively reach
steady state as they approach phase equilibrium. If these models are initialized at equilibrium,
they should not oscillate. The equilibrium cell cycle phase distributions are determined by
setting their derivative to zero (see Appendix E for an extended derivation).
For CCP-ODEs, the equilibrium cell cycle phase distributions are given by the real root
of Eq (E.14) for G%,SS and by Eq (E.11) and (E.12) for M%,SS and S%,SS respectively. The
log-growth coefficient is calculated as:
dT
dt
1
T
=
1
τM
·M%,SS = µ (5.40)
Similarly, Eq (E.27)-(E.29) represent the steady state cell cycle distribution for CCP-DDEs,
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with log-growth coefficient:
dT
dt
· 1
T
=
1
τM
·MSS,% ·
(
2 · e−γ·τM −1)+ 1
τG
·GSS,% ·
(
e−γ·τG−1)+ 1
τS
·SSS,% ·
(
e−γ·τS−1)= γ
(5.41)
Finally, the steady state cell cycle distribution (intra-phase as well as phase totals if summed)
for CCP-PBM is given by Eq (E.60)-(5.38), with the log-growth coefficient calculated as:
dT
dt
· 1
T
=
nB
∑
b=1
Mb,SS,T % · rM→G,b ·νB = α (5.42)
5.2.3 Results & discussion
5.2.3.1 Satisfying short-term kinetics
Defining the transient state requires identifying the significant parameters for each model short-
term (for the first cell cycle) and finding their values through parameter estimation with exper-
imental data.
5.2.3.1.1 What parameters are needed short-term?
Global sensitivity analysis (GSA) was performed for all three models and the sensitivity to the
parameters they have in common (phase durations) was compared for the three phases (Figure
5.13) over one cell cycle (22h) at 0h, 1h and 5h intervals subsequently. It was confirmed
that phase times were significant, especially in their own (cell exit) and the following phases
(cell entrance). For CCP-ODEs (5,000 intervals used in GSA), sensitivity indexes become
approximately constant after 10h, while CCP-DDEs’ sensitivity indices (2,000 intervals) do
not follow any particular pattern and CCP-PBMs (20,000 intervals) seem to keep their indexes
relatively constant and with a lower value.
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Figure 5.13: Comparison of sensitivity indices in G, S or M fractions for τG, τS and τM parameters in
CCP-PBM, CCP-DDEs, CCP-ODEs (MOLT-4).
5.2.3.1.2 Can the models fit experimental data?
To compare the ability of all three models to fit experimental data, we used the synchronous
experimental data of Fuentes-Garı´ et al. [34] together with the CCP-PBM simulation results
reported. Results for all three models can be seen in Figure 5.14, and parameter estimates
for DDE and ODE in Table 5.5. The CCP-PBM and CCP-DDE presented here can capture
synchronous oscillatory behavior while the CCP-ODE fail to account for this intra-phase het-
erogeneity, resulting in a lack of fit of this particular model, as confirmed by the residual
sum of squares (Table 5.6). Linear stability analysis (LSA) is a model analysis technique that
determines systems of differential equations’ dynamic behavior prior to any simulation, by as-
sessing the stability of its steady states[31]. LSA was performed on CCP-ODE revealing that
a decaying amplitude oscillatory behavior is expected for the whole working parameter range
(see Appendix F for details). Spatial (such as protein expression in CCP-PBM) or temporal
(such as the delay history in CCP-DDE) distributions easily facilitate capturing oscillations
computationally. The fitted model parameters are always lower for CCP-DDE and higher for
CCP-PBM. For CCP-ODE, the fitted parameters do not follow any specific patterns, but in
Chapter 5 Marı´a Fuentes Garı´ 107
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Figure 5.14: Comparison of experimental phase percents in 3 leukemia cell lines (K-562, MEC-1,
MOLT-4) with simulation results for CCP-ODE, CCP-DDE, CCP-PBM.
general are closer to the ones of CCP-PBM. Overall difference between values outside the ex-
perimental range is 2h for CCP-PBM, 10.3h for CCP-DDE and 4.7h in CCP-ODE. Therefore,
the CCP-PBM cell cycle times are consistently the closest to the ones measured experimentally
and are thus the most biologically meaningful.
In summary, CCP-ODE do not capture the short-term oscillatory behavior required; CCP-
DDE capture it well but its parameters do not correlate to the underlying biology; finally, CCP-
PBM produce both the oscillations required and parameters in the range of the ones found
experimentally.
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Table 5.5: Phase time parameters estimated in each of the three models as compared to the ones obtained
experimentally.
Cell line CC phase time CCP-PBM CCP-DDE CCP-ODE Exp. measurements
τG 9.0h 4.4h 5.8h 6 ± 2h
K-562 τS 10.0h 6.6h 12.0h 10 ± 2h
τM 5.0h 2.7h 3.9h 4 ± 2h
τG 8.5h 4.6h 8.4h 7 ± 2h
MEC-1 τS 7.5h 2.9h 5.6h 8.5 ± 2h
τM 3.0h 2.6h 4.7h 5 ± 2h
τG 12.0h 5.0h 4.2h 10 ± 2h
MOLT-4 τS 15.0h 8.5h 10.3h 12 ± 2h
τM 2.0h 1.4h 1.1h 2 ± 2h
Table 5.6: Residual sum of squares (RSS) for the parameter vs. experimental measurement bounds in
each model, for each cell line.
Cell line CCP-PBM CCP-DDE CCP-ODE
K-562 0.1017 0.1038 0.6527
MEC-1 0.1046 0.0461 0.3550
MOLT-4 0.0488 0.0468 0.3906
5.2.3.2 Satisfying short-term and long-term kinetics
The previous section showed that transient kinetics for 1 cell cycle is successfully captured
by both CCP-DDE and CCP-PBM, albeit with parameter discrepancies compared to the ac-
tual experimental measurements for CCP-DDE. For a short-term scenario (1 cell cycle), cell
cycle durations sufficiently simulate phase kinetics; alternatively, steady state parameters may
be used to calculate them (see Appendix E). Phase variabilities can be set at their nominal
level since they are not significant in the short-term. If protein kinetics is also required, then
minima and thresholds for each of them have to be determined for the CCP-PBM. This was
further confirmed by the GSA results [34]. However, transient kinetics provides only partial
information, as steady state behavior represents a major component of leukemia growth in the
resting periods between chemotherapy cycles (Figure 5.15).
5.2.3.2.0.1 Defining the oscillatory behavior required The oscillatory behavior is char-
acterized by its time to steady state, value at the steady state and oscillation amplitude (all
Chapter 5 Marı´a Fuentes Garı´ 109
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Figure 5.15: Summary of model parameters needed to describe short-term cell cycle kinetics.
observable experimentally, Figure 5.16), for each of the phases. It is worth mentioning that
previous steady state analyses performed on one compartment models have determined ana-
lytically the rate at which oscillations decay over time [67]. The exponential rate at which
oscillations decay has not been found in models similar to CCP-PBM with three distributed
compartments[9]. However, numerical simulations can be run for specific cases and relevant
parameters such as the amplitude of the oscillations or the time to steady state can be obtained.
The equations reproduced here are for G phase but equations for S and M would be obtained
similarly. The time to steady state (TSS,G) is defined as the time it takes for oscillations to
dampen to a level lower than a certain tolerance ε , or:
|GSS,%−Gpeak,%(TSS,G)|
GSS,%
< ε (5.43)
As a standard, ε = 1% will be used in the simulations subsequently, since the experimental
error is in the 1% range and does not allow identifying oscillations under that threshold.
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The value at steady state is calculated as discussed in the Model Definitions Section, while
the amplitude of the oscillations (AG) represents the deviation from the steady state value at
each of the peaks:
AG =
|GSS,%−Gpeak,%(t)|
GSS,%
(5.44)
In order to satisfy oscillations at all three levels mathematically, three degrees of freedom per
phase are required.
5.2.3.2.0.2 Can the model satisfy both? For CCP-DDE and CCP-ODE, all parameters
have already been utilized for the initial dynamics; they do not have enough degrees of freedom
to validate both the transient state and the steady state and will have a significant limitation
tackling long-term dynamic problems. Adjusting oscillatory behavior at all dimensions (TSS,G,
TSS,S, TSS,M, GSS,%, SSS,%, MSS,%, AG, AS and AM) is only possible in CCP-PBM. Up to now,
only 2 parameters per phase have been exploited: phase times and initial conditions. However,
there is a parameter that did not appear significant in the first few hours in PBM, but has
an important influence in those oscillatory properties later on: the standard deviation for the
transitions in G and M. In fact, it is the interplay between phase duration and variability in
the transition that defines the CCP-PBM’s oscillatory characteristics. Different values of τG
and σE were tested (all else being equal) based on MOLT-4 parameters; results are shown in
Figure 5.16. Increasing variability decreases TSS, GSS and AG (after the first oscillation), while
resulting in a more pronounced first oscillation. Conversely, increasing τG does not have such
a significant impact on TSS, with increased variation in GSS, and a clear difference in AG for
the first oscillation (moderately later). Finally, higher deviations from GSS in the initial phase
percents result in longer TSS and larger AG, but no effect is seen in the actual value GSS (as
expected since the initial conditions do not appear in the steady state equations).
5.2.3.2.0.3 What parameters are needed long-term? To accurately define the param-
eters needed long term, we performed a GSA on the CCP-PBM for 500h, varying the phase
times (τG, τS and τM) and phase variabilities (σE and σB). The initial conditions were already
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not significant at 100h in previous analyses so they were not included here. The sensitivity of
the phase fraction amplitudes (AG, AS and AM) was monitored over time, while the sensitiv-
ity of the steady state variables (GSS,%, SSS,% and α) and the time to steady state (TSS) were
recorded at the end of the 500h period (when all dynamic simulations had reached steady state
as defined by ε).
The GSA results reported in Figure 5.17 reveal that G2/M phase parameters are not very
relevant to the overall oscillatory behavior (it is the shortest phase by hours). Next, we see
that τS is very significant for AG and AM initially but decreases with time, as τG sensitivity
increases mildly. τG is equally significant for AS and decreases only slightly with time. The
effect of variables from previous phases on the entrance of cells is confirmed long-term (for
G0/G1, it is τS that becomes relevant since G2/M is very short). Additionally, σE becomes
more significant in the long-term (although its sensitivity index (SI) stays below the one of
τG). Therefore, the amplitude of the oscillations depends partly on the variability in G phase,
which was also observed in cell automata models[1] and experimentally[55]. To summarize,
the amplitude of the oscillations is controlled by phase durations at earlier times and by a
balance of phase durations and phase variability at later times. For the steady state values, only
τG and τS appear significant (SI ≥ 0.1). Surprisingly, for TSS, only τS is important.
5.2.3.2.1 Can the necessary parameters be measured?
The necessary parameters for CCP-DDE and CCP-ODE are the initial conditions and either
the steady state distribution + log-growth coefficient (“steady state parameters”) or the phase
times (“dynamic parameters”). CCP-PBM will require additionally the transition variabilities
for G and M (Figure 5.18).
Obtaining dynamic parameters experimentally requires labeling a cellular subset (S phase
cells which incorporate the DNA label during the duplication process) in culture and tracking
its phase-to-phase movement over one cell cycle; this is because natural asynchrony makes
it impossible to watch cells move in a unified manner between phases. State variable levels
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Figure 5.16: Capturing oscillatory properties: a. experimental evolution of G0/G1 % (MOLT-4 cell
line) over 40h, vs CCP-PBM output under different scenario: b. varying the standard deviation of the
transition probability; c. varying the phase time; or d. varying the initial phase fraction (all else being
equal).
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Figure 5.17: Global sensitivity analysis of CCP-PBM oscillations over 500h (MOLT-4), varying phase
times and variabilities. Outputs monitored are the amplitude of the oscillations in each phase (top 3
panels) and the steady state variables (at 500h).
Figure 5.18: Experimental protocols to carry out in order to obtain each of the parameter sets. “Dy-
namic parameters” require culturing cells for some period of time, while “steady state parameters” can
be obtained directly from any samples.
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(cyclins E and B, and DNA content) are monitored in parallel in order to seamlessly validate
CCP-PBM’s phase progression features. Tracking typically occurs over the course of one cycle
(20-40hrs for cell lines) and needs a minimum sampling frequency to shape phase oscillations
(2-4hrs). Cell cycle times (τG, τS and τM) are extracted directly from experimental data, and
then the model can be validated against the dynamic phase evolution.
In contrast, steady state parameters, as their name suggests, need only selected static data
to be determined. For the steady state phase distribution (GSS,%, SSS,%, MSS,%), a single sam-
ple (in exponential growth conditions) is sufficient, as the experimental measurement itself
gives directly the phase fractions. For the log-growth parameter (α , γ or µ , depending on the
model), at least two samples from different times (taken from the same unchanged culture) are
needed. However, increased sample numbers give a higher accuracy for both parameter types.
Typically, these measurements can be obtained in parallel with others (no need for cell cycle-
specific experiments) and during convenient times (not limited to specific times within one cell
cycle). As a downside, the data obtained is insufficient to reliably validate the simulations.
In vitro, any of the two parameter sets can be obtained, albeit with significantly different
experimental effort. Because both parameter sets are linked through the steady state equations
(Appendix E), they can be used interchangeably in silico. Since models provide this flexibility,
and parameters are generally extremely difficult to obtain in vivo, the solution with the lowest
sampling and requiring only standard blood samples (no experimentation on patients), which
corresponds to the steady state parameters, will be best (however this method still remains to
be validated experimentally).
5.2.4 Conclusions
Three different models representing cell cycle kinetics were presented here and analyzed for
their ability to capture oscillations under the same steady state behavior. When fitted to experi-
mental data, only CCP-DDE and CCP-PBM performed well, with CCP-PBM having the most
biologically relevant parameters (additionally to accurately predicting intracellular protein ex-
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pression as reported in Fuentes-Garı´ et al. [34]). A procedure for converting a set of in vitro
measured model parameters to a different set of model parameters that define model dynamics
equally well is then presented. An important advantage of this is that the new set of parameters
could potentially be obtained in vivo from static measurements (blood tests), becoming more
relevant clinically (as opposed to the initial set of parameters requiring dynamic data and thus
cell cultivation, although this remains to be demonstrated experimentally). A second advan-
tage of interconvertibility in parameter sets was homogeneity and unequivocal definition with
respect to expected behavior under PK/PD conditions, which are the subject of the next section.
5.3 Coupling cell cycle models to a PK/PD model of chemother-
apy for AML
5.3.1 Introduction
Since cell cycle phase ODEs (CCP-ODEs) provide only a simplified representation of cell
cycle progression, we hypothesize that the cell cycle model itself, in addition to its parameters,
would have an impact on simulated chemotherapy response. More complex types of models
such as population balance models (PBM) which are distributed in a second progression-related
variable, or delay differential equation models (DDE) which account for the phase-induced
time delay, could be more suited for the purpose. The cell cycle is typically an oscillating
system; its equilibrium lies at the steady state cell cycle distributions and log-growth. However,
when taken out of the equilibrium, cell fractions undergo a transient state that is characterized
by the oscillatory properties of the specific model chosen[31]. Under chemotherapy treatment,
oscillations play a key role as they determine how much room there is for chemotherapy action
(favorable times: target phase highs; unfavorable times: target phase lows)[35].
In order to compare models based purely on the output resulting from their structural prop-
erties, an expected behavior has to be defined to couple each cell cycle model to a pharmacoki-
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netic/pharmacodynamic model of chemotherapy delivery.
5.3.2 Aims & methodology
The application of the cell cycle model developed is clearly in upgrading the existing PK/PD
model with a detailed description of cell cycle kinetics, which were found to be the most signif-
icant factor affecting overall treatment response. The models presented in the previous section
will therefore be compared in their performance under chemotherapy treatment as dictated by
the PK/PD model of Pefani et al. [101].
5.3.2.1 Embedding CC models into a previously developed PK/PD model
Pefani et al. [101] developed a PK/PD model simulating patient response to chemotherapy
delivery with two common drugs, cytarabine (Ara-C) and daunorubicin (DNR). Ara-C acts
by interfering with DNA duplication (in S phase only)[49]. DNR attacks S phase cells by
DNA intercalation but also G1 cells by inhibition of macromolecular biosynthesis[40]. The
treatment prescribed by the physician is used as an input variable consisting of drug dose
and administration route. Parameters adjustable on a case-by-case basis included height and
weight, age and cell cycle times (Figure 2.4).
Pharmacokinetics (PK) considers the transport and transformation the drug undergoes once
it reaches the blood streams, and in turn the relevant organs which absorb it at different rates.
Mass balances are performed in each of these organs, giving the drug concentration profiles,
which are the main input for pharmacodynamics (PD). In the PD model, the drug effect on cells
is computed according to cell cycle kinetics. Since chemotherapy acts only during specific cell
cycle phases, detailed cell cycle equations modeling the point of drug action are needed (as
confirmed by their global sensitivity analysis).
The drug effect term is applied differently in each model. The effects occur only in the G
and S compartments and are accounted for through kd,G and kd,S death rates, respectively. In
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the original CCP-ODE model, they are included directly into each equation as:
dG
dt = 2 ·M/τM−G/τG − kD,G ·G
dS
dt = G/τG−S/τS − kD,S ·S
dM
dt = S/τS−M/τM
(CCP-ODE-PD)
When moving to CCP-DDE, the temporal delay has to be considered: cells in those phases are
subject to chemotherapy for as long as the delay lasts.
dG(t)
dt = 2 ·M(t− τM)/τM−G(t)/τG − kD,G(t) ·G(t)
dS(t)
dt = G
∗(τG)/τG−S(t)/τS − kD,S(t) ·S(t)
dM(t)
dt = S
∗(τS)/τS−M(t)/τM where:
dG∗(t∗)
dt∗ =−kd,G ·G∗(t∗) with G∗(0) = G(t− τG)
dS∗(t∗)
dt∗ =−kd,S ·S∗(t∗) with S∗(0) = S(t− τS)
(CCP-DDE-PD)
Finally, the drug is applied similarly to CCP-PBM, in a homogeneous manner throughout the
relevant phases:
dGe
dt = (1−δ (e−1)) ·Ge−1 · rG ·νE −Ge ·
(
rG ·νE + rG→S,e ·νE + kd,G
)
+2δ (e−1) ·
nB
∑
b=1
Mb · rM→G,b ·νB ∀e ∈ {1, . . . , nE}
dSd
dt = (1−δ (d−1)) ·Sd−1 · rS ·νD−Sd ·
(
rS ·νD+ kd,S
)
+δ (d−1) ·
nE
∑
e=1
Ge · rG→S,e ·νE
∀d ∈ {1, . . . , nD}
dMb
dt = (1−δ (b−1)) ·Mb−1 · rM ·νB−Mb ·νB ·
(
rM + rM→G,b
)
+δ (b−1) ·SnD · rS ·νD
∀b ∈ {1, . . . , nB}
(CCP-PBM-PD)
Note that the percentage of cells killed at a given time point is the same in all three models,
however CCP-DDE-PD and CCP-PBM-PD incorporate drug effects (due to phase distribution
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Table 5.7: Cell cycle times converted from CCP-DDE to CCP-PBM and CCP-ODE for the steady state
conditions chosen (GSS,% = 79.3%, SSS% = 16.0%, MSS% = 4.8%, α = µ = γ = 0.0157h−1)
CCP-PBM CCP-DDEs CCP-ODEs
τG 36.8h 16.6h 41h
τS 8.9h 4.7h 10h
τM 3.4h 1.5h 3h
in either time or space) in a time-cumulative manner while CCP-ODE-PD only account for
instantaneous effects of that particular dose.
5.3.2.2 Setting the grounds for comparison
At this point, and given the limitations CCP-DDE and CCP-ODE inherently display to satisfy
both dynamic and steady state constraints, a choice has to be made between both. If we choose
to satisfy dynamic constraints (lacking degrees of freedom), only short term, transient kinetics
will be well captured. On the contrary, if steady state constraints are satisfied, total cell kinetics
and cell cycle distribution will be correctly simulated long-term, at the expense of initial dy-
namics. The decision should be taken based on the application envisaged: since the purpose of
cell cycle models is to capture the response to chemotherapy (long-term process that starts at
steady state, highly dependent on total cell number), ensuring an accurate steady state response
is critical. Based on this choice, and for CCP-PBM/CCP-DDE/CCP-ODE comparisons to be
fair, the total kinetics (so that the cell number is equal) and the cell cycle distribution (so that
the percentage of cells likely to be affected when chemotherapy starts) will have to be equal at
steady state.
Equaling α = γ = µ (Eq (5.40)-(5.42)) and two of the phase fractions (GSS,%,CCP-ODE =
GSS,%,CCP-DDE =GSS,%,CCP-PBM; SSS,%,CCP-ODE = SSS,%,CCP-DDE = SSS,%,CCP-PBM), cell cycle
times can be converted from one system (CCP-ODE, CCP-DDE, CCP-PBM) to another. Given
the cell cycle times in the CCP-DDE system (which is the most complex to solve practically),
all other cell cycle times can be obtained through this process of equaling the total growth rate
and the phase distributions at steady state (see sample parameter conversion in Table 5.7).
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5.3.3 Results & discussion
5.3.3.1 How sensitive is the model to chemotherapy effects?
We have seen that both CCP-PBM and CCP-DDE are capable of fitting synchronous exper-
imental data, a fact that is critical in modeling chemotherapy due to its phase-specific action
(G1 and S phase) and subsequent aggregation of cells into synchronized populations [119]. In
this section, each model will be embedded into a PK/PD model of chemotherapy delivery in
leukemia [102] and tested for its sensitivity to chemotherapy (as captured by the chemother-
apy drug effect parameters kD,S and kD,G for S and G1 phases respectively in CCP-ODE-PD,
CCP-DDE-PD and CCP-PBM-PD).
An example male patient that is 167.5cm tall and 79.3kg in weight, 80 years old, receiving
a chemotherapy treatment of 100 mg/m2 Ara-C (12h infusion twice a day for 10 days) and 50
mg/m2 DNR (pulse dose on days 1, 3 and 5) is selected for a PK/PD comparison. The latter
are the input parameters for the PK model.
Comparing total cell evolution over the treatment period in the three models (Figure 5.19),
we observe that the CCP-ODE-PD sensitivity to chemotherapy is effectively lower due to its
inherent tendency to allow the passage of cells from phase to phase (Figure 5.20). Its absence of
intra-phase distribution results in a fraction of the cells in S always eligible to move to the next
phase. Conversely, CCP-DDE-PD and CCP-PBM-PD allow for cells to be distributed in each
phase (temporally and spatially, respectively), creating a downward trend in the percentage of
cells in the distribution. This is in accordance with the intuitive fact that subjecting cells to
drug effects throughout a phase will make it less likely to find cells at the end of the phase.
As a result, fewer cells are found in CCP-DDE-PD and CCP-PBM-PD in G2/M (Figure 5.19).
CCP-ODE-PD reach higher G2/M phase percents, representing the higher fraction of S phase
cells coming in. The percentage of G2/M cells becomes critical due to its impact on total cell
duplication (if cells do not reach mitosis, duplication cannot occur).
Drug sensitivity is reflected in the slope (logarithmic) of the decrease in the total leukemia
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cells: moderate for CCP-ODE-PD, intermediate for CCP-DDE-PD and steep for CCP-PBM.
CCP-DDE-PD response seems to be halfway between CCP-PBM-PD and CCP-ODE-PD, in
that cell totals are 2-3 orders of magnitude above CCP-PBM-PD and below CCP-ODE-PD,
while the cell cycle distribution oscillatory behavior can be broadly said to be a combination
of CCP-ODE-PD (peak timings) and CCP-PBM-PD (central value). Note that CCP-PBM-
PD and CCP-DDE-PD fluctuate approximately around the steady state value for S and G0/G1
fractions during treatment, while CCP-ODE-PD remain at a high for G%, compensated by a low
S%. Oscillations post-treatment are the most sustained for CCP-PBM-PD, while CCP-DDE-
PD take 1-2 cell cycles to stabilize and CCP-ODE-PD immediately reach steady state. Further,
when changing the σ /τ balance in G0/G1 and G2/M for the CCP-PBM-PD (always maintaining
the same steady state), oscillations decrease in amplitude when increasing σ (Figure 5.21) and
may converge to a shape similar to the CCP-DDE-PD oscillations (see σ = 50%). Similarly,
totals become lower at the end of treatment with decreasing σ .
Cojoracu and Agur [16] obtained a similar result related to increased resistance of higher
standard deviations of phase durations. Even with the highest variability tested (σ = 50%), the
total number at the end of treatment (day 10) is lower than the one for CCP-DDE-PD (despite
the cycle fractions being very similar). The simple fact that the CCP-PBM-PD’s oscillatory
behavior can be adjusted allows for the possibility of taking into account these discrepancies
in treatment response. Incorporating phase duration variability in CCP-DDE-PD could help
overcome some of its limitations by increasing flexibility, however CCP-PBM-PD’s biological
relevance paired with the possibility to assign progression coordinates outmatch the predicted
advantages of an improved CCP-DDE-PD model. Significant differences have been observed
in model behavior especially when all efforts have been made to make model conditions as
close as possible.
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Figure 5.20: Model mechanics under chemotherapy effects. Observe that total cell kill at time t is the
same, however the drug effect bin after bin (for CCP-PBM-PD, or time after time, for CCP-DDE-PD)
results in decreasing percentages of the population that initially entered the phase reaching the final bins
(for CCP-PBM-PD, or times for CCP-DDE-PD).
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5.3.4 Conclusions
Each of the models was embedded in a PK/PD model of chemotherapy for AML and a pa-
tient case was run. Throughout the treatment, CCP-ODE had the highest percent of cells in the
G2/M phase and the lowest amount of cell kill, which was explained by their inability to capture
intra-phase distributions, letting cells transition to the next phase as soon as they have entered
(thus escaping continuous phase exposure to the chemotherapy effect). Conversely, CCP-PBM
and CCP-DDE set a spatial or temporal restriction to the eligibility of cells to transition to the
next phase, and subject those cells for a minimum phase time to the effect of chemotherapy
(leading to a lower percent of G2/M cells and a higher cell kill at the end of the treatment). Re-
sults suggest that the particular cell cycle model chosen highly affects the simulated treatment
outcome, given the same steady state kinetic parameters and drug dosage/scheduling.
The CCP-PBM model presented here provides a good trade-off between capturing more
complex pathway and protein kinetics, which are normally reported in mechanistic models
only, and maintaining a computationally efficient solution representing global cell kinetics,
of which the CCP-ODE discussed is a clear example. Importantly, treatment personalization
requires defining measurable parameters representing patient heterogeneity[68]. Our CCP-
PBM is seamlessly linked to experimentally measurable parameters that have been reported
to be highly heterogeneous among AML patients [110, 43]. Due to its distributed structure,
our CCP-PBM captures cell cycle oscillatory complexity to a great extent, despite being an
aggregate model. Moving to more detailed, experimentally validated models is clearly the way
forward.
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5.4 Capturing clonal heterogeneity in leukemia
5.4.1 Introduction
Heterogeneity in the context of AML plays a major role in the prognosis and individual treat-
ment outcomes. For instance, AML patients with the NPM1+ mutation have been reported to
have a good prognosis overall [30, 115]. However, when in tandem with the FLT3-ITD muta-
tion, prognosis becomes poorer [134, 114, 37]. In this work, we investigated: (i) the impact of
S phase durations on the outcomes of either NPM1+ or FLT3/ITD+NPM1+ patients, and (ii)
whether the treatment could affect dominance of one clone over the other during treatment.
5.4.2 Aims & methodology
The aim of this section is to demonstrate that heterogeneity in cell cycle kinetics plays a key
role in the evolution of the clonal pool, and that our model is capable of predicting positive and
negative chemotherapy outcomes based on clonal contents and their properties alone.
Since S phase duration and overall doubling times were the most critical factors for chemother-
apy, we use the CCP-PBM-PD model to predict outcomes[98] under a standard 3+10 DA treat-
ment consisting of 3 doses of 60mg/m2 daunorubicin (DNR, 1h on days 1, 3, 5) and 2 short
pulses a day of cytarabine (Ara-C, 100mg/m2); the resting period was assumed to be 35 days.
A hypothetical female patient of 69 years, 156cm tall and weighing 60.7kg was used, with
an initial bone marrow (BM) blast percent of 71%. Three situations were considered at the
start of treatment: only NPM1+ blasts, only FLT3-ITD+/NPM1+ blasts, or combined popu-
lations of NPM1+ and FLT3-ITD+/NPM1+ cells (heterogeneous sub-populations). Since the
NPM1+ mutation seems to appear earlier in the disease, there could be a transition period
when FLT3/ITD+NPM1+ cells and FLT3/ITD-NPM1+ would coexist and therefore the third
situation is plausible. We assumed that: (i) leukemic cells proliferate at the same rate all the
time (before, during and after treatment); (ii) chemotherapy drugs affect cells at any part inside
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the phase with equal intensity; and (iii) S phase duration (TS) ranges 3-50h on average [110].
Median bone marrow doubling times were obtained from Ommen et al. [93], who reported 15
days (NPM1+) and 7.4 days (FLT3/ITD+NPM1+).
5.4.3 Results & discussion
5.4.3.1 The impact of S phase kinetics in slow and fast growing clones’ response to
chemotherapy
The first experiment consisted in simulating the evolution of the leukemic population through-
out the treatment in different S phase duration scenario, since both DNR and Ara-C act during
DNA duplication. Two different phenomena were observed (Fig. 5.22): (1) since NPM1+ had
a longer cell cycle time than FLT3/ITD+NPM1+, cells were overall less often in S phase and
so less likely to be affected by chemotherapy (cell kill was lower in most of the cases); and (2)
for the same population (equal cell cycle time), an increase in the S phase duration lead to a
higher efficacy in the chemotherapy treatment (more cells killed). On the other hand, prolifer-
ation occurred faster in FLT3/ITD+NPM1+, so cells recovered more quickly than NPM1+ by
the end of the resting period.
5.4.3.2 “The clone wars”
In the second experiment we simulated the same patient having varying ratios of both clones
(10%/90%, 50%/50% and 90%/10%) with different S phase times for each population: slow
(18h), intermediate (9-10h) and fast (3.5h) (Fig. 5.23). Three outcomes at the end of the resting
period were observed: (a) NPM1+ dominant (light orange background), (b) FLT3/ITD+NPM1+
dominant (light blue background) and (c) a situation where the two populations break even
(white background). (a) occurred when FLT3/ITD+NPM1+ had slow phase kinetics (for any
content of each population) or intermediate kinetics for NPM1+ equal or higher than 50%. (b)
happened for fast FLT3/ITD+NPM1+ S phase kinetics with 50% or more FLT3/ITD+NPM1+
content, and for intermediate kinetics with 90% FLT3/ITD+NPM1+. (c) only in two cases did
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Figure 5.22: Comparison of leukemic population response under DA treatment of either NPM1+ (red)
or FLT3-ITD+NPM1+ cells (grey). Increase in S phase duration results in a higher treatment efficacy.
the two populations break even by the end of the resting period, consisting of fast FLT3/ITD+NPM1+
and intermediate or slow NPM1+ S phase kinetics, and only for 90% FLT3/ITD+NPM1+. In
conclusion, the S phase time of FLT3/ITD+NPM1+ was critical for the final outcome, while TS
for NPM1+ had a limited impact on it. Additionally, the initial percentage of each population
was important to determine when (during the resting period) the populations would break even.
5.4.4 Conclusions
Clinicians now know that patients exhibiting certain mutations, such as FLT3-ITD+, have less
favorable prognoses than those with less aggressive ones such as NPM1+. However, those
patients still receive the same treatment regardless of clonal contents. It is currently unknown
whether the treatment provides a therapeutic effect or on the contrary imbalances the clonal
pool towards the more aggressive clones. The type of information presented here could poten-
tially inform clinicians on the frame of time when resting is acceptable and at which point a
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second cycle of chemotherapy is necessary. Treatments could also be tailored to favor desir-
able outcomes (i.e., majority of a good prognosis clone such as NPM1+) based on cell cycle
characteristics of each of the sub-populations. Finally, treatment combinations targeting one
clone (or responsive group of clones) at a time could be designed to maximize the chances of
success. This becomes of relevance especially with the advent of novel clone-specific agents
[117].
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Chapter 6
Clinical application (in vivo platform)
The results presented so far pave the way towards the optimization of chemotherapy treatment
strategies in leukemia, featuring in vitro and in silico components. However, suitable transfor-
mations that allow the simulation of the disease in real time and in a clinical environment are
required.
6.1 Towards obtaining patient-specific parameters for the sim-
ulation and optimization of leukemia
Section 5.2.3.2.1 demonstrated the possibility of the CCP-PBM model to admit steady-state,
static parameters (which can be obtained from a fresh patient sample, without the need of fur-
ther culturing) in replacement of dynamic parameters (requiring the culture of those cells, with
the implied delays in receiving the simulation results and the possible experimental problems
related to the fidelity of the original cells). From the in silico perspective, this strategy is vi-
able and clearly the way forward. However, it has not been tested yet experimentally and is
therefore not yet a solution.
An alternative method to extract patient-specific parameters is to observe the clonal popu-
lations contained in their bone marrow samples. New technology allows the detection of a vast
variety of clones in a short period of time. The clonal content can therefore already be assessed
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clinically in a reasonable time from the start of treatment, typically hours or few days. What
we propose is the creation of parameter libraries associated to specific clones that will feed
the model with the required information to run the model. Personalization in this case would
be made according to the clonal fractions measured clinically, and not the dynamic properties
of the clones themselves, which is far more time consuming and is not open to real time im-
plementation in a clinical setting. Inherently, this method requires a very extensive research
in order to cover at least the most common leukemia clones found in AML patients; even if
some can be obtained from previous clinical studies, intensive experimentation confirming the
applicability of the method to different patients would have to be carried out.
6.2 Developing a prototype clinical advisory tool for bedside
optimization of personalized rational therapies
As it stands, there is at least one key stakeholder per environment (as defined in Section 2.5):
clinicians for the in vivo, experimentalists for the in vitro and modelers for the in silico, with
deliverables to receive and data to collect under their environment and exchange with others.
This creates interactions between different stakeholders in an interdisciplinary manner that al-
low the correct flow of information to take place (Figure 6.1). However, for the process to
run in an automated manner, there is a need to centralize the data management system. Clos-
ing the loop between the in vitro, in silico and in vivo requires introducing in the clinic an
easy-to use, compact and fast tool which simulates and optimizes patient-specific treatments
by collecting data available under all three environments (dashed blocks and arrows on Figure
6.1). This tool will use the complete model presented in Chapter 5. Section 5.2.3.2.1 presented
an alternative technique to derive measurable patient parameters directly from fresh primary
samples (without the need to culture them) and could be useful when fast predictions are re-
quired (for example simultaneous treatment in vivo and in silico prediction. We have started
moving in that direction by developing a prototype iPad app, “ChemoApp”, which receives as
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Figure 6.1: Summary of key stakeholders and interactions required. Solid lines and blocks repre-
sent the current situation while dashed elements indicate the new workflow including ChemoApp
inputs the parameters required by the model in each category: patient characteristics, cellular
characteristics and treatment characteristics.
Patient characteristics include all measurements available clinically that allow the model
to perform the pharmacokinetic calculations for drug transport and absorption: weight, height,
liver and heart function, age, sex. Cellular characteristics are needed by the cell cycle model to
simulate cell growth and are composed by: percentage of blasts, cellularity, percent of cells in
each phase at the start of treatment, duration of the cell cycle. Finally, treatment characteristics
define the dose, duration and schedule planned by the clinician, which are required by the
pharmacodynamic model to calculate the drug susceptibility of cells (and suggest an improved
treatment, Figures 6.2 and 6.3).
At the moment, ChemoApp is only composed of a working interface for demonstration
purposes, but has no simulation capabilities (the treatments shown are static, pre-run simula-
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tions for specific patients). In order to have a dynamic tool that can independently function
in a clinical setting, a connection between the iOS interface and gPROMS will have to be
established. For this, we envision an intermediary central computer at the hospital that will
receive all the simulation requests via intranet, execute them and send the results back to the
iPad where they originated. The predicted treatment response and optimized treatment results
can then be displayed on the iPad, so that physicians and potentially patients can visualize an
anticipated treatment outcome and perhaps take action based on that.
ChemoApp is in process of receiving a trademark status. As soon as it is given, ChemoApp
will be further developed into a real time visualization tool. We are also in the process of
requesting clinical approval for the prediction of patient outcomes in real time (outside the
clinic).
136 Marı´a Fuentes Garı´ Chapter 6
Chapter 7
Conclusions
In this project, a population balance model of the cell cycle maintaining fidelity to the un-
derlying biological system was developed. The model is composed of three compartments
(G, S and M) corresponding to the four proliferative phases biologically. Progression in each
compartment is governed by the expression of phase-specific proteins (cyclins E (G phase)
and B (M phase)) and DNA duplication (S phase), while transition from phase to phase oc-
curs in a probabilistic fashion according to a cyclin expression threshold. Sensitivity analysis
identified the most significant parameters needed to run the model. Those parameters were
obtained experimentally and the model predictions were validated against cell cycle kinetics
(phase fractions and protein expression) for three different leukemia cell lines. Heterogeneous
cyclin production patterns originate as a result of cell cycle mutations (e.g., cyclins D1 and
E1, KIP1, INK4B and INK4A, CDK4, Rb [74]), making them leukemia-specific. Predicting
the intensity and timing of cyclin concentration increase can become critical in defining the
optimal dose and schedule of current as well as novel treatment strategies [102, 112]. Due to
their critical role in the control of cell cycle progression, cyclin-blockade strategies arrest pro-
liferation, without the risk of additional mutagenesis inherent in traditional chemotherapeutics.
Specific cell cycle drug targets, such as cyclin D and CDK1-cyclin B complexes [64, 89], may
be identified and tracked using the PBM platform developed herein and used to identify the best
dose and schedule pre-clinically, expediting drug development trajectories. The availability of
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individual clone sensitivities to each drug (EC50) and the use of accurate models simulating
drug distribution in the human body will be key for simulating cell death by chemotherapy.
The PBM’s high resolution in describing intra-phase events allows incorporating cell death not
only in a phase-specific, but also in a phase coordinate-specific manner.
The model was then challenged with two new situations in the context of leukemia hetero-
geneity, where the cell cycle is central. Experimentally, the three leukemia cell lines used are
mixed in a blinded setup (9 different mixtures in total) and cultured together for 30 h. The first
test involves predicting forward and backward culture dynamics using only the initial condi-
tions and the parameters previously obtained for single cell lines. The ability to assess both
backward and forward evolution of cell clonal content using the PBM model presented herein
provides a quantitative tool for the estimation of population dynamics and the study of leukemia
progression in both treated and untreated patients [27, 132, 139]. This tool also has the poten-
tial to evaluate clonal models of leukemogenesis [61, 27, 118] in order to better understand the
pathogenesis of disease. In the context of CCS drug dosage and scheduling, the PBM could
give a narrower window of action than what is currently used in treatment regimens, thereby
limiting drug toxicity yet improving efficacy [102]. Drugs, such as small molecule inhibitors,
currently being tested that specifically target leukemia sub-clones (e.g. those expressing FLT3-
ITD, [117]) could be dosed and scheduled to optimize cell kill during therapy according to
anticipated sub-clonal composition. Ultimately, balancing CCS chemotherapy with more ad-
vanced gene-targeted treatments will require detailed knowledge of sub-population evolution,
kinetics and dynamics during treatment calculated and manipulated using computational meth-
ods such as those presented herein for designer therapies.
The second test identifies the nature of each mixture based on the dynamic culture evolu-
tion. Genome-based methods are currently employed in order to define mutational heterogene-
ity in AML subclones, thereby identifying evolution of disease throughout treatment [27]. In
order to optimize treatments in AML, we pursued a complementary strategy of clonal identi-
fication by using cell cycle kinetics to effectively represent heterogeneity. Cells may acquire
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proliferative mutations that modify cell cycle times through bypassing of cell cycle controls;
overexpression of p21 enables cells with DNA damage to continue to the next phase prema-
turely [130], while mutations in Cdc20 delay the timing of cyclin B degradation, and pRb or
E2F mutations promote early entry into S phase by premature increase in the concentration of
cyclin E [113]. A plethora of sub-populations, each with specific cell cycle signatures arises;
the PBM can estimate cell cycle evolution for each of them and capture overall behavior. Since
cell cycle duration has been shown to correlate with prognosis in response to treatment [110],
an a priori classification of sub-populations according to slow/intermediate/fast cell cycle ki-
netics may be initially developed. A more sophisticated extrapolation for patient cell popu-
lations (rather than the dynamic counterparts) was developed and tested on an additional cell
line, which could potentially be measured in the diagnostic bone marrow or peripheral blood
sample at disease presentation. Technology now exists wherein patient AML mutations and
subclones are identified routinely. Put together with cell cycle data (which could be done at
diagnosis and throughout treatment if needed by assessment of S-Phase or cyclin expression by
flow cytometry), PK/PD combined models are being developed to optimize chemotherapy dose
and schedule according to anticipated clonal output [102, 35]. With this method, there is the
potential to tailor treatments by manipulating leukemic heterogeneity and instilling long-term
control of tumor growth, limiting expansion of more pathogenic clones [76, 142].
In order to highlight the superiority of the PBM as compared to other descriptive differential
equation models of the cell cycle (ODEs, DDEs), the three models are fitted to the single cell
line data and evaluated in their ability to capture oscillations and their parameters assessed for
fidelity to the measured experimental values. Next, the three models are coupled to an existing
PK/PD model of leukemia chemotherapy and several hypothetical patient cases are reviewed.
A greater sensitivity to chemotherapy effects on PBM as compared to ODE and, to a lesser
extent, DDE, was observed. We concluded that cell cycle model selection has a critical impact
on predicted chemotherapy response. Current standards in PK/PD rely on cell cycle models
that are not always accurate enough and that have not necessarily been validated. For more
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advanced use of these models, such as for optimal control of chemotherapy delivery[81, 14, 28]
and drug scheduling [32], a precise representation of cell cycle processes becomes critical
(deconvoluting total growth kinetics into cell cycle phases, capturing intra-phase progression).
Cell cycle models for chemotherapy optimization should be carefully selected and suited to
their application. A first and critical consideration is whether the model parameters are relevant
in vitro/in vivo and are measurable (or can be converted into a new set of parameters that are).
A second consideration is whether both the dynamic (transient) and steady state behaviors
obtained are accurate in representing the underlying biology and clinical response (sensitivity
to drugs). Finally, the trade-off between model complexity and matching the required degrees
of freedom exhibited by the system needs to be taken into account.
Moving towards the application in patients, the feasibility of the cyclin measurement meth-
ods in patient samples was validated on six real cases, as well as the ability to culture and
expand the primary cells in a suitable platform for 4 weeks.
Finally, the first steps were taken towards the implementation of this research into a tool
for the bedside optimization of personalized leukemia chemotherapy. A prototype iPad app
was designed where the necessary parameters are input and a simulation of the treatment is
displayed (currently for two patient cases only). Options for moving this tool forward, and the
way it could seamlessly work with the simulation software are discussed.
The development of detailed models of the cell cycle that are experimentally validated
is critical in the implementation of more advanced pharmacokinetic/pharmacodynamic models
[129, 36]. Additionally, linking a small subset of measurable variables to unique characteristics
of the individual is necessary for the development of personalized treatment. The PBM we have
developed paves the way in connecting both. Ultimately, the application of such a tool could
inform not only optimal timing and type of personalized treatment for improved outcomes, but
also provide a platform for pre-clinical assessment of novel targeted therapies for leukemia and
other cancers.
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Future work
The model developed exhibits very promising features; however, bridging the bench-to-bedside
gap remains a challenge and appropriate adaptations of the existing methods in vitro and model
capabilities in silico have to be carried out to meet the clinical requirements, both at the patient
applicability and parameter measurability levels. The areas requiring future work are outlined
below:
8.1 Combining clinical patient data with the corresponding
in vitro cellular patient data
An ethics proposal was recently submitted to the NHS presenting a protocol for the simultane-
ous collection of patient clinical data and patient primary samples for experimental use. The
conclusions of this thesis provide guidelines on the way the clinical set of parameters could
inform the PK part of the model while the experimental set of parameters could be used in the
cell cycle part of the model.
Challenges in this area include: (i) obtaining patient- and/or clone-specific sensitivities to
each drug type (EC50), since the data used up to now is generalized based on empirical results
in vitro collected from literature; (ii) validating the proposed method of an alternative static
parameter set in patients; (iii) testing the actual treatment given to the patient on the primary
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cells under 3D cultures in vitro.
8.2 Predicting actual clone evolution data from patients
A second ethics proposal was recently submitted to the NHS for the live collection of patient
data, simulation over the course of the actual chemotherapy regimen and comparison of the
predicted results to the real outcome at the end of treatment.
Patients generally have a variety of clones, some of which are known and some of which
are unique to the particular patient. Because of the effort required to isolate clone-specific
parameters, it has been suggested parameter libraries gathering the data for the most frequent
clones could be built. For the remaining clones, a coarser categorisation based on overall
cell cycle kinetics or S phase kinetics (slow, intermediate and fast growing clones) could be
envisaged. It remains to be investigated the depth at which clonal composition needs to be
analyzed to obtain a representative sample of clonal contents. New technologies assessing the
genetic features of cells are emerging that lower the detection limit for rare or low content
clones.
8.3 Developing ChemoApp into a commercially viable tool
All the codes from this thesis as well as the PK/PD models [102] are written in the gPROMS
environment. PSE (the company owning gPROMS) has already been approached and has given
consent / displayed interest in helping take this project forward by providing support on the
software compatibility part. Imperial Innovations, the Imperial College bureau for translating
research into commercial developments have similarly agreed to help take this project forward.
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Appendix A
Approximation of cumulative distribution
function
The cumulative distribution function, also called error function (Equations 5.7 and 5.8), is
approximated using Press’ method [106], with x being a normally distributed variable with a
mean of 0 and a standard deviation equal to 1:
erf(x) =

1− τ for x> 0
τ−1 for x < 0
(A.1)
where:
τ = t · exp(−x2−1.26551223+1.00002368 · t+0.37409196 · t2
+0.09678418 · t3−0.18628806 · t4+0.27886807 · t5
−1.13520398 · t6+1.48851587 · t7−0.82215223 · t8+0.17087277 · t9)
(A.2)
and
t =
1
1+0.5 · |x| (A.3)
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CB,b and CE,e are converted to standard normally distributed variables as follows:
xE,e =
CE,e−CE, thr
σE
∀ e ∈ {0, ..., nE} (A.4)
and
xB,b =
CB,b−CB, thr
σB
∀ b ∈ {0, ..., nB} (A.5)
xE,e or xB,b can be replaced in equations A.2 and A.3 and the resulting erf(xE,e) or erf(xB,b)
can be calculated.
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Appendix B
Summary of PBM variables and
parameters
The following measured and derived parameters are required to run the discretised PBM:
• nE ×CE levels, nB×CB levels and nD×DNA levels (derived)
• nE ×ΓCE,e and nB×ΓCB,b transition probabilities (derived)
• nE × rG→S,e and nB× rM→G,b transition rate coefficients (derived)
• growth rates rG, rS and rM (derived)
• discretisation factors νE , νD and νB (derived)
• initial conditions GEdU−,0,%, SEdU−,0,% and MEdU−,0,% (measured)
• cyclin minima CE,min and CB,min (measured)
• cyclin thresholds CE, thr and CB, thr (measured)
• cyclin maxima CE,max and CB,max (derived)
• cell cycle phase durations TG, TS and TM (measured)
• intra S phase distributions S0,1, S0,2 and S0,3 (measured)
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• transition variabilities σE and σB (theoretically measured, but not significant according
to GSA)
The following variables are calculated when running the discretized PBM:
• nE ×Ge, nB×Mb, nD×Sd and T cell numbers
• nE ×Ge,%, nB×Mb,% and nD×Sd,% phase percentages
• geometric mean of cyclin E and B: GeomE and GeomB
Since we have set nE = 60, nD = 20 and nB = 60, the total number of measured and derived
parameters is 400 and the total number of variables is 283.
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Appendix C
Ensemble model of the cell cycle
A very basic ensemble model featuring a cube of cells and states over time was built at the
beginning of the project. The model was composed of a 3D matrix organized as follows (Figure
C.1):
• Rows: each row refers to a single cell. The total number of cells is therefore given by
the total number of rows
• Columns: each column corresponds to a discrete time point.
• Depth: each of the five layers in depth (z-axis) represents a cellular property: state, cell
age (time from birth), cyclin E content, DNA content and cyclin B content. Cell state is
an artificial computational variable created to summarize cell cycle events (pre-transition,
post-transition, division or birth).
For analysis purposes, cell row (y), time (column - x) and property (depth - z) information can
be combined. At the vector level, fixing y and z, reads the evolution of a property for that
particular cell (cyclin E over time etc.), while at the matrix level, a “cell life story” can be
deciphered. Similarly, fixing x and z provides the instantaneous global vision of cellular states
(“50% of cells in S phase” or “average cyclin E level in G1 is 15%”). Finally, fixing x and y
returns the values of all properties for a particular cell at a particular time point.
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Cells	  
Time	  
1.  State	  
2.  Age	  
3.  [CycE]	  
4.  DNA	  
5.  [CycB]	  
1	  
2	  
3	  
4	   5	  
Cell	  life	  story	  
Figure C.1: Visual representation of the cell cycle ensemble model developed. Each cell is repre-
sented by a row; columns represent discrete time points and layers in depth account for cell age, cyclin
E content, DNA and cyclin B content.
At the matrix level, global data can be obtained. For example, fixing z to cyclin E delivers a
“layer” with all the information related to cyclin E in all cells over time which can be combined
in a statistical manner (for example by calculating the geometric mean as shown in Section
5.1.2.2).
As with any ensemble model, the relevance is limited by the total number of cells simu-
lated. CPU memory limitations did not allow us to model more than 1,000 cells (even though
the algorithm was refined by eliminating cells that had already divided). An example is shown
in Figure C.2. Observe how phase fractions never stabilize (bottom left panel); this is char-
acteristic of ensemble models and is due to their stochastic nature. Nevertheless, each phase
fraction tends towards a constant region, which makes it plausible that the model could be
compared head-to-head with all other models presented in this thesis.
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Appendix D
DDE handling by a dynamic solver
gPROMS is a dynamic solver and as such does not explicitly allow the user to access previous
time points. gPROMS does not have a standard DDE solver provided either. This becomes a
problem when implementing DDEs, due to the delay terms. Because of this, a small module for
retaining data from previous time points (up to one phase time earlier) was created. It consisted
of a set of vectors Gindex, Gvalue of length nG (number of discretization intervals) and a series of
selectors to facilitate data handling and vector updates. The example here is given for G phase
but equivalent equations can be derived for the other two phases.
The interval in hours between two subsequent history bins will be:
Ginterval = τG/nG (D.1)
The save index (sG) is only reset to 1 when it reaches nG+1, otherwise it increases as:
dsG
dt
=
1
Ginterval
(D.2)
The lookup index (LG) is reset to 1 when sG > nG, otherwise it is calculated as:
LG = sG+1 (D.3)
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The history vector (Gvalue) is built as:
dGvalue(iG)
dt
= 0 or
dGvalue(iG)
dt
=−kd,G ·Gvalue(iG) (under chemotherapy)
when ((sG ≥ iG+1)∪ (iG 6= nG))∩ ((sG DIV 1 = 1)∪ (iG = nG))
(D.4)
dGvalue(iG)
dt
= G(t) when (sG DIV 1 = iG) (D.5)
The index vector (Gindex) takes 0 and 1 values according to which vector cells correspond to
the current time (which is defined by LG):
Gindex(iG) = 1 when (iG+1 > LG)∪ (iG ≤ LG)
Gindex(iG) = 0 otherwise
(D.6)
Finally, the value of the G phase total τG hours before the current time can be retrieved as:
G(t− τG) =
nG
∑
iG=1
Gvalue(iG) ·Gindex(iG) (D.7)
In order to initialise the DDEs, the steady state distribution (for PK/PD problems) was used
backward. Mathematically, this is equivalent to the following (equivalent equations can be
derived for the other two):
Gvalue,0(iG) = G0 · exp
(−γ · τG · (nG− iG)
nG
)
(D.8)
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Appendix E
Steady state analysis
A steady state is defined by the absence of change in a variable over time. Mathematically, it
is achieved by setting the derivative (change) of the particular variable to zero and calculating
its constant value. Steady states are reached at the phase fraction and log-growth levels. Each
model will therefore be solved in its phase fraction form.
E.1 CCP-ODE
In terms of phase distributions, defining a new variable T:
T = G+S+M = G% ·T +S% ·T +M% ·T (E.1)
dG
dt
=
dG% ·T
dt
=
dG%,SS
dt
·T + dT
dt
·G%,SS (E.2)
dS
dt
=
dS%,SS ·T
dt
=
dS%,SS
dt
·T + dT
dt
·S%,SS (E.3)
dM
dt
=
dM%,SS ·T
dt
=
dM%,SS
dt
·T + dT
dt
·M%,SS (E.4)
Starting from Eq (E.2)-(E.4) the equilibrium phase percents can be calculated by solving
CCP-ODE with the additional information that, at steady state, the derivatives of G%,SS, S%,SS
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and M%,SS are zero:
dT
dt
· G%,SS
T
= 2 · k3 ·M%,SS− k1 ·G%,SS (E.5)
dT
dt
· S%,SS
T
= k1 ·G%,SS− k2 ·S%,SS (E.6)
dT
dt
·M%,SS
T
= k2 ·S%,SS− k3 ·M%,SS (E.7)
Summing for all three phases:
dT
dt
1
T
= k3 ·M%,SS = µ (E.8)
Substituting into Eq (E.5) and (E.6):
k3 ·M%,SS ·G%,SS = 2 · k3 ·M%,SS− k1 ·G%,SS (E.9)
k3 ·M%,SS ·S%,SS = k1 ·G%,SS− k2 ·S%,SS (E.10)
Further,
M%,SS =
−k1 ·G%,SS
k3 ·G%,SS−2 · k3 (E.11)
S%,SS =
k1 ·G%,SS
k3 ·M%,SS+ k2 (E.12)
Since G%,SS+S%,SS+M%,SS = 1:
G%,SS+
k1 ·G%,SS
k3 ·
( −k1·G%,SS
k3·G%,SS−2·k3
)
+ k2
+
−k1 ·G%,SS
k3 ·G%,SS−2 · k3 = 0 (E.13)
Which, after some rearrangement, becomes:
a ·G3%,SS− (4a+b+d) ·G2%,SS+(c+4a+2b+4d+ ε) ·G%,SS− (4d+2ε) = 0 (E.14)
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with:
a = k1 · k3+ k3 · (k2− k1) (E.15)
b = 2 · k3 · k1+ k1 · (k2− k1) (E.16)
c = 2 · k21 (E.17)
d = k3 · (k2− k1) (E.18)
ε = 2 · k3 · k1 (E.19)
Solving the cubic equation[77] within the bounds G%,SS ∈ [0, . . . , 1] gives a unique solution
for G%,SS, from which M%,SS (Eq E.11), S%,SS (Eq E.12) and µ (Eq E.8) can be derived.
E.2 CCP-DDE
An important assumption will be made in this section: since both CCP-PBM and CCP-ODE
exhibit exponential total cell growth, a similar behavior is attributed to DDEs. We will see that
this initial assumption is validated later in the demonstration. We start from the CCP-DDE and
similarly to the previous sections, we change variables to reflect percent over all phases:
dT (t)
dt
· G%(t)
T (t)
= 2 · k3 ·M%(t− τM) · T (t− τM)T (t) − k1 ·G%(t) (E.20)
dT (t)
dt
· S%(t)
T (t)
= k1 ·G%(t− τG) · T (t− τG)T (t) − k2 ·S%(t) (E.21)
dT (t)
dt
·M%(t)
T (t)
= k2 ·S%(t− τS) · T (t− τS)T (t) − k3 ·M%(t) (E.22)
Because we’re dealing with steady state, G%(t)=G%,(t−τG), S%(t)= S%,(t−τS) and M%(t)=
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M%,(t−τM). Summing across all populations:
dT (t)
dt
· 1
T (t)
= k3 ·M%(t) ·
(
2 · T (t− τM)
T (t)
−1
)
+ k1 ·G%(t) ·
(
T (t− τG)
T (t)
−1
)
+ k2 ·S%(t) ·
(
T (t− τS)
T (t)
−1
) (E.23)
Using now the assumption that the total cell number at steady state grows exponentially:
dT (t)
dt
· 1
T (t)
= γ (E.24)
and T(t−x) = T (t) · e−γ·x (E.25)
Substituting into Eq (E.23) and replacing G%(t), S%(t) and M%(t) by their constant steady
state values GSS,%, SSS,% and MSS,%:
γ = k3 ·MSS,% ·
(
2 · e−γ·τM −1)+ k1 ·GSS,% · (e−γ·τG−1)+ k2 ·SSS,% · (e−γ·τS−1) (E.26)
Substituting Eq (E.24) and (E.25) into CCP-DDE, we finally reach the equalities:
MSS,% = GSS,% · γ+ k12 · k3 · e−γ·τM (E.27)
SSS,% = GSS,% · k1 · e
−γ·τG
γ+ k2
(E.28)
Substituting Eq (E.27) and (E.28) into Eq (E.23):
GSS,% =
γ
k1 · (e−γ·τG−1)+ k3 · (2 · e−γ·τM −1) · γ+k12·k3·e−γ·τM + k2 · (e−γ·τS−1) · k1·e
−γ·τG
γ+k2
(E.29)
Because the sum of GSS,%, SSS,% and MSS,% has to be one:
GSS,% · γ+ k12 · k3 · e−γ·τM +GSS,% ·
k1 · e−γ·τG
γ+ k2
+GSS,% = 1 (E.30)
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We can now substitute GSS,% from Eq (E.29) into Eq (E.30) and solve for γ .
E.3 CCP-PBM
The equilibrium distribution in this case can be calculated for the intra-phase distribution as
well (and, by extension, for each of the total phase distributions). First, the problem is ap-
proached from the single phase distribution side, i.e.:
dGe,G%
dt
= 0 with Ge,G% =
Ge
∑Ge
(E.31)
dSd,S%
dt
= 0 with Sd,S% =
Sd
∑Sd
(E.32)
dMb,M%
dt
= 0 with Mb,M% =
Mb
∑Mb
(E.33)
For simplicity, we will use G = ∑Ge, S = ∑Sd and M = ∑Mb. Noting that Ge = Ge,G% ·G,
Sd = Sd,S% ·S and Mb = Mb,M% ·M and differentiating:
dGe
dt
=
dGe,G% ·G
dt
=
dGe,G%
dt
·G+ dG
dt
·Ge,G% = dGdt ·Ge,G% ∀e ∈ {1, . . . , nE}
(E.34)
dSd
dt
=
dSd,S% ·S
dt
=
dSd,S%
dt
·S+ dS
dt
·Sd,S% = dSdt ·Sd,S% ∀d ∈ {1, . . . , nD}
(E.35)
dMb
dt
=
dMb,M% ·M
dt
=
dMb,M%
dt
·M+ dM
dt
·Mb,M% = dMdt ·Mb,M% ∀b ∈ {1, . . . , nB}
(E.36)
Appendix E Marı´a Fuentes Garı´ 181
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
The equations considered are the discretized CCP-PBM equations.
dGe
dt
=
dG
dt
·Ge,G% = Ge−1(t) · rG ·νE −Ge(t) ·νE ·
(
rG+ rG→S,e
) ∀e ∈ {2, . . . , nE}
(E.37)
dSd
dt
=
dS
dt
·Sd,S% = Sd−1(t) · rS ·νD−Sd(t) · rS ·νD ∀d ∈ {2, . . . , nD}
(E.38)
dMb
dt
=
dM
dt
·Mb,M% = Mb−1(t) · rM ·νB−Mb(t) ·νB ·
(
rM + rM→G,b
) ∀b ∈ {2, . . . , nB}
(E.39)
For the boundary conditions:
dG1
dt
=
dG
dt
·G1,G% = 2 ·
nB
∑
b=1
Mb · rM→G,b ·νB−G1(t) · rG ·νE −G1(t) · rG→S,1 ·νE (E.40)
dS1
dt
=
dS
dt
·S1,S% =
nE
∑
e=1
Ge · rG→S,e ·νE −S1(t) · rS ·νD (E.41)
dM1
dt
=
dM
dt
·M1,M% = SnD · rS ·νD−M1(t) · rM ·νB−M1(t) · rM→G,1 ·νB (E.42)
Summing across all intra-phase populations for each phase and assuming GnE ≈ 0 and MnB ≈ 0:
dG
dt
·
nE
∑
e=1
Ge,G% =
dG
dt
·1 = 2 ·
nB
∑
b=1
Mb · rM→G,b ·νB−
nE
∑
e=1
Ge · rG→S,eνE (E.43)
dS
dt
·
nD
∑
d=1
S1,S% =
dS
dt
·1 =
nE
∑
e=1
Ge · rG→S,e ·νE −SnD · rS ·νD (E.44)
dM
dt
·
nB
∑
b=1
M1,M% =
dM
dt
·1 = SnD · rS ·νD−
nB
∑
b=1
Mb · rM→G,b ·νB (E.45)
Summing for all three phases, setting T = G+S+M:
dG
dt
+
dS
dt
+
dM
dt
=
dT
dt
=
nB
∑
b=1
Mb · rM→G,b ·νB (E.46)
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If we now set:
dGe,T %
dt
= 0 with Ge,T % =
Ge
T
(E.47)
dSd,T %
dt
= 0 with Sd,T % =
Sd
T
(E.48)
dMb,T %
dt
= 0 with Mb,T % =
Mb
T
(E.49)
Then Eq (E.46) becomes:
dT
dt
= T ·
nB
∑
b=1
Mb,T % · rM→G,b ·νB = T ·α (E.50)
From Eq (E.47)-(E.49)
dGe
dt
=
dGe,T % ·T
dt
=
dGe,T %
dt
·T + dT
dt
·Ge,T % = dTdt ·Ge,T % ∀e ∈ {1, . . . , nE} (E.51)
dSd
dt
=
dSd,T % ·T
dt
=
dSd,T %
dt
·T + dT
dt
·Sd,T % = dTdt ·Sd,T % ∀d ∈ {1, . . . , nD} (E.52)
dMb
dt
=
dMb,T % ·T
dt
=
dMb,T %
dt
·T + dT
dt
·Mb,T % = dTdt ·Mb,T % ∀b ∈ {1, . . . , nB} (E.53)
CCP-PBM can also be rewritten as:
dGe
dt
· 1
T
=
dT
dt
· Ge,T %
T
= Ge−1,T % · rG ·νE −Ge,T % ·νE ·
(
rG+ rG→S,e
) ∀e ∈ {2, . . . , nE}
(E.54)
dSd
dt
· 1
T
=
dT
dt
· Sd,T %
T
= Sd−1,T % · rS ·νD−Sd,T % · rS ·νD ∀d ∈ {2, . . . , nD} (E.55)
dMb
dt
· 1
T
=
dT
dt
·Mb,T %
T
= Mb−1,T %(t) · rM ·νB−Mb,T % ·νB ·
(
rM + rM→G,b
) ∀b ∈ {2, . . . , nB}
(E.56)
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Using the result from Eq (E.50):
Ge,T % ·α = Ge−1,T % · rG ·νE −Ge,T % · rG ·νE −Ge,T % · rG→S,e ·νE ∀e ∈ {2, . . . , nE}
(E.57)
Sd,T % ·α = Sd−1,T % · rS ·νD−Sd,T % · rS ·νD ∀d ∈ {2, . . . , nD}
(E.58)
Mb,T % ·α = Mb−1,T % · rM ·νB−Mb,T % · rM ·νB−Mb,T % · rM→G,b ·νB ∀b ∈ {2, . . . , nB}
(E.59)
Reorganizing:
Ge,T % = Ge−1,T % · rG ·νErG ·νE + rG→S,e ·νE +α ∀e ∈ {2, . . . , nE} (E.60)
Sd,T % = Sd−1,T % · rS ·νDrS ·νD+α ∀d ∈ {2, . . . , nD} (E.61)
Mb,T % = Mb−1,T % · rM ·νBrM ·νB+ rM→G,b ·νB+α ∀b ∈ {2, . . . , nB} (E.62)
For the boundary conditions:
G1,T % =
2 ·α
rG ·νE + rG→S,1 ·νE +α (E.63)
S1,T % =
nE
∑
e=1
Ge,% · rG→S,e ·νE
rS ·νD+α =
β
rS ·νD+α (E.64)
M1,T % = SnD,T % ·
rS ·νD
rM ·νB+ rM→G,1 ·νB+α (E.65)
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Summing across all populations:
1 =
nE
∑
e=1
Ge,T %+
nD
∑
d=1
Sd,T %+
nB
∑
b=1
Mb,T %
= G1,T % ·
(
1+
nE
∑
e=2
e
∏
e′=1
rG ·νE
rG ·νE + rG→S,e′ ·νE +α
)
+S1,T % ·
(
1+
nD
∑
d=2
d
∏
d′=1
rS ·νD
rS ·νD+α
)
+M1,T % ·
(
1+
nB
∑
b=2
b
∏
b′=1
rM ·νB
rM ·νB+ rM→M,b′ ·νB+α
)
=
2 ·α
rG ·νE + rG→S,1 ·νE +α ·
(
1+
nE
∑
e=2
e
∏
e′=1
rG ·νE
rG ·νE + rG→S,e′ ·νE +α
)
+
β
rS ·νD+α ·
(
1+
nD
∑
d=2
d
∏
d′=1
rS ·νD
rS ·νD+α
)
+
(
nD
∏
d=2
rS ·νD
rS ·νD+α
)
· β
rS ·νD+α ·
rS ·νD
rM ·νB+ rM→G,1 ·νB+α
·
(
1+
nB
∑
b=2
b
∏
b′=1
rM ·νB
rM ·νB+ rM→M,b′ ·νB+α
)
(E.66)
Observing additionally that:
β =
nE
∑
e=1
Ge,% · rG→S,e ·νE
= G1,T % · rG→S,1 ·νE +G1,T % ·
nE
∑
e=2
rG→S,e ·νE ·
e
∏
e′=1
rG ·νE
rG ·νE + rG→S,e′ ·νE +α
(E.67)
Combining Eq (E.60) and (E.67)
β =
2 ·α ·νE
rG ·νE + rG→S,e ·νE +α ·
(
rG→S,1+
nE
∑
e=2
rG→S,e ·
e
∏
e′=1
rG ·νE
rG ·νE + rG→S,e′ ·νE +α
)
(E.68)
The system of 2 equations (Eq E.68 and E.66) with 2 unknowns (α and β ) can be solved using
any standard method[106]. The solution defines all values for each of Ge,T %, Sd,T %, Mb,T % in
cascade.
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Linear stability analysis of CCP-ODE
In order to derive the oscillatory properties of differential systems of equations, linear stability
analysis (LSA) has to be performed. This technique allows to predict the dynamics of the
systems without explicitly finding a solution (which becomes useful when ODEs can only be
solved numerically). The process is as follows[31]:
• Calculation of steady state distribution (as in Appendix E)
• Determination of the derivatives of equations in the form x˙ = a · x+b · y with respect to
x, y
• Setup of the linear system of derivative coefficients in matrix format, replacing remaining
x and y variables with their steady state solutions
• Calculation of its eigenvalues
• Evaluation of dynamic stability according to the resulting eigenvalues (see table F)
The LSA is carried out in CCP-ODE, since it was important to determine if different pa-
rameter values would result in a different behavior than the one observed.
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Table F.1: Summary of system dynamics expected according to eigenvalues
Eigenvalue System dynamics
Real, positive Driven away from SS
Real, negative Driven towards SS
Zero Stays at the initial state
Complex, positive real part Oscillates around SS (increasing amplitude)
Complex, negative real part Oscillates around SS (decreasing amplitude)
Complex, imaginary Oscillates around SS (constant amplitude)
Starting from CCP-ODE and replacing k1 = 1/τG, k2 = 1/τS and k3 = 1/τM:
dG%
dt
+
dT
dt
· G%
T
=−k1 ·G%+2 · k3 ·M% (F.1)
dS%
dt
+
dT
dt
· S%
T
=−k2 ·S%+ k1 ·G% (F.2)
dM%
dt
+
dT
dt
·M%
T
=−k3 ·M%+ k2 ·S% (F.3)
Summing across all three phases:
dT
dt
· 1
T
= k3 ·M% (F.4)
Replacing into each Eq (F.1)-(F.3):
dG%
dt
=−k1 ·G%+2 · k3 ·M%− k3 ·G% ·M% (F.5)
dS%
dt
=−k2 ·S%+ k1 ·G%− k3 ·S% ·M% (F.6)
dM%
dt
=−k3 ·M%+ k2 ·S%− k3 ·M2% (F.7)
Next, we take the derivative of the RHS of Eq (F.5)-(F.7) over each of G%, S%, M% and place
it in matrix form:
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
d
dG%
d
dS%
d
dM%
Eq(F.5) −k1− k3 ·M%,SS 0 2 · k3− k3 ·G%,SS
Eq(F.6) k1 −k2− k3 ·M%,SS −k3 ·S%,SS
Eq(F.7) 0 k2 −k3−2 · k3 ·M%,SS
 = A
To find the eigenvalues, we need to solve the equation:
det(A−λ I˙) = 0 (F.8)
If we perform the following substitutions:
u =−k1− k3 ·M%,SS (F.9)
v =−k2− k3 ·M%,SS (F.10)
w =−k3−2 · k3 ·M%,SS (F.11)
Then the problem is reduced to solving the following cubic equation[77] for λ :
0 =−λ 3+(u+ v+w) ·λ 2− (u · v+u ·w+ v ·w+ k2 · k3 ·S%,SS) ·λ
+(u · v ·w+ k1 · k2 · k3 · (2−G%,SS)+ k2 · k3 ·u ·S%,SS)
(F.12)
Considering k1, k2 and k3 are defined as the inverse of the phase time, they will typically range
[0.01-1] (times varying between 1h and 100h) therefore solving within ki ∈ {0,1} for i= 1,2,3
would cover the possible parameter space. As shown in Fig. F.1, the real part of the complex
eigenvalues is always negative. The real eigenvalue solution is also negative in all cases (data
not shown). We conclude that, locally for ki ∈ {0,1}, CCP-ODE oscillates around the steady
state found in the previous section, with decreasing amplitude.
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Figure F.1: Real part of complex eigenvalues for varying ki parameter space
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GSA: Sobol’s method
GSA is a powerful technique in the analysis of model robustness with respect to each of its
parameters. Briefly, performing GSA involves varying all of the estimated/experimentally de-
termined parameters simultaneously using Sobol’s method, and observing the model’s output.
When the output is highly altered in correlation with varied specific parameters, these are said
to be significant and an accurate determination of each of them is needed. Conversely, if the
output remains unchanged, the parameters are not significant and they can be estimated or
left at their nominal values without significant impact on the model’s predictions. A concise
overview of the GSA method is given below. The Sobol’s sensitivity analysis method is a vari-
ance based approach based on the ANOVA decomposition 1,2. If f is an integrable function
defined on the unit hypercube In and x ∈ In, x = (x1, ,xn) the input variables, the output f (x) of
the function may be expressed as:
f (x) = f0+
n
∑
s=1
n
∑
i1<...<is
fi1...is(xi1, ...,xis) (G.1)
f0 is the mean response of f and the terms fi(xi) and fi j(xi,x j) represent the first and second
order terms and so on. The formula above is termed ANOVA decomposition. The component
1Sobol IM (2001) Global sensitivity indices for nonlinear mathematical models and their Monte Carlo esti-
mates. Mathematics and Computers in Simulation 55(1-3):271-280.
2Sobol IM & Kucherenko SS (2005) On Global sensitivity analysis of quasi-Monte Carlo algorithms. Monte
Carlo Methods and Applications 11(1):83-92.
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functions may then be expressed as integrals of f :
∫
f (x)dx = f0 (G.2)∫
f (x)∏
k 6=i
dxk = f0+ fi(xi) (G.3)∫
f (x) ∏
k 6=i, j
dxk = f0+ fi(xi)+ fi j(xi,x j) (G.4)
Assuming f is square integrable over In, we have:
∫
f 2(x)dx− f0 =
n
∑
s=1
n
∑
i1<...<is
∫
fi1...isdx1...dxs (G.5)
D =
∫
f 2(x)dx− f0 and Di1...is =
∫
fi1...isdx1...dxs (G.6)
The terms represent the variance and partial variance respectively. The Sobols sensitivity
indices (SI) are given by:
Si1...is =
Di1...is
D
(G.7)
where
n
∑
s=1
n
∑
i1<...<is
Si1...is = 1 (G.8)
If a set of variables y = (x1, ,xs) is considered and z a set of the complementary variables, we
note x = (y,z). Using the previous definition of the variance the total variance of the subset y
can be computed as:
Dtoty = D−Dz (G.9)
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and
Stoty =
Dtoty
D
(G.10)
The following inequality holds:
0≤ Sy ≤ Stoty ≤ 1 (G.11)
If Sy = Styot = 0 then f does not depend on y. If Sy = S
t
yot = 1 then f only depends on y.
The indices help rank variables and discard unessential variables. Sensitivity analysis in-
dices are usually computed through Monte-Carlo numerical integration3.
Dy =
∫
f (x) f (y,z)dxdz− f 20 (G.12)
3Sobol IM (2001) Global sensitivity indices for nonlinear mathematical models and their Monte Carlo esti-
mates. Mathematics and Computers in Simulation 55(1-3):271-280.
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Appendix H
DDE construction and conservation
aspects
The DDE model developed has the following form:
dG(t)
dt = 2 ·M(t− τM)/τM−G(t)/τG
dS(t)
dt = G(t− τG)/τG−S(t)/τS
dM(t)
dt = S(t− τS)/τS−M(t)/τM
T (t) = G(t)+S(t)+M(t)
(H.1)
However an alternative model with balanced conditions is possible:
dG(t)
dt = 2 ·M(t− τM)/τM−G(t− τG)/τG
dS(t)
dt = G(t− τG)/τG−S(t− τS)/τS
dM(t)
dt = S(t− τS)/τS−M(t− τM)/τM
T (t) = G(t)+S(t)+M(t)
(H.2)
wherein cells entering S phase equal cells exiting G phase at any point in time (idem for all
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other phases). Although a priori such a model appears more correct from a conservation point
of view, it has several drawbacks. The first is that it produces unstable oscillations when sim-
ulated (instead of tending to the steady state, it is driven away from it), Figure H.1. This is
highly inconvenient since it’s not the behavior observed experimentally and becomes difficult
to tackle for the solvers (which struggle to find a solution when any of the positive variables G,
S or M reaches a value of 0). The second is that for some specific cases, the DDE model can
be reduced to the ODE model presented (CCP-ODE). Notably, if all three delays are equal, we
can write:
τG = τS = τM = τ (H.3)
with a change of variable: t− τ = t∗ (H.4)
dG
dt
=
dG
dt∗
· dt
∗
dt
=
dG
dt∗
(H.5)
Therefore the model H.2 becomes:
dG(t)
dt∗ = 2 ·M(t∗)/τM−G(t∗)/τG
dS(t)
dt∗ = G(t
∗)/τG−S(t∗)/τS
dM(t)
dt∗ = S(t
∗)/τS−M(t∗)/τM
T (t∗) = G(t∗)+S(t∗)+M(t∗)
(H.6)
which is precisely the CCP-ODE model presented if t∗ is substituted by t.
To assess the error made by using the CCP-DDE as in H.1, we ran the model until steady
state (exponential growth conditions and constant phase distribution) with the duplication fac-
tor set to 1 (so that cells do not duplicate and we can clearly see any changes in total cell
196 Marı´a Fuentes Garı´ Appendix H
A mathematical model of cell cycle heterogeneity for personalizing leukemia chemotherapy
Figure H.1: Simulation of models H.1 (unbalanced DDE) and H.2 (balanced DDE) with a chosen
parameter set. Observe how H.1 tends to the steady state while H.2 escapes from it.
number):
dG(t)
dt = 1 ·M(t− τM)/τM−G(t)/τG
dS(t)
dt = G(t− τG)/τG−S(t)/τS
dM(t)
dt = S(t− τS)/τS−M(t)/τM
T (t) = G(t)+S(t)+M(t)
(H.7)
We then removed all cells from S phase (and from the history vector, i.e, S(t− τS) = 0 for
the duration τS) and let the model run back to steady state (Figure H.2). We observed that the
cell loss caused a small perturbation in the transient state of the total cells that lasted for around
10h and resulted in a maximum (transient) 3% change in the total population. We consider this
error is acceptable and will not cause any major conservation issues in the model.
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Figure H.2: Simulation of model H.7 (unbalanced DDE) with a chosen parameter set. S phase
cells are removed at t=100h (when the system is at the steady state). Total cells and S phase
cells present the evolution of both variables in the actual simulation. Total cells (accounting for
S phase cells lost) sums the actual total S phase cells removed from the system from t=100h (i.e.,
T (accounting for S phase cells lost)(t) = T (t)+S(t = 100h)). On the right we present the relative cells
lost vs t<100h ( T (accounting for S phase cells lost)(t)T (accounting for S phase cells lost)(t=100h) ).
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Table I.1: CCP-ODE definitions
Symbol Description Units Source
State
Variables
t Time, phase time [hr]
Measurable
Model
Parameters
G0,% Initial cellular fraction in G [–]
S0,% Initial cellular fraction in S [–]
M0,% Initial cellular fraction in M [–]
τG Cell cycle time in G phase [hr]
τS Cell cycle time in S phase [hr]
τM Cell cycle time in M phase [hr]
GSS,% G phase fraction at steady state [%]
SSS,% S phase fraction at steady state [%]
MSS,% M phase fraction at steady state [%]
µ Log-growth parameter at steady state [hr−1]
Model
variables
G Cells in G0/G1 phase [cells] CCP-ODE
S Cells in S phase [cells] CCP-ODE
M Cells in G2/M phase [cells] CCP-ODE
T Total cells in all phases [cells] CCP-ODE
G% Fraction of cells in G0/G1 phase [%] CCP-ODE
S% Fraction of cells in S phase [%] CCP-ODE
M% Fraction of cells in G2/M phase [%] CCP-ODE
Table I.2: CCP-DDE definitions
Symbol Description Units Source
State
Variables
t Time [hr]
Measurable
Model
Parameters
G0 Initial cellular fraction in G [–]
S0 Initial cellular fraction in S [–]
M0 Initial cellular fraction in M [–]
τG Cell cycle time in G phase [hr]
τS Cell cycle time in S phase [hr]
τM Cell cycle time in M phase [hr]
GSS,% G phase fraction at steady state [%]
SSS,% S phase fraction at steady state [%]
MSS,% M phase fraction at steady state [%]
γ Log-growth parameter at steady state [hr−1]
Model
variables
G(t) Cells in G0/G1 phase at time t [cells] CCP-DDE
S(t) Cells in S phase at time t [cells] CCP-DDE
M(t) Cells in G2/M phase at time t [cells] CCP-DDE
T (t) Total cells in all phases at time t [cells] CCP-DDE
G%(t) Fraction of cells in G0/G1 phase at time t [%] CCP-DDE
S%(t) Fraction of cells in S phase at time t [%] CCP-DDE
M%(t) Fraction of cells in G2/M phase at time t [%] CCP-DDE
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Table I.3: CCP-PBM definitions
Symbol Description Units Source
Cell Lines
K562 Chronic Myeloid Leukemia; ATCC Cat. #CCL243
MEC1 B-Cell Chronic Lymphocytic Leukemia; DSMZ Cat. #ACC495
MOLT4 Acute Lymphocytic Leukemia; ATCC Cat. #CRL1582
Cell Cycle
Phases
G Aggregated phase including G0 (resting) & G1 (growth
preparing for DNA synthesis) phases
S Synthesis phase; cells replicate their DNA
M Aggregated phase incorporating G2 (growth preparing for
mitosis) & M (mitosis) phases
State Variables
CB Cyclin B; Increased expression during G2 phase normalized cyclin
CE Cyclin E; Increased expression during G1→ S transition normalized cyclin
DNA Deoxyribonucleic acid; Doubles during S phase [copies]
t Time [hr]
Measurable
Model
Parameters
CE,min Minimum value of cyclin E
CB,min Minimum value of cyclin B
CE, thr Transition threshold of cyclin E
CB, thr Transition threshold of cyclin B
CE,max Maximum value of cyclin E
CB,max Maximum value of cyclin B
G0 Initial cellular fraction in G [%]
S0 Initial cellular fraction in S [%]
M0 Initial cellular fraction in M [%]
S0,1 Fraction of S phase cells in first quarter of S phase [%]
S0,2 Fraction of S phase cells in second quarter of S phase [%]
S0,3 Fraction of S phase cells in third quarter of S phase [%]
S0,4 Fraction of S phase cells in last quarter of S phase [%]
σ Standard deviation of cyclin distribution
TG Cell cycle time in G phase [hr]
TS Cell cycle time in S phase [hr]
TM Cell cycle time in M phase [hr]
Discretised
Model
Parameters
nE Number of bins in the G phase
nD Number of bins in the S phase
nB Number of bins in the M phase
Ge Cells in the eth bin of G; e ∈ {1, . . . , nE} [cells]
Sd Cells in the dth bin of S; d ∈ {1, . . . , nD} [cells]
Mb Cells in the bth bin of M; b ∈ {1, . . . , nB} [cells]
νE Cyclin E to bin width conversion factor [–] Eq (5.16)
νD DNA to bin width conversion factor [–] Eq (5.17)
νB Cyclin B to bin width conversion factor [–] Eq (5.18)
rG dCE/dt; Increasing rate of CE expression during G phase [normalized cyclin/ hr] CCP-PBM
rS dDNA/dt; Increasing rate of DNA during S phase [copies / hr] CCP-PBM
rM dCB/dt; Increasing rate of CB expression during M phase [normalized cyclin/ hr] CCP-PBM
rG→S,e Transition rate from G to S phase [normalized cyclin/ hr] CCP-PBM
rM→G,b Transition rate from M to G phase [normalized cyclin/ hr] CCP-PBM
ΓG,e Probability distribution for transition according to cyclin
levels in G
[–] Eq (5.9)
ΓM,b Probability distribution for transition according to cyclin
levels in M
[–] Eq (5.10)
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